 [STUDY_ID_REMOVED] 
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular 
Date Uploaded:  April 14, 2020  
Document  Date:  January 18, 2017 
Bevacizumab for children and adults with NF2  
Protocol Version Date:  May 13, 2016 Version 1.4  
Protocol Version Date: May 13, 2016 
Sp
onsor Information:   USMRMC, Office of the Congressionally Directed Medical 
Research Programs (CDMRP), Department of Defense (DOD)  
and Genentech  
IND NUMBER:  112096 
Ti
tle:  Open -label, phase 2 study of bevacizumab  in children and 
adults with neurofibromatosis 2 and progressive vestibular 
schwannomas that are poor candidates for standard 
treatment with surgery or radiation    
Pr
incipal Investigator : Scott R. Plotkin, MD, PhD 
Yawkey 9E, Massachusetts General Hospital  
55 Fruit Street 
Boston, MA  02114 
Phone: 617-726-3650 E-mail address: splotkin@partners.org
Op
erations Center: Bruce R. Korf, MD, PhD, Operations Center PI 
University of Alabama, Birmingham  
1720 2nd Avenue South– Kaul 230  
Birmingham, AL  35294-0024 Phone:  205-934-9411 Fax: 205-934-9488 E-mail address: bkorf@uabmc.edu
PD II:  Karen  Cole-Plourde: kplourde@uab.edu
Co-I
nvestigators:  
Ja
mes Tonsgard, MD 
University of Chicago 5841 South Maryland Avenue, MC 3055 Chicago, IL  60637 Phone:  773-702-6488 tonsgard@midway.uchicago.edu
 
Ni
cole Ullrich, MD, PhD 
Children’s Hospital Boston Department of Neurology 300 Longwood Avenue  
Boston, MA 02115 Phone:   617-355-3193 nicole.ullrich@childrens.harvard.edu
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  Elizabeth Schorry, MD  
Cincinnati Children’s Hospital Medical Center  
3333 Burnet Avenue – ML 4006 Cincinnati, OH  45229-3039 Phone:  513-636-4760 Elizabeth.Schorry@cchmc.org
 
 
Statistician:  Gary Cutter, PhD  
 Director, Dept. of Biostatistics  
School of Public Health Univ. of Alabama at Birmingham  
1665 University Boulevard, RPHB 410B Phone:  205-934-4937 Fax: 205-975-2540 Cutterg@uab.edu
 
 Joan E Hilner, MPH, MA Dept. of Biostatistics  
School of Public Health  Univ. of Alabama at Birmingham 1665 Univ. Blvd., RPHB 514D Phone:   205-934-4943 Fax:  205-975-2500 jhilner@uab.edu
 
 
 Operations Center  
Research Nurse Manager:  Liz Davis, RN,  MPH,  CCRC 
  Dept. of Genetics  
  U niv. of Alabama at Birmingham  
  1720 2
nd Avenue South, MCML 252 
 Birmingham, AL  35294- 0024  
 Phone: 205- 934-5376  
 Fax:  205- 934- 3543  
 lvdavis@uab.edu  
 
Operations Center  Karen A. Cole- Plourde, BS  
Program Director:  Dept. of Genetics  
 Univ . of Alabama at Birmingham  
 1720 2nd Avenue South, MCML 256 
 Birmingham, AL  35294- 0024  
 Phone: 205-934-5140  
 Fax: 205-934-3543  
 kplourde@uab.edu  
  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  Research Compliance   Roy McDonald , MPH  
Manager:        Dept. of Genetics  
          Univ. of Alabama at Birmingham  
          1720 2nd Avenue South, MCML 262A          
          Birmingham, AL  35294- 0024  
          Phone: 205- 975-4075  
             Fax:  205- 934- 3543  
          rmcdonald@uab.edu   
 
Central Pharmacy:  Rebecca Quinn, PharmD  
Investigational Drug Service (IDS) Pharmacy  
UAB Hospital  
North Pavilion, room 3470  
1802 6th Avenue South  
Birmingham, AL   35249  
Phone: 205-934-719  
Fax: 205-975-6647  
UAB paging: 205-934-3411, pager 4295 rquinn@uabc.edu
  
 Medical Monitor:     Christopher Moertel, MD  
 Medical Director, Neuro -oncology and    
 Comprehensive Neurofibromatosis Clinics  
 Professor of Pediatrics  
 MMC 484  
 420 Delaware Street SE  
 Minneapolis, MN 55455  
 moert001@umn.edu
 
 Agent(s):  Bevacizumab (NSC# 704865) – Supplier: Genentech  
 
Consortium Participating Sites  
 
Bruce Korf, MD, PhD  
University of Alabama at Birmingham  
1720 2nd Ave So uth -  KAUL  230 
Birmingham, Alabama  35294-0024 Phone:  205-934-9411/Fax: 205-934-9488 bkorf@uabmc .edu
 
 Elizabeth Schorry, MD  
Cincinnati Children’s Hospital Medical Center  
3333 Burnet Avenue - ML 4006 Cincinnati, OH  45229 Phone:  513-636-4760 elizabeth.schorry@cchmc.org
 
 
Michael Fisher , MD  
Children’s Hospital of Philadelphia 34
th Street & Civic Center Boulevard  
Philadelphia, PA 19096 Phone:  215-590-2800/Lab: 215-590-2107 
fisherm@email.chop.edu  James Tonsgard, MD  
University of Chicago 5841 South Maryland Avenue, MC 3055 Chicago, IL  60637 Phone:  773-702-6488 
tonsgard@midway. uchicago.edu  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.    
Roger Packer, MD  
Children’s National Medical Center  
111 Michigan Avenue, NW  
Washington, DC  20010 
Phone:  202-884-2120 rpacker@cnmc.org
 David Viskochil, MD, PhD  
University of Utah  
50 North Medical Drive – 2C412 SOM 
Salt Lake City, UT  84132 Phone:  801-581-8943 dave.viskochil@hsc.utah.edu
 
Wade Clapp, MD  
Indiana University  1044 West Walnut Street  Cancer Center, Room 402A  Indianapolis, IN  46202 Phone: 317-278-9290 dclapp@iupui.edu
 
 David Gutmann, MD, PhD  
Washington University School of Medicine 660 South Euclid Avenue – Box 811 St. Louis, MO  63110 Phone: 314-362-7379  gutmannd@neuro.wustl.edu
 
 
 
Tena Rosser, MD  
Children’s Hospital Los Angeles  
300 Medical Plaza Box 696824 Los Angeles, CA  90095 Phone: 323-361-2471 trosser@chla.usc.edu
 
 Jeffrey Allen, MD  
New York Univ.  Pediatrics  
160 E. 32nd Street – 2nd Floor 
Hassenfeld Children’s Center  
New York, NY 10016 Phone: 212-263-9907 Jeffrey.Allen@nyumc.org
  
  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  Affiliate sites   
 
Massachusetts  General Hospital (Ullrich; Plotkin)  
Dana Farber (Ullrich; Kieran)  
UCLA (Rosser; Silva)  
Johns Hopkins (Packer; Blakeley) Ohio State University  (Schorry) 
Northwestern University Hospital (Tonsgard; Listernick and Goldman)   
 
Data and Safety Monitoring B oard (DSMB)  Members  
 Christopher Moertel, MD, Chair  
University of Minnesota Department of Pediatrics  
MMC 484 420 Delaware Street S.E.  
Minneapolis, MN  55455 Phone: (612) 625-3229 Fax: (612) 626-2815 Email: moert001@umn.edu
 
 Edwin Choy, MD, Member  
MGH, Dana Farber/Harvard Cancer Center  
Division of Hematology Oncology 55 Fruit Street Boston MA 02114 Phone: (617) 643-0230 Fax: (617) 724-3166 Email: echoy@partners.org
 
 Dr. Domenic Reda,  PhD,  Member (Statistician)  
Director, Cooperative Studies Program Coordinating Center  
Hines VA Hospital, CSPCC (151K) 5000 South 5th Avenue, Building 1, Room B240,  Hines, IL  60141-3030 Phone: 708-202-5853 Fax: 708-202-2116 Email : domenic.reda@va.gov
 
   
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  ABBREVIATIONS:  
 
AAO- HNS: American Academy of Otolaryngology, Head and Neck Surgery  
ASCO: American Society of Clinical Oncology  
ABI: auditory brainstem implant  
AST/ALT : alanine transaminase/alanine transaminase  
ATE: arterial thromboembolic events 
BAER: brainstem auditory evoked responses  
BMD: bone mineral density  
CHF: congestive heart failure  
CNS : central nervous system  
COV: coefficient of variation  
CRC: colorectal cancer  
CRF: case report form  
CTC: Common Terminology Criteria for Adverse Events  
CTCAE: Common Terminology Criteria for Adverse Events  DBP: diastolic blood pressure DF/HCC: Dana Farber/Harvard Cancer Center  
DPOAE: distortion product otoacoustic emissions  
DMAC: Data Management and Analysis Center  
DSMB: Data and safe ty monitoring board  
EGFR: epidermal growth factor receptor  
FU/LV : fluorouracil/leucovorin  
HIV: human immunodeficiency virus  
HTN: hypertension  
LMWH: low molecular weight heparins  
IAC: internal auditory canal  
I.B.: investigator brochure IgG: immunoglobulin G IMP:  investigational medicinal product 
IV: intravenous LVEF: left ventricular ejection fraction  
MAb: monoclonal antibody MLV: monitored live voice MTD: maximum tolerated dose  
NF2: neurofibromatosis 2 NSCLC: non- small cell lung cancer  
OAE: otoacoustic emissions  
PDGFR: platelet derived growth factor receptor  
PI: Principal Investigator  
P.I.: package insert  
PK: pharmacokinetics 
PTA: pure -tone average  
RECIST: Response Evaluation Criteria in Solid Tumors RPLS:  Reversible Posterior Leukoencephalopathy Syndrome  
SAE: serious adverse event 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  SRT: speech reception threshold 
TE: thromboembolic TIA: transient ischemic attack  
ULN: upper limit of normal UPC: urine protein: creatinine VEGF: vascular endothelial growth factor VEGFR: vascular endothelial growth factor receptor  
VS(s): vestibular schwannoma (s) 
VTE : venous thromboembolism 
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  PRECIS  
 
Background 
 
• Bilateral vestibular schwannomas are the hallmark of neurofibromatosis 2 (NF2) .  As these 
tumors enlarge, they cause sensorineural hearing loss and, ultimately, complete hearing loss.   
• Sporadic and NF2 -related vestibular schwannomas express vascular endothelial growth 
factor (VEGF).   
• Bevacizumab  is a humanized IgG1 monoclonal antibody (MAb) that binds all 
biologically active isoforms of human VEGF with high affinity . 
• The initial experience treating ten NF2 patients at risk for complete hearing loss with 
bevacizumab outside of a clinical trial showed promising results with 6/10 pati ents 
experiencing ≥ 20% reduction in tumor volume and 4/7 evaluable patients having 
significantly improved word recognition scores . 
 
Primary Objective  
 
• To determine the hearing response rate at 24 weeks  after treatment with  bevacizumab for 
symptomatic vestibular schwannomas (VS) in children and young adults with NF2 . 
 Eligibility  
 
• Patients  ≥ 6 years old with NF2 
• Subjects must have a target VS with the following qualities: 
o Not amenable to surgery due to p atient preference or  high risk for surgical 
complications  
o Associated with a word recognition score of < 85%  and > 5%  
o Documented clinical progression defined as EITHER: 
• Progressive hearing loss ( defined as a decline in word recognition score below 
the 95% critical differenc e interval from baseline score , Appendix A) related 
to VS .  
OR 
• Progressive tumor growth in the preceding 18 months, defined as ≥ 20% 
increase in volume. 
 
Design  
• Bevacizumab will be  administered  by IV infusion at a dose of 10 mg/kg every 2 weeks for 
24 weeks (induction therapy). 
• Clinical response will be assessed by audiology and MRI at weeks 12 and 24.  Subjects 
with hearing decline during induction therapy  (defined as a decline in word recognition 
score below the 95% critical differenc e interval from baselin e score, Appendix A) will be 
taken off of protocol (section 5.5).   
• At week 2 5, patients with a clinical response or stable disease (together comprising 
“clinical benefit”) will transition to maintenance therapy with bevacizumab.   
• During the maintenance phase, subjects will be treated with open -label bevacizumab 5 
mg/kg every 3 weeks for up to 72 weeks. 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  • During maintenance therapy, subjects will be allowed to increase their bevacizumab dose 
to 10 mg/kg every 2 weeks if they experience hearing decline  compar ed to their highest 
word recognition score  during treatment.  Subjects will be taken off of study if their word 
recognition drops below  the 95% critical difference  (new hearing baseline defined as the 
word recognition score leading subject to receive 10 mg /kg dose every 2 weeks) after 
receiving bevacizumab 10 mg/kg every 2 weeks  for at least 12 weeks  (section 5.5).   
       
SCHEMA  
 
 
 NF2 patients 
with 
progressive 
VS who are 
not good 
candidates 
for surgery 
or radiationBevacizumab
10 mg/kg IV q 
2 weeks 
for 6 months
Response 
evaluation
at months 3 
and 6Hearing 
Improvement
Stable 
hearing
Hearing 
deteriorationBevacizumab 
5 mg/kg IV q 
3 weeks for 
18 months
Off protocolResponse 
evaluation
every 3 monthsInduction Maintenance
N = 22 subjects
Accrual = 2 per monthMonths 1 -6 Months 7 -24
Determine 
bevacizumab 
doseHearing 
Improvement 
or stable 
hearing
Hearing 
deterioration
< 10 mg/kg dose
Off protocol10 mg/kg doseContinue 
up to 18 
months
Increase 
bevacizumab 
dose per protocol
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  TABLE OF CONTENTS  
The Table of Contents was auto-generated in Microsoft Word and does not update automatically 
when you change the protocol document. To update the Table of Contents, put your cursor in the Table of Contents and press F9  to update it or ctrl -a F9 to update all fields.  When you update 
the Table of Contents, always choose to update the Entire Table. 
PRECIS  .................................................................................................................................................................... viii 
Background  .............................................................................................................................................................. viii 
Primary Objectiv e ................................................................................................................................................... viii 
Eligibility  .................................................................................................................................................................. viii 
OR ............................................................................................................................................................................. viii 
Design  ....................................................................................................................................................................... viii 
1. OBJECTIVES  .................................................................................................................................................... 1  
1.1 Study Design  .................................................................................................................................................... 1  
1.2 Primary Objectives  .......................................................................................................................................... 1  
1.3 Secondary Objectives  ...................................................................................................................................... 1  
2. BACKGROUND  ................................................................................................................................................ 1  
2.1 Neurofibromatosis 2  ........................................................................................................................................ 1  
2.2 Study Agent(s)  ................................................................................................................................................. 5  
2.3 Rationale  ....................................................................................................................................................... 14 
2.4 Correlative Studies Background .................................................................................................................... 14 
3. PARTICIPANT SELECTION  ........................................................................................................................ 15 
3.1 Eligibility Criteria  ......................................................................................................................................... 15 
3.2 Exclusion Criteria  ...................................................................................................................................... 17 
3.3 Inclusion of Women, Minorities and Other Underrepresented Populations  ................................................. 19 
4. REGISTRATION PROCEDURES  ................................................................................................................ 19 
4.1 General Guidelines for NF Consortium Institutions  ..................................................................................... 19 
4.2 Registration Process  for NF Consortium Institutions  ............................................................................ 19 
4.3 General Guidelines for all Participating Institutions ......................................................................... 20 
4.4 Registration Process for All Participating Institutions  ................................................................................ 20 
5. TREATMENT PLAN  ...................................................................................................................................... 20 
5.1 Pre-treatment Criteria  ................................................................................................................................. 21 
5.2 Bevacizumab Administration  .................................................................................................................. 23 
5.3 Definition of Dose -Limiting Toxicity  ..................................................................................................... 23 
5.4 General Concomitant Medication and Supportive Care Guidelines  ............................................................. 23 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  5.5 Duration of Therapy  ....................................................................................................................................... 24 
5.6 Duration of Follow -Up .................................................................................................................................. 25 
5.7 Criteria for Removal from Study  ................................................................................................................... 25 
6. EXPECTED TOXICITIES AND DOSING DELAYS/DOSE MODIFICATIONS  .................................... 26 
6.1 Anticipated Toxicities  .................................................................................................................................... 27 
6.2 Toxicity Management  .................................................................................................................................... 29 
6.3 Dose Modifications/Delays  ........................................................................................................................... 29 
7. DRUG FORMULATION AND ADMINISTRATION  ................................................................................. 33 
7.1 Bevacizumab .................................................................................................................................................. 33 
8. CORRELATIVE/SPECIAL STUDIES  .......................................................................................................... 38 
8.1 Pharmacokinetic Studies  ............................................................................................................................... 38 
8.2 Pharmacodynamic Studies  ............................................................................................................................ 38 
8.3 Laboratory correlative markers  .................................................................................................................... 38 
9. STUDY CALENDAR  ...................................................................................................................................... 41 
10. MEASUREMENT OF EFFECT ..................................................................................................................... 46 
10.1 Antitumor Effect– Solid Tumors  ............................................................................................................... 46 
10.2 Antitumor Effect – Hematologic Tumors  .................................................................................................. 50 
10.3 Other Response Parameters: Hearing Response  ...................................................................................... 50 
11. ADVERSE EVENT REPORTING REQUIREMENTS  ............................................................................... 50 
11.1 Definitions  ................................................................................................................................................ 50 
11.2 Methods and Timing for Assessing and Recording Safety Variable  ......................................................... 52 
11.3 Procedures for Eliciting, Recording, and Reporting Adverse Events  ....................................................... 53 
11.4 Adverse Event Reporting to the US Army  ................................................................................................. 57  
11.5 Reporting Requirements  ........................................................................................................................... 57 
11.6 Reporting to the Study Sponsor  ................................................................................................................ 58 
11.7 Reporting to the Institutional Review Board (IRB) ................................................................................... 59 
11.8 Reporting to the Food and Drug Administration (FDA)  .......................................................................... 59 
11.9 Reporting to the NIH Office of Biotechnology Activities (OBA)  .............................................................. 61 
11.10  Reporting to the Institutional Biosafety Committee (IBC)  ........................................................................ 61 
11.11  Reporting to Hospital Risk Management  .................................................................................................. 61 
11.12  Monitoring of Adverse Events and Period of Observation  ....................................................................... 61 
12. DATA AND SAFETY MONITORING  .......................................................................................................... 61 
12.1 Data Reporting  ......................................................................................................................................... 61 
12.2 Safety Meetings  ......................................................................................................................................... 63 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  12.3 Monitoring  ................................................................................................................................................ 63 
12.4 Privacy ...................................................................................................................................................... 63 
12.5 Confidentiality  .......................................................................................................................................... 64 
13. REGULATORY CONSIDERATIONS  .......................................................................................................... 64 
13.1 Protocol Review and Amendments  ........................................................................................................... 64 
13.2 Informed Consent  ..................................................................................................................................... 64 
13.3 Ethics and Good Clinical Practice  (GCP)  ............................................................................................... 64 
13.4 Study Documentation  ................................................................................................................................ 66 
13.5 Records Retention  ..................................................................................................................................... 66 
13.6 Multi-center Guidelines  ............................................................................................................................ 66 
13.7 Cooperative Research and Development Agreement (CRADA)/Clinical Trials Agreement (CTA)  .......... 67 
14. STATISTICAL CONSIDERATIONS  ............................................................................................................ 67 
14.1 Study Design/Endpoints  ............................................................................................................................ 67 
14.2 Sample Size/Accrual Rate  ......................................................................................................................... 67 
14.3 Stratification Factors  ................................................................................................................................ 67 
14.4 Analysis of Secondary Endpoints  .............................................................................................................. 67 
14.5 Reporting and Exclusions  ......................................................................................................................... 69 
15. PUBLICATION PLAN  .................................................................................................................................... 69 
16. REFERENCES  ................................................................................................................................................. 70 
17. APPENDICES  .................................................................................................................................................. 74 
Appendix A: Hearing Response Guidelines  ............................................................................................................ 74 
Appendix B:  NFTI -QOL (Neurofibromatosis 2 impact on quality of life)  .......................................................... 76 
Appendix C: Performance Status Criteria  .............................................................................................................. 79 
Appendix D:  Grading and management of hypertension for adults and for children 6 through 17 years old.  80 
Appendix E: Management of Bone Related Toxicity.  ............................................................................................ 84 
Appendix F: Audiology Procedures  ......................................................................................................................... 85 
Appendix G: MRI Protocols ..................................................................................................................................... 97 
Appendix H: Tinnitus Reaction Questionnaire (TRQ) a ...................................................................................... 106 
Bevacizumab for children and adults with NF2    
Protocol Version Date:  May 13, 2016 Version 1.4  
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
 
1 1. OBJECTIVES  
 
1.1 Study Desig n 
 
Subjects will be treated with open- label bevacizumab 10  mg/kg every 2 weeks for 24 weeks  
(induction therapy).  Clinical response will be assessed by audiology and MRI a t weeks 12 
and 24.  Subjects with hearing decline at weeks 12 or 24 will be taken off of protocol.  At 
week 24 , patients with a clinical response or stable disease (together comprising “clinical 
benefit”) will transition to maintenance therapy with bevacizumab.  During the maintenance 
phase, subjects will be treated with open- label bevacizumab 5 mg/kg every 3 weeks for up to 
72 weeks.  Subjects will be followed with audiology and MRI scans every 12 weeks .  The 
total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance).  
   
Subjects  will be allowed to incr ease their bevacizumab dose to 10  mg/kg every 2 weeks  
during maintenance therapy  if they experience hearing decline during maintenance therapy 
(defined as decrease in word recognition score below the 95% critical difference  compared 
with the word recognition score at baseline, Appendix A).  Subjects will be taken off of study if their word rec ognition score does not remain within the 95% critical difference after 
receiving bevacizumab 10 mg/kg every 2 weeks .   
 
1.2 Primary Objectives  
 
The primary objective of this study is to determine the hearing response rate at 24 weeks in children and young adults with neurofibromatosis 2 (NF2) treated with bevacizumab for symptomatic vestibular schwannomas.   
 
1.3 Secondary Objectives  
 
The secondary objectives are: (1) to determine the safety and tolerability of bevacizumab in this patient population; (2)  to determine the radiographic response rate (defined as  an 
decrease in VS volume by ≥ 20%  compared to baseline) during bevacizumab treatment ; (3) 
to determine the durability of hearing response, as measured by freedom from hearing loss  
from  the time of hearing response (defined as a decrease in word recognition score below the 
upper limit of the 95% critical difference of the baseline word recognition score, Appendix 
A); (4) to determine the durability of radiographic response, as measured from the time of 
first response to tumor progression (define d as an increase in volume of > 20% compared to 
lowest tumor volume during treatment) (5) to determine changes in function of the auditory system during bevacizumab treatment; (6) to explore chang es in tinnitus  during treatment.  
 
2. BACKGROUND  
 
2.1 Neurofibromatosis 2 
 
An estimated 43,800 primary brain tumors were diagnosed in 2005 and 16,600 (38%) of these tumors were meningiomas or nerve sheath tumors.  Surprisingly, meningiomas and vestibular schwannom as (VSs) are as common as all types of gliomas combined.
1 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
2  
Neurofibromatosis 2 (NF2) is a tumor suppressor syndrome characterized by multiple 
schwannomas, meningiomas,  and ependymomas.  The birth prevalence is estimated to be 1 in 
25,000 births and NF2 affects more than 10,000 individuals in the United States.  The average age at onset of symptoms is 17 to 21 years.  
 
Despite the benign histology of schwannomas, meningiomas, and ependymomas, NF2 patients experience significant morbidity and mortality related to their disease.  Actuarial survival after diagnosis of NF2 is 85% at 5 years, 67% at 10 years, and 38% at 20 years.
2  Bilateral VSs are the 
hallmark of NF2.  As these tumors enlarge, they cause sensorineural hearing loss and, ultimately, complete hearing loss.  In addition, half of all patients have intracranial meningiomas and 75% 
have spinal tumors ( i.e., schwannomas, meningiomas, ependymomas).  Most patients require 
surgery during their lifetime and most patients have multiple procedures.  Morbidity related to NF2 is severe and includes early deafness, facial weakness, blindness, seizures, and hemiparesis.   
 
There are two forms of hearing loss in patients with NF2.  Gradual hearing loss is the rule, and it most commonly occurs with progression of tumor size over  time.  Although there is a rough 
correlation with tumor size, gradual hearing loss can occur with tumors of any size.  Although surgical implantation of cochlear and auditory brainstem implants provides benefit for a small minority of patients, there is no widely effective treatment for this type of hearing loss.  In addition, some patients can experience episodes of sudden hearing loss superimposed on baseline hearing dysfunction.  Treatment with a short course of corticosteroids can often correct this ac ute 
hearing loss.  The mechanism of acute hearing loss is not clearly understood but probably involves compression of the auditory nerve from tumor mass and associated edema.  Previous studies of pressure within the internal auditory canal (IAC) of patient s with VSs suggest that 
intracannalicular pressure is directly correlated with the amount of tumor in the IAC and may be inversely associated with preoperative hearing.
3 Thus, therapies that reduce edema, a common 
cause of increased pressure in brain tumors, are a rational approach to treating hearing loss in NF2 patients.  
 
In patients with NF2, standard therapy involves surgery for progressive, symptomatic tumors.  Due to the large number of tumors encountered in the brain and spinal cord, surgical removal of all tumors is not possible or advisable.  Iatrogenic morbidity aft er surgery for NF2 -related lesions 
is, unfortunately, relatively common due to the intimate association between tumors and vital neurologic structures.  For example, complete surgical resection of VSs typically results in ipsilateral anacusis except in a m inority of tumors that are smaller than 1.5 cm and smooth in 
outline. As well, facial palsy, spinal fluid leaks and infection are all common complications of VS resection.  
 
Radiation has been used in a subset of tumors that progress despite surgical treat ment or in 
individuals who are considered high risk for surgical complications.  However, this modality should be used with caution since secondary malignancies after treatment have been reported.
4  
In addition, many patients lose functional hearing after provision of radiation with hearing preservation rates of 73% at 1 year, 59% at 2 years, and 48% at 5 years after radiosurgery.
5  
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
3 There are no known effective medical treatments for NF2 -related tumors.  Given the limitations 
of surgery or radiation and the devastating impact of these tumors, medical treatments are 
desperately needed.  We have recently identified VEGF inhibition as a possible therapy. The 
initial experience treating ten NF2 patients at risk for complete hearing loss with bevacizumab outside of a clinical trial showed promising results with 6/10 patients experiencing ≥ 20% 
reduction in tumor volume and 4/7 evaluable patients having significantly improved word recognition scores .
6  Trials of other tar geted agents for treatment of NF2 -related tumors are 
currently underway.  A phase 2 study of the VEGF inhibitor PTC299 for NF2 -related vestibular 
schwannoma ( [STUDY_ID_REMOVED] ) has completed stage 1 of accrual, and a phase 2 study of the 
HER1/HER2 inhibitor lapa tinib for NF2 -related tumors has completed enrollment 
([STUDY_ID_REMOVED] ).  Other planned studies include trials of everolimus ( [STUDY_ID_REMOVED], 
[STUDY_ID_REMOVED], [STUDY_ID_REMOVED] ). 
 
Hearing loss and NF2  
 Hearing loss is a critical problem for patients with NF2. Unlike patients with sporadic VSs who 
can function with unilateral hearing loss, patients with NF2 are at risk for complete deafness. This hearing loss typically occurs during late adolescence or early adulthood and leads to social isolation and underemployment. Although hearing loss is related to VSs, the degree of hearing 
sensitivity (threshold) is only loosely correlated with tumor size. This dissociation may be due to direct compression of the auditory nerve, presence of intratumoral edema, disruption of blood flow to the cochlea, degeneration of certain cochlear structures, and distortion of auditory centers in the brainstem. There is evidence that the cochlea, as well as the 8th cranial nerve, is a site of both cell degeneration and the accumulation of precipitate in cases of VS.
7 This means that sites 
anywhere along the auditory pathways —from the periphery to the brainstem —may contribute to 
the obser ved loss of hearing function. Thus, we will use the full range of audiologic diagnostic 
tools available to assess function of the pathway.  
 Hearing is monitored in clinical practice by measuring pure tone thresholds, word recognition scores, brainstem audi tory evoked responses (BAERs), and otoacoustic emissions (OAEs).   
 Pure tone thresholds measure the minimum sound level that an ear can perceive.  Thresholds are typically measured at octaves and half -octaves from 250 Hz to 8000 Hz. An average of 
threshol ds at 500, 1000, 2000 and 4 000 Hz (PTA) is recommended as a standard outcome 
measure by the American Academy of Otolaryngology, Head and Neck Surgery (AAO -HNS) for 
reporting in cases of VS.   
 Word recognition scores measure the ability to recognize (as op posed to detect) auditory 
information. Patients are presented a list of 50 words at a fully audible level and the percentage identified correctly is the score. This study will use full 50 -item monosyllable lists and 
standardized recordings.  
 
Brainstem aud itory evoked responses are small electrical voltage potentials recorded from the 
scalp in response to auditory stimuli (such as clicks). These signals originate from auditory structures ( e.g., the cochlea, 8th cranial nerve, and auditory brainstem) and provide information 
about the synchronous conduction of auditory information to the brain. The latency (ms) and 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
4 amplitude of the peaks of waves I and V will be differentially evaluated to show the status of 
peripheral versus brainstem effects.   
 Otoacoustic emissions (OAEs) are sounds that are generated from within the cochlea as it acts to 
amplify incoming sounds. OAEs are a sensitive measure of cochlear health and often disappear after the cochlea has been damaged. The presence (significantly above noise -floor) of measurable 
emissions, called distortion product otoacoustic emissions (DPOAEs) across frequencies from 1000 to 8000 Hz will be used as an indicator of functioning cochlear regions.  
 Because tumors associated with NF2 have benign histology, overall survival is not an appropriate 
endpoint for clinical trials in this condition. Instead, the goal of treatment is to minimize neurologic morbidity (including hearing loss) and to defer surgical treatments that may cause iatrogenic dysfunction. For this reason, hearing function is the most important way to monitor the activity of new agents designed to treat VSs.   
 Word recognition is the measure most closely associated with daily hearing function since it measures the ability to comprehend speech (rather th an “detect” it). If word recognition quality 
improves, the patient can converse successfully, even if a hearing aid is needed to make sounds sufficiently loud. Statistical methods have been developed to determine significant changes in this measure. Word r ecognition scores represent summary scores from a collection of binary 
endpoints (correct/incorrect responses) and thus follow a binomial distribution ( e.g., non -
Gaussian distribution).  Although it is tempting to use a set change in word recognition score  
(e.g., fifteen percentage points) as a clinical response, this approach is inappropriate given the 
binomial model of variance.  A more rigorous approach involves the use of the 95% (p=0.05) critical difference table 
8 (Appendix A).  The 95% critical differences for 50 -word lists as 
propose d here have been used in previous studies9 and in clinical trials evaluating the effect of 
drug treatment on hearing.  
Quality of life and NF2  
 NF2 is associated with decreased quality of life.  Recently, there have been efforts to develop a 
reliable and validated score to measure disease -specific quality of life (QOL) in NF2 patients .  
This effort has resulted in an 8- item scale that is called NFTI-QOL  (Appendix B) .
10  The eight 
questions include items about balance, hearing, facial weakness, sight, mobility, functional role, pain, and mood.  In a sample of 50 subjects  with NF2, NFTI -QOL  score correlated w ith two 
established quality of life measures: the EuroQOL and the SF -36 (Pearson correlation, p≤0.001). 
In addition, there was a strong significant correlation with physician -ranked disease severity 
(Pearson correlation, p<0.001).  
 
Imaging vestibular schwannomas  
 Although many clinicians believe that hearing loss related to VSs is irreversible, there are cases with transient hearing restoration after a course of corticosteroids or decompression of the auditory canal without removal of the tumor. Our pr eliminary observations indicate that 
neutralizing VEGF can reverse profound hearing loss and subsequently maintain hearing.   Based on these experiences, we hypothesize that the restoration of hearing function with bevacizumab is 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
5 in part due to reduction i n intraneural edema that compresses the auditory nerve. In this proposal , 
we will investigate the mechanism(s) by which bevacizumab inhibits tumor growth and/or 
induces hearing recovery using advanced MRI techniques specifically designed to assess the vascular profile of tumors and the tumor environment.   
 Internal auditory canal (IAC) imaging. The vestibular and auditory nerves together comprise 
the 8th cranial nerve. The nerve exits the lateral  brainstem, travels through the subarachnoid 
space in the IAC  to terminate in the cochlea (auditory nerve) and semicircular canals (vestibular 
nerve). Detailed imaging of the IAC is essential to identify and follow VSs in patients with NF2. MRIs must therefore include thin cuts through the IAC (3mm, no skip) in addi tion to the 
traditional pre - and post -contrast images (5 mm, 1 mm skip) that are performed for malignant 
brain tumors.  
 Volumetric analysis . Traditionally, VSs have been measured using either 1- dimensional 
measurements (in the long axis) or 2 -dimensional m easurements (calculated by taking the square 
root of the product of the short axis * long axis measured to the plane perpendicular to the face of the temporal bone).
11  However, the irregular shape of VSs, as determined by the unique anatomy 
of the IAC and cerebellopontine angle, makes it difficul t for linear measurements to accurately 
and fully represent growth for the entire tumor. As a result, VS growth may be underestimated by linear measurement criteria. Semi -automated volumetric analysis overcomes these limitations 
since it uses data from 3 d imensions. The coefficient of variation (COV) ranges from 0.6% to 
6.8% and is generally below 5% for lesions greater than 1 cc.
12  Volumetric analysis not only 
better reflects tumor size, but also allows accurate detection of smaller changes in tumor size compared to standard solid tumor response criteria ( e.g., RECIST criteria). This ability to detect 
small changes in size is critical for tumors with slow growth rates such as VS, and, when used in clinical trials, helps limit exposure to potentially  toxic and/or inactive agents. Trials for NF -
related tumors, such as plexiform neurofibromas, are now routinely using volumetric changes as the primary endpoint, typically choosing a 20% increase for progression and 20% decrease for radiographic response.
13-15 
 
2.2 Study Agent(s)  
 
2.2.1 Bevacizumab (NSC #704865)  
 Bevacizumab  is a humanized IgG1 monoclonal antibody (MAb) that binds all 
biologically active isoforms of human vascular endothelial growth factor  (VEGF, or 
VEGF -A) with high affinity (k
d = 1.1 nM) (40).  The antibody consists of a human IgG1 
fram ework and the antigen- binding complementarity -determining regions from the 
murine anti-VEGF MAb A.4.6.1.16-18 
 Mechanism of Action  
Of known proangiogenic factors, VEGF is one of the most potent and specific, and has been identified as a crucial regulator of both normal and pathological angiogenesis. VEGF is a secreted, heparin -binding protein that exists in multiple isoforms. Action of 
VEGF is primarily mediated through binding to the receptor tyrosine kinases, V EGFR -1 
(Flt-1) and VEGFR- 2 (KDR/Flk -1). The biological effects of VEGF include endothelial 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
6 cell mitogenesis and migration, increased vascular permeability, induction of proteinases 
leading to remodeling of the extracellular matrix, and suppression of dendr itic cell 
maturation. Neutralization of VEGF by A.4.6.1 or bevacizumab has been shown to inhibit the VEGF -induced proliferation of human endothelial cells  in vitro , and decrease 
microvessel density and interstitial pressure in tumor xenografts  in vivo . In patients, 
preliminary results from a neoadjuvant trial in rectal cancer demonstrated a decrease in blood perfusion/permeability and interstitial fluid pressure in tumors after one dose of bevacizumab .
19 
 
Nonclinical Studies  
The murine parent MAb of bevacizumab, A4.6.1, has demonstrated potent growth inhibition in vivo  in a variety of human cancer xenograft and metastasis models, 
including those for SK- LMS -1 leiomyosarcoma, G55 glioblastoma multiforme, A673 
rhabdomyosarcoma, Calu-6, and MCF- 7 cell lines.
16, 18, 20, 21  The antitumor activity was 
enhanced with the combination of A4.6.1 and chemotherapeutic agents compared to either agent alone.  C ombined blockage of the VEGF and other growth factor pathways 
(e.g., EGFR or PDGFR) has also demonstrated additive effects in vivo .
22, 23 Associated 
with the anti- tumor activity of anti- VEGF MAbs were findings of reduced intratumoral 
endothelial cells and microcapillary counts as well as reduced vascular permeability and interstitial pressure   
 
Nonclinical toxicology studies have examined the effects of bevacizumab on female reproductive function, fetal development, and wound healing. Fertility may be impaired in cynomolgus monkeys administered bevacizumab, which led to reduced endometrial proliferation and uterine weight as well as a decrease in ovarian weight and number of 
corpora lutea. Bevacizumab is tera togenic in rabbits, with increased frequency of fetal 
resorption, as well as specific gross and skeletal alterations. In juvenile cynomolgus monkeys with open growth plates, bevacizumab induced physeal dysplasia, which was partially reversible upon cessation of therapy.  Bevacizumab also delays the rate of wound healing in rabbits. This effect appeared to be dose- dependent and characterized b y 
a reduction of wound tensile strength. 
 
Clinical Studies in Adults  
To date, over 7000 patients have been treated in clinical trials with bevacizumab as monotherapy or in combination regimens.
17 
 
Pharmacokinetics  
The pharmacokinetics (PK) of bevacizumab have been characterized in several phase 1 and phase 2 clinical trials, with doses ranging from 1 to 20 mg/kg administered weekly, every 2 weeks, or every 3 weeks. The estimated half -life of bevacizumab is 
approximately 21 days (range 11- 50 days). The predicted time to reach steady state was 
100 days. The volume of distribution is consistent with limited extravascular distribution.     
Maximum Tolerated Dose 
The maximum tolerated dose (MTD) of bevacizumab has not been determined; however, 
the dose level of 20 mg/kg was associated severe headaches.
24 The dose schedule of 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
7 either 10 mg/kg q2w or 15 mg/kg q3w is used in most phase 2 or 3 trials with only a few 
exceptions ( e.g., the pivotal phase 3 trial in colorectal cancer, in which bevacizumab was 
given at 5 mg/kg q2w).25 
Bevacizumab  has been studied in a multitude of Phase I, II, and III clinical trials in more 
than 5000 patients and in multiple tumor types. In addition, data are available from 3,863 patients enrolled in two post- marketing studies in metastatic colorectal cancer (CRC ).  
Approximately 130,000 patients have been exposed to bevacizumab as a marketed product or in clinical trials.  The following discussion summarizes bevacizumab’s safety profile and presents some of the efficacy results pertinent to this particular trial.  Please 
refer to the bevacizumab Investigator Brochure for descriptions of all completed Phase I, II, and III trials reported to date.  In a large phase III study (AVF2107g) in patients with metastatic colorectal cancer, the addition of bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor (VEGF), to irinotecan/5 -fluorouracil/leucovorin (IFL) chemotherapy 
resulted in a clinically and statistically significant increase in duration of survival, with a hazard ratio of death of 0.67 (median survival 15.6 vs. 20.3 months; p < 0.001).  Similar increases were seen in progression -free survival (6.2 vs. 10.6 months; p < 0.001), overall 
response rate (35% vs. 45%; p < 0.01) and duration of response (7.1 vs. 10.4 months; p < 0.01) for the combination arm versus the chemotherapy only arm.
17 
 Based on the survival advantage demonstrated in Study AVF2107g, bevacizum ab was 
designated for priority review and was approved on 26 February 2004 in the United 
States for first -line treatment in combination with IV 5 -FU−based chemotherapy for 
subjects with metastatic colorectal cancer.  
 
Additional data from Phase III trials in metastatic CRC (E3200), non− small cell lung 
cancer (NSCLC; E4599), and metastatic breast cancer (E2100) have also demonstrated 
clinical benefit from bevacizumab when added to chemotherapy.  In Study E3200, the addition of bevacizumab to FOLFOX chemotherapy resulted in improved overall survival 
compared with FOLFOX alone (13.0 vs. 10.8 months, respectively, HR =  0.75; p <  0.01) 
in a population of previously treated CRC patients.   
 There was also improved overall survival in first- line NSCLC patients (E45 99) treated 
with carboplatin/paclitaxel +  bevacizumab compared with chemotherapy alone (12.3 vs. 
10.3 months, respectively; HR =  0.80; p = 0.003).  The results from this trial were the 
basis for FDA approval of bevacizumab for use in combination with 
carbo platin  + paclitaxel as first- line treatment of patients with unresectable, locally 
advanced, recurrent or metastatic, non-squamous NSCLC in October 2006.  Finally, 
patients with untreated metastatic breast cancer (E2100) who received bevacizumab in combination with weekly paclitaxel had a marked improvement in PFS compared with 
chemotherapy alone (13.3 vs. 6.7 months, respectively; HR =  0.48; p <  0.0001) (see the 
Bevacizumab Investigator Brochure for additional details). 
 
  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
8 Clinical Studies in Children  
Compassionate-use and p hase 1 trial s of bevacizumab as single agent have  been 
completed for children with refractory solid tumors.26, 27 In th ese studies , doses from 5 
mg/kg to 15 mg/kg every 2 weeks were well tolerated.   In the phase 1 study, eighteen of 
21 children completed ≥ 1 treatment cycle (median number of cycles 3, range 1 -16 
cycles). No dose limiting toxicity was seen nor was hemorrhage/thrombosis noted.  
Interestingly, the typical adverse events seen in adults —hypertension, proteinuria, arterial 
thromboembolic events, hemorrhage, congestive heart failur e (CHF), gastrointestinal 
perforations, wound healing complications, reversible posterior leukoencephalopathy syndrome and fistula formation—were not seen in children.
28 Bony toxicity was not 
observed, but cumulative toxicity could not be evaluated given the fairly short treatm ent 
duration with bevacizumab. Based on these results, phase 2 studies at doses similar to adults were recommended.  
 Additional studies of bevacizumab in combination with chemotherapy have been performed.
29-32  In one study of 10 patients with recurrent low grade gliomas, durable 
objective responses (up to 22 months) to combination chemotherapy with improvement in clinical function.  No dose- limiting toxicity was reported.
29  In a separate phase 2 study 
of 31 patients with recurrent malignant glioma and diffuse brainstem glioma, bevacizumab plus irinotecan was not effective; toxicity associated with chemotherapy included fatigue, hypertension, CNS hemorrhage (grade 1), and CNS ischemia (grade 4 in 2 patients).
30  In a retrospective study of 30 patients with a range of primary CNS 
tumors, bevacizumab was given with chemotherapy at a median dose of 9.5 mg/kg every 2 weeks.  No hemorrhage or thrombosis was noted in this cohort.  The toxicity profile was consistent with other studies including hypertension, proteinuria, lymphopenia, and delayed wound healing.
31 
 
Safety Profile 
 
Infusion -Related Reactions : Infusion reactions with bevacizumab were uncommon 
(<3%) and rarely severe (0.2%).  Infusion reactions may include rash, urticaria, fever, 
rigors, hypertension, hypotension, wheezing, or hypoxia. Currently, there is no adequate information on the safety of retreatment with bevacizumab in patients who have experienced severe infusion -related reactions.  
 In the initial Phase I and II clinical trials, four potentia l bevacizumab -associated safety 
signals were identified: hypertension, proteinuria, thromboembolic events, and hemorrhage.  Additional completed Phase II and Phase III studies of bevacizumab as well as spontaneous reports have further defined the safety profile of this agent. Bevacizumab-associated adverse events identified in phase III trials include congestive heart failure (CHF) primarily in metastatic breast cancer, gastrointestinal perforations, wound healing complications, and arterial thromboembolic events (ATE). These and other safety signals are described in further detail as follows and in the bevacizumab Investigator Brochure. 
 
Hypertension : An increased incidence of hypertension has been observed in patients 
treated with bevacizumab.  Grade 4 and  5 hypertensive events are rare. Clinical sequelae 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
9 of hypertension are rare but have included hypertensive crisis, hypertensive 
encephalopathy, and reversible posterior leukoencephalopathy syndrome (RPLS).33, 34  
 There is no information on the effect of bevacizumab in patients with uncontrolled hypertension at the time of initiating bevacizumab therapy.  Therefore, caution should be exercised before initiating bevacizumab therapy in these patients.  Monitoring of blood pressure is recommended during bevacizumab therapy.  Optimal control of blood pressure according to standard public health guidelines is recommended for patients on treatment with or without bevacizumab.   
 
Temporary interruption of bevacizumab therapy is recommended in patients with hypertension requiring medical therapy until adequate control is achieved.  If hypertension cannot be controlled with medical therapy, bevacizumab therapy should 
be permanently discontinued.  Bevacizumab should be permanently discontinued in patients who develop hypertensive crisis or hypertensive encephalopathy.  Proteinuria :  An increased incidence of proteinuria has been observe d in patients treated 
with bevacizumab compared with control arm patients.  In the bevacizumab-containing treatment arms of clinical trials (across all indications), the incidence of proteinuria (reported as an adverse event) was up to 38% (metastatic CRC Study AVF2192g). The severity of proteinuria has ranged from asymptomatic and transient events detected on routine dipstick urinalysis to nephrotic syndrome; the majority of proteinuria events have been grade 1. NCI -CTC Grade 3 proteinuria was reported in up to 3% of bevacizumab-
treated patients, and Grade 4 in up to 1.4% of bevacizumab- treated patients.  The 
proteinuria seen in bevacizumab clinical trials was not associated with renal impairment and rarely required permanent discontinuation of bevacizumab therapy.  Bevacizumab should be discontinued in patients who develop Grade 4 proteinuria (nephrotic syndrome).  Patients with a history of hypertension may be at increased risk for the development of proteinuria when treated with bevacizumab.  There is evidence from the dose-finding, Phase II trials (AVF0780g, AVF0809s, and AVF0757g) suggesting that Grade 1 proteinuria may be related to bevacizumab dose.  Proteinuria will be monitored by urine protein:creatinine (UPC) ratio at least every 6 weeks.  If the U PC ratio is not available, a dipstick urinalysis may be used to allow 
treatment to proceed.  
 Thromboembolic Events : Both venous and arterial thromboembolic (TE) events, ranging 
in severity from catheter -associated phlebitis to fatal, have been reported in patients 
treated with bevacizumab in the colorectal cancer trials and, to a lesser extent, in patients treated with bevacizumab in NSCLC and breast cancer trials.  
 
Venous thromboembolism (including deep venous thrombosis, pulmonary  
embolism, and thrombophlebitis) :  In the phase III pivotal trial in metastatic CRC, there 
was a slightly higher rate of venous TE events in patients treated with bevacizumab plus 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
10 chemotherapy compared with chemotherapy alone (19% vs. 16%).  
 
In Study AVF2107g, a Phase III, pivotal trial in metastatic CRC, VTE events, including deep venous thrombosis, pulmonary embolism, and thrombophlebiti s, occurred in 15.2% 
of patients receiving chemotherapy alone and 16.6% of patients receiving 
chemotherapy  + bevacizumab.  
 
The incidence of NCI- CTC Grade ≥  3 venous VTE events in one NSCLC trial (E4599) 
was higher in the bevacizumab -containing arm compared to the chemotherapy control 
arm (5.6% vs. 3.2%).  One event (0.2%) was fatal in the bevacizumab-containing arm; 
not fatal events were reported in the carboplatin/paclitaxel arm (see Bevacizumab Investigator Brochure).  In metastatic CRC clinical trials, the incidence of VTE events 
was similar in patients receiving chemotherapy  + bevacizumab and those receiving the 
control chemotherapy alone.  
 In clinical trials across all indications the overall incidence of VTE events was 
2.8%−17.3% in the bevaci zumab -containing arms compared with 3.2% −15.6% in the 
chemotherapy control arms.  The use of bevacizumab with chemotherapy does not 
substantially increase the risk of VTE event compared with chemotherapy alone.  However, patients with metastatic CRC who re ceive bevacizumab and experienced a 
VTE event may be at higher risk for recurrence of VTE event.  
 
Arterial Thromboembotic Events :  An increased incidence of ATE events was observed 
in patients treated with bevacizumab compared with those receiving a control treatment.  
ATE events include cerebrovascular accidents, myocardial infarction, transient ischemic attacks (TIAs), and other ATE events.  In a pooled analysis of data from five randomized Phase II and III trials (mCRC [AVF2107g, AVF2192g, AVF0780g]; loc ally advanced or 
metastatic NSCLC [AVF0757g]; metastatic breast cancer [AVF2119g]), the incidence rate of ATE events was 3.8% (37 of 963) in patients who received 
chemotherapy  + bevacizumab compared with 1.7% (13 of 782) in patients treated with 
chemotherapy alone.  ATE events led to a fatal outcome in 0.8% (8 of 963) of patients 
treated with chemotherapy  + bevacizumab and 0.5% (4 of 782) of patients treated with 
chemotherapy alone.  Cerebrovascular accidents (including TIAs) occurred in 2.3% of 
patients tr eated with  chemotherapy  + bevacizumab and 0.5% of patients treated with 
chemotherapy alone.  Myocardial infarction occurred in 1.4% of patients treated with 
chemotherapy  + bevacizumab compared with 0.7% of patients treated with chemotherapy 
alone. (S ee the Bevacizumab Investigator Brochure for additional details .) 
 
Aspirin is a standard therapy for primary and secondary prophylaxis of arterial 
thromboembolic events in patients at high risk of such events, and the use of aspirin ≤ 325 mg daily was allowed in the five randomized studies discussed above. Use of aspirin was assessed routinely as a baseline or concomitant medication in these trials, though safety analyses specifically regarding aspirin use were not preplanned. Due to the relatively small numbers of aspirin users and arterial thromboembolic events, 
retrospective analyses of the ability of aspirin to affect the risk of such events were inconclusive. However, similarly retrospective analyses suggested that the use of up to 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
11 325 mg of aspirin daily does not increase the risk of grade 1-2 or grade 3-4 bleeding 
events, and similar data with respect to metastatic colorectal cancer patients were presented at AS CO 2005.
35 Further analyses of the effects of concomitant use of 
bevacizumab and aspirin in colorectal and other tumor types are ongoing.  Gastrointestinal perforation :  Patients with metastatic carcinoma may be at increased 
risk for the development of gastrointestinal perforation and fistula when treated with bevacizumab and chemotherapy. Bevacizumab should be permanently discontinued in patients who develop gastrointestinal perforation. A c ausal association of intra-abdominal 
inflammatory processes and gastrointestinal perforation to bevacizumab  treatment has not been established. Nevertheless, caution should be exercised when treating patients with intra -abdominal inflammatory processes with bevacizumab. Gastrointestinal 
perforation has been reported in other trials in non-colorectal cancer populations ( e.g., 
ovarian, renal cell, pancreas, breast, and NSCLC) and may be higher in incidence in some tumor types.  Fistula :  Bevacizumab use has been associated with serious cases of fistulae including 
events resulting in death.  Fistulae in the GI tract are common (1% –10% incidence) in 
patients with metastatic CRC, but uncommon (0.1% −1%) or rare (0.01% –0.1%) in other 
indications.  In addition, fistulae that involve areas of the body other than the GI tract (e.g., tracheoesophageal, bronchopleural, urogenital, biliary) have been reported 
uncommonly (0.1% –1%) in patients receiving bevacizumab in clinical studies and 
postmarketing reports.  Events were reported at various time points  during treatment, 
ranging from 1  week to >  1 year following initiation of bevacizumab, with most events 
occurring within the first 6  months of therapy. 
 Permanently discontinue bevacizumab in patients with tracheoesophagea l fistulae , new 
gastrointestinal fistula (any grade),  or any Grade 4 fistula.  Limited information is 
available on the continued use of bevacizumab in patients with other fistulae.  In cases of internal fistula not arising in the GI tract, discontinuation of bevacizumab should be considered.  Wound healing complications : Wound healing complications such as wound dehiscence 
have been reported in patients receiving bevacizumab. In an analysis of pooled data from two trials in metastatic colorectal cancer, patients undergoing surgery 28-60 days before study treatment with 5 -FU/LV plus bevacizumab did not appear to have an increased risk 
of wound healing complications compared to those treated with chemotherapy alone.
36 
Surgery i n patients currently receiving bevacizumab is not recommended. No definitive 
data are available to define a safe interval after bevacizumab exposure with respect to wound healing risk in patients receiving elective surgery; however, the estimated half life  
of bevacizumab is 21 days. Bevacizumab should be discontinued in patients with severe wound healing complications.  If patients receiving treatment with bevacizumab require elective major surgery, it is recommended that bevacizumab be held for 4–8 weeks p rior to the surgical procedure.  
Patients undergoing a major surgical procedure should not begin or restart bevacizumab 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
12 until 4 weeks after that procedure. I n the case of high -risk procedures ( such as liver 
resection, thoracotomy, or neurosurgery) , it is recommended that chemotherapy be 
restarted no earlier than 6 weeks and bevacizumab no earlier than 8 weeks after surgery.  
 
Hemorrhage : Overall, grade 3 and 4 bleeding events were observed in 4.0% of 1132 
patients treated with bevacizumab in a pooled database from eight phase I, II, and III clinical trials in multiple tumor types.
17 The hemorrhagic events that have been observed 
in bevacizumab clinical studies were predominantly tumor- associated hemorrhage (see 
below) and minor mucocutaneous hemorrhage.   
Tumor -Associated Hemorrhage :  Major or massive pulmonary hemorrhage or 
hemoptysis has been observed primarily in patients with NSCLC.  Life- threatening and 
fatal hemoptysis was identified as a bevacizumab -related adverse event in NSCLC trials.  
These events occurred suddenly and presented as major or massive hemoptysis.  Among the possible risk factors evaluated (including squamous cell histology, treatment with anti-rheumatic/anti- inflammatory drugs, treatment with anticoagulants, prior 
radiotherapy, bevacizumab therapy, previous medical history of atherosclerosis, central tumo r location, and cavitation of tumors during therapy), the only variables that showed 
statistically significant correlations with bleeding were bevacizumab therapy and squamous cell histology. 
 GI hemorrhages, including rectal bleeding and melena have been reported in patients with CRC, and have been assessed as tumor- associated hemorrhages.  
 Tumor- associated hemorrhages were also seen rarely in other tumor types and locations, 
including a case of CNS bleeding in a patient with hepatoma with occult CNS metas tases 
and a patient who developed continuous oozing of blood from a thigh sarcoma with necrosis.  
 
Mucocutaneus Hemorrage :  Across all bevacizumab clinical trials, mucocutaneous 
hemorrhage has been seen in 20% -40% of patients treated with bevacizumab. These  were 
most commonly NCI-CTC Grade 1 epistaxis that lasted less than 5 minutes, resolved without medical intervention and did not require any changes in bevacizumab treatment regimen.  
 There have also been less common events of minor mucocutaneous hemorrhage in other locations, such as gingival bleeding and vaginal bleeding.  
 
Reversible Posterior Leukoencephalopathy Syndrome (RPLS) :  There have been rare 
reports of bevacizumab -treated patients developing signs and symptoms that are 
consistent with RPLS, a rare neurologic disorder that can present with the following signs 
and symptoms (among others):  seizures, headache, altered mental status, visual disturbance, or cortical blindness, with or without associated hypertension.  Brain imaging is mandatory to c onfirm the diagnosis of RPLS.  In patients who develop RPLS, 
treatment of specific symptoms, including control of hypertension, is recommended along with discontinuation of bevacizumab.  The safety of reinitiating bevacizumab therapy in 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
13 patients previously experiencing RPLS is not known.33, 34   
 
Congestive heart failure  (CHF) :  In clinical trials CHF was observed in all cancer 
indications studied to date, but predominantly in patients with metastatic breast cancer.  In the Phase III clinical trial of metastatic breast cancer (AVF2119g), 7 (3%) bevacizumab -treated patients exper ienced CHF, compared with two (1%) control arm 
patients.  These events varied in severity from asymptomatic declines in left ventricular ejection fraction (LVEF) to symptomatic CHF requiring hospitalization and treatment.  All the patients treated with bev acizumab were previously treated with anthracyclines 
(doxorubicin cumulative dose of 240− 360 mg/m
2).  Many of these patients also had prior 
radiotherapy to the left chest wall.  Most of these patients showed improved symptoms and/or left ventricular function following appropriate medi cal therapy .
37 
 In a randomized, Phase III trial of patients with previously untreated metastatic breast cancer (E2100), the incidence of LVEF decrease (defined as NCI -CTC Grade 3 or 4) in 
the paclitaxel  + bevacizumab arm was 0.3% versus 0% for the paclitaxel alone arm  
 No information is available on patients with preexisting CHF of New York Heart 
Association (N YHA) Class II −IV at the time of initiating bevacizumab therapy, as these 
patients were excluded from clinical trials.  
 
Prior anthracyclines exposure and/or prior radiotherapy to the chest wall may be possible risk factors for the development of CHF.  Caution should be exercised before initiating bevacizumab therapy in patients with these risk factors.  A Phase II trial in patients with refractory acute myelogenous leukemia reported 5  cases 
of cardiac dysfunction (CHF or LVEF decrease to < 40%) among 48 patients treated with 
sequential cytarabine, mitoxantrone, and bevacizumab.  All but 1 of these patients had significant prior exposure to anthracyc lines as well.
38  
 Other studies in patients with various tumor types and either a history of anthracycline exposure or concomitant use with bevacizumab are ongoing.   Patients receiving concomitant anthracyclines or with prior exposure to anthracyclines should have a baseli ne MUGA scans or echocardiograms (ECHOs) with a normal LVEF.  
 
Neutropenia :  Increased rates of severe neutropenia, febrile neutropenia, or infection 
with severe neutropenia (including some fatalities) have been observed in patients treated 
with some myelotoxic chemotherapy regimens plus bevacizumab in comparison to chemothe rapy alone.
39 
 Fertility and P regnancy.  Clinical data are lacking regarding the immediate or long -term 
effect of bevacizumab on fertility and pregnancy. However, bevacizumab is known to be teratogenic and detrimental to fetal development in animal models. In addition, bevacizumab may alter corpus luteum development and endometrial proliferation, thereby having a negative effect on fertility. As an IgG1, it may also be secreted in 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
14 human milk. Therefore, fertile men and women on bevacizumab studies must use 
adequate contraceptive measures  and women should avoid breast feeding.  The duration 
of such precautions after discontinuation of bevacizumab should take into consideration the half -life of the agent (average 21 days, ranging from 11 to 50 days). 
 Immunogenicity.  As a therapeutic protei n, there is a potential for immunogenicity with 
bevacizumab. With the currently available assay with limited sensitivity, high titer human anti-bevacizumab antibodies have not been detected in approximately 500 patients treated 
with bevacizumab.  
 Additiona l Adverse Events :  See the bevacizumab Investigator Brochure for additional 
details regarding the safety experience with bevacizumab.  
 
2.3 Rationale 
 
Patients with NF2 develop multiple tumors, including bilateral vestibular schwannomas, meningiomas, and ependymomas.  As bilateral VS enlarge, they cause sensorineural hearing loss and, ultimately, complete deafness. Disease -specific mortality is extremely high for NF2 with 
greater than 90% of NF2 patients dying from their disease or from complications in th e 
immediate post -operative period.
40 Standard treatment options for VS include surgery or 
radiation, which often cause hearing loss or cranial nerve dysfunction.  Sporadic and NF2- related 
vestibular schwannomas express vascular endothelial growth factor (VEGF).  Bevacizumab is an antibody that binds VEGF with high affinity and is approved for treatment of multiple cancers including glioblastoma.  Our initial experience treating ten NF2 p atients at risk for complete 
hearing loss or brainstem compression with bevacizumab on compassionate -care basis showed 
promising results with 6/10 patients experiencing ≥ 20% tumor volume reduction and 4/7 experiencing significantly improved hearing.
6  The proposed trial is designed to confirm the 
clinical response rate of bevacizumab in a larger cohort of pediatric patients with NF2 treated at multip le centers.  Because patients with NF2 have long life expectancy, the optimum duration of 
treatment with bevacizumab is an important question to address.  An exploratory aim of this study is to determine the durability of clinical response to bevacizumab i n subjects with 
progressive vestibular schwannomas who either respond to therapy or experience stable disease after initial treatment.  
  
2.4 Correlative Studies Background  
 Our study and others suggest that there are dose - and time -dependent increases in soluble 
VEGF and PlGF and decreases in soluble VEGFR following treatment with anti -angiogenic 
agents  
19, 41, 42. Our studies have also shown that circulating biomarkers can help predict 
tumor progression. For example, progression of glioblastoma during treatment with AZD2171 is ass ociated with significant increases in basic fibroblast growth factor (b -FGF) 
and stromal cell -derived factor 1 alpha (SDF -1α), whereas progression in hepatocellular 
carcinoma after sunitinib is correlated with increases in IL -6 and SDF -1α. Finally, we found 
that baseline sVEGFR1 concentration in plasma may predict response to bevacizumab therapy in rectal cancer patients 
41. 
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
15 There is no published data on  molecular biomarkers for anti -VEGF agents in patients with 
NF2 and this study proposes to analyze baseline biomarkers with respect to outcomes 
(response) as well as the possible effect of bevacizumab on bioma rker levels over time  (see 
section 8.3.1). 
 
3. PARTICIPANT SELECTION  
 
3.1 Eligibility Criteria  
 
Participants must meet the following criteria on screening examination to be eligible to 
participate in the study:  
3.1.1 Patients must have a confirmed diagnosis of neurofibromatosis 2 by fulfilling 
National Institute of Health (NIH) criteria or Manchester criteria, or by detection of a causative mutation in the NF2  gene.     
   The NIH criteria
43 includes presence of:  
• Bilateral vestibular schwannomas, OR  
• First-degree relative with NF2 and EITHER  unilateral eighth nerve mass 
OR two of the following: neurofibroma, meningioma, glioma, 
schwannoma, juvenile posterior subcapsular lenticular opacity. 
     The Manchester criteria
44 includes presence of:  
• Bilateral vestibular schwannomas, OR  
• First-degree relative with NF2 and EITHER  unilateral eighth nerve mass 
OR two of the following: neurofibroma, meningioma, glioma, 
schwannoma, juvenile posterior subcapsular lenticular opacity, OR 
• Unilateral vestibular schwannoma AND any two of: neu rofibroma, 
meningioma, glioma, schwannoma, juvenile posterior subcapsular lenticular opacity, OR  
• Multiple meningiomas (two or more) AND unilateral vestibular 
schwannoma OR  any two of: schwannoma, glioma, neurofibroma, 
cataract . 
3.1.2 Patients must have measurable disease, defined as at least one VS   > 0.4 ml (on 
volumetric analysis ) that can be accurately measured by contrast -enhanced cranial 
MRI scan with fine cuts through the internal auditory canal (3 mm slices, no skip).  
 
3.1.3 Age  ≥ 6 years  on day 1 of t reatment .   
 
3.1.4 Life expectancy of greater than 1 year.  
 
3.1.5 Karnofsky performance status  ≥ 70 (see Appendix C). 
  
3.1.6 Participants must have normal organ and marrow function as defined below: 
• Leukocytes > 3,000/mcL  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
16 • Absolute neutrophil count > 1,500/mcL  
• Platelets > 100,000/mcL  
• Total bilirubin within normal institutional limits  
• AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal  
• Patients must have a creatinine clearance or radioisotope GFR 
≥60ml/min/1.73 m2 or a normal serum creatinine based on age /gender 
described in the table below :     
 
Age 
 Maximum Serum  
Creatinine (mg/dL)  
 Male  Female  
6 to < 10 years  1 1 
10 to < 13 years  1.2 1.2 
13 to < 16 years  1.5 1.4 
≥ 16 years  1.7 1.4 
 The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and stature data published by the CDC. 
 3.1.7 Subjects must have a target VS with the following qualities:  
• Not amenable to surgery due to patient refusal , high risk for surgical 
complications ( e.g., damage to lower cranial nerve function, tumor size > 3 
cm in longest diameter, or multilobulated tumor appearance on MRI scan).  
• Associated with a word recognition score of < 85%  and > 5%  
• Documented clinical progression defined as EITHER :  
• Progressive hearing loss ( defined as a de cline in word recognition score 
below the 95% critical differenc e interval from baseline score (Appendix A ) 
related to VS ( i.e., not due to prior interventions such as surgery or 
radiation)   
OR  
• Progressive tumor growth in the preceding 1 8 months, defined as ≥ 20% 
increase in volume  
3.1.8 The effects of bevacizumab on the developing human fetus are unknown. For this reason and because bevacizumab agents are known to be teratogenic, women of child -bearing potential and men must agree to use adequate contraception 
(hormonal or barrier method of birth control; abstinence ; surgical sterilization ) prior 
to study entry and for the duration of study participation. Should a woma n become 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
17 pregnant or suspect she is pregnant while participating in this study, she should 
inform her treating physician immediately.  
   
3.1.9 Ability to understand and the willingness to sign written informed consent and assent documents.  
 
3.1.10  Must have established  relationship with primary care physician and provide contact 
information  
 
3.2 Exclusion Criteria  
 Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study.  
 
3.2.1 Patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.  Prior radiation treatment to the target vestibular schwannoma is allowed if provided 3 years prior to participation in the clinical trial.  Prior radiation treatment to non -
target tumors is allowed.   
 3.2.2 Participants may not be receiving any other study agents.  
 
3.2.3 Patients with nervous sy stem tumors associated with NF2 ( e.g., schwannomas, 
meningiomas, ependymomas, or gliomas) will not be excluded from this clinical 
trial unless (in the opinion of the investigator) these tumors are growing and are 
likely to require treatment during the clinical trial. 
 
3.2.4 History of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab. 
 
3.2.5 Patients with known hypersensitivity of Chinese hamster ovary cell products, other recombinant human antibodies, or compounds of  similar chemical or 
biologic composition to bevacizumab.  
 
3.2.6 Inability to tolerate periodic MRI scans or gadolinium contrast.  
 
3.2.7 Uncontrolled intercurrent illness including, but not limited to ongoing or active 
infection, unstable angina pectoris , or psychiatric illness/social situations that 
would limit compliance with study requirements.  
 
3.2.8 History of arterial/myocardial disease . 
 
3.2.9 Clinically significant cardiovascular disease, such as : 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
18 • Inadequately controlled HTN (for adults: SBP > 160 mmHg and/or DBP > 
90 mmHg despite antihypertensive medication ; for children: please refer to 
Appendix D for age -appropriate values indicating ≥ Grade 2 ) 
• History of CVA within 12 months 
• Myocardial infarction or unstable angina within 12 months 
• New York heart association grade II or greater congestive heart failure  
• Serious and inadequately controlled cardiac arrhythmia 
• Significant vascular disease ( e.g., aortic aneurysm, history of aortic 
dissection) 
• Clinically significant peripheral vascular disease  
 
3.2.10  Pregnant women are ex cluded from this study because bevacizumab  is an anti -
angiogenic agent with the potential for teratogenic or abortifacient effects. Because 
there is an unknown but potential risk of adverse events in nursing infants 
secondary to treatment of the mother with bevacizumab , breastfeeding should be 
discontinued if the mother is t reated with bevacizumab . These potential risks may 
also apply to other agents used in this study.  
  
3.2.11  HIV-positive patients or cancer survivors are eligible for this study if they fulfi ll all 
other eligibility criteria . 
 
3.2.12  Concurrent use of anti -coagulant drugs (not including prophylactic doses), history 
of coagulopathy, or evidence of bleeding diathesis or coagulopathy.  
 
3.2.13  Imaging (CT or MRI) evidence of hemorrhage deemed significant by the  treating 
physician  (> grade 1) .  Subjects with history of CNS hemorrhage are not eligible . 
 
3.2.14  Urine protein should be screened by urine analysis for Urine Protein Creatinine (UPC) ratio.  For UPC ratio > 0.5, 24 -hour urine protein should be obtained and the  
level should be <1000 mg for patient enrollment. NOTE : UPC ratio of spot urine is 
an estimation of the 24 -urine protein excretion. A  UPC ratio of 1 is roughly 
equivalent to a 24 -hour urine protein of 1 gm.  UPC ratio is calculated using one of 
the followi ng formula s: 
•  [urine protein]/[urine creatinine] – if both protein and creatinine are reported in mg/dL 
•  [(urine protein) x0.088]/[urine creatinine] – if urine creatinine is reported in mmol/L  
3.2.15  Serious or non- healing wound, ulcer or bone fracture.  
3.2.16  History of abdominal fistula, gastrointestinal perforation or intra -abdominal abscess 
within 6 months prior to Day 1.  
3.2.17  Invasive procedures defined as follows:  
• Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1 therapy  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
19 • Brain biopsy within 28 days prior to day 1 of therapy (wounds must be fully 
healed from brain biopsies performed more than 28 days prior to Day 1 of therapy)  
• Anticipation of need for major surgical procedures during the course of the study 
• Core biopsy within 7 days prior to D ay 1 of therapy  
3.2.18  Prior treatment with bevacizumab.  
3.3 Inclusion of Women, Minorities and Other Underrepresented Populations  
 
Both men and women, and members of all races and ethnic groups are eligible for this trial.   
 
4. REGISTRATION PROCEDURES  
   
4.1 General Guidelines for NF Consortium Institutions  
 
Institutions will register eligible participants through a web -based data entry 
system created for that purpose by the NF Consortium Data Management and 
Analysis Center  (DMAC) . Registration must occur prior to the initiation of therapy. 
Any participant not registered to the protocol before treatment begins will be considered ineligible and registration will be denied.  
 
A physician on  the study team will confirm eligibility criteria and complete the 
protocol -specific eligibility checklist.  
  
Following registration, participants may begin protocol treatment. Issues that 
would cause treatment delays should be discussed with the  protocol  Principal 
Investigator (PI) .  
 
4.2 Registration Process  for NF Consortium Institutions  
 
The registration procedures are as follows:  
 
1. Obtain written informed consent from the participant prior to the performance of any study related procedures or assessments.  
 
2. Complete the protocol -specific eligibility checklist using the eligibility 
assessment documented in the participant’s medical/research record. To be 
eligible for registration to the study, the participant must meet each 
inclusion and exclusion criteria listed on the eligibility checklist.  
 
3. Enrollment and exclusion criteria will be entered through the NF Consortium ’s 
web-based data entry system after receiving email confirmation from the 
Protocol PI ( or his designee) that consented subject is eligible for study entry.  
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
20 4. NF Consortium ’s web-based data entry system  will send enrollment 
confirmation via automated email alerts to study protocol team, Operations 
Center , site PI and site study coordinator. 
 
4.3 General Guidelines for all Participating Institutions  
 
The required forms  for subject registration can be found on the UAB  online entry 
system . 
 
Following registration, participants should begin protocol treatment within 28 days . 
Issues that would cause treatment delays should be discussed with the Principal 
Inves tigator. If a participant does not receive protocol therapy following registration, 
the participant’s protocol status must be changed. The Research Nurse Manager  
(Operations Center)  should be notified of participant status changes  as soon as 
possible by email.  
 
Each participating institution will order the study agent from  the UAB Research 
Pharmacy . A participating site may order the agent  only after the initial IRB approval 
for the site has been forwarded by the Operations Center . 
 
4.4 Registration Process f or All Participating Institutions  
 
To register a participant, the following documents should be completed and information 
entered online by the study  coordinator or designee:  
• CBC, Chemistry -12, urinalysis, urine protein:creatinine ratio  
• Confirmation of signed study consent form 
• Confirmation of HIPAA authorization form  
• Confirmation of acceptability of baseline audiology by clinical research team 
in Principal Investigator’s office (Dr. Scott Plotkin) or Dr. Chris Halpin 
(Massachusetts Eye and Ear Infirmary)  
• Confirmation of baseline MRI scan including internal auditory ca nal 
protocol (3 mm slic es, 0 mm gap)  
• Completion of Inclusion/ Exclusion , Eligibility Checklist, and 
Registration form s located on the  UAB  web -based data entry  system . 
 
NOTE : Registration with NF Consortium’s  web-based data entry system can be 
conducted anytime , but the DMAC  support can only be provided during the business 
hours of 8am – 5pm CST Monday through Friday.  Study sites are responsible for 
arranging initial and follow -up study treatments.   
 
5. TREATMENT PLAN   
 
Treatment will be a dministered on an outpatient basis. Expected toxicities and potential 
risks as well as dose modifications for bevacizumab are described in Section 6 (Expected 
Toxicities and Dosing Delays/Dose Modification).  Reported adverse events and potential risks are  described in Section 2.1.  N o investigational or commercial agents or therapies 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
21 other than those described below may be administered with the intent to treat the 
participant’s malignancy.  
 Bevacizumab is administered  by IV infusion at a dose of 10 mg/kg e very 2  weeks for 24 
week s (induction therapy, see Schema).  One cycle lasts 28 days and includes two infusions 
of bevacizumab.  Clinical response will be assessed by audiology and MRI at weeks 13 and 25.  Subjects with hearing decline at weeks 1 3 and 2 5 will be taken off of protocol.  A fter 
week 2 5, patients with a clinical response or stable disease (together comprising “clinical 
benefit”) will transition to maintenance therapy with bevacizumab.  During the maintenance phase, subjects will be treated wi th open- label bevacizumab 5 mg/kg every 3 weeks for up 
to 72 weeks.  Subjects will be followed with audiology and MRI scans every 12 weeks.  The 
total time of the study will be 96 weeks ( 24 week  induction + 72 weeks maintenance).  
   
During maintenance therapy, subjects will be allowed to increase their bevacizumab dose to 10 mg/kg every 2 weeks if they experience hearing decline (defined as decrease in word recognition score below the 95% critical difference compared with the word recognition score at baseline, Appendix A) compared with the highest  word recognition score during 
treatment .  Subjects will be taken off of study if their word recognition drops below the 95% 
critical difference  (new hearing baseline defined as  the word recognition score leadi ng 
subject to receive 10 mg/kg dose every 2 weeks) after receiving bevacizumab 10 mg/kg every 2 weeks  for at least 12 weeks .   
 
The planned treatment duration will be 96 weeks, but continued therapy on study will be allowed at the study chair’s discretion based on individual risk- benefit assessment. The 
consequence of treatment interruption/discontinuation in subjects who respond to treatment is not known. For example, discontinuation of VEGF receptor inhibitors has been associated with rebound edema in som e patients with recurrent glioblastoma.
45   
 
5.1 Pre-treatment Criteria  
 
5.1.1 Cycle 1, Day 1  
   Patients must have organ and marrow function as defined below: 
 
• leukocytes >3,000/mcL 
• absolute neutrophil count >1,500/mcL 
• platelets  >100,000/mcL 
• creatinine  < 1.5 ULN for age 
• total bilirubin  ≤2 X institutional ULN  
• AST(SGOT)/ALT(SGPT)  ≤2.5 X institutional ULN  
• urine protein:creatinine ratio  ≤ 1 
    
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
22 5.1.2 Subsequent Cycles, Day 1  
 
  Patients must have organ and marrow function as defined below:  
• leukocytes >3,000/mcL 
• absolute neutrophil count >1,500/mcL 
• platelets  >100,000/mcL 
• creatinine  < 1.5 ULN for age 
• total bilirubin  ≤2 X institutional ULN  
• AST(SGOT)/ALT(SGPT)  ≤2.5 X institutional ULN  
• urinary dipstick /urinalysis ≤ 2+ protein 
• urine protein:creatinine ratio  < 3.5 (if urine dipstick > 2+) 
 
Special Precautions/Safety Issues  
Prior to each treatment, the patient should be carefully assessed with special attention to 
blood pressure, proteinuria, bleeding and cardiovascular events, as well as symptoms or signs of bowel perforation and RPLS.  Decisions for retreatment or dose modification/interruption should follow the dose modification guidelines in Section 6.3. 
 
Patients who have an ongoing study agent-related serious adverse event upon study completion or at discontinuation from the study will be contacted by the investigator or  
his/her designee periodically until the event is resolved or determined to be irreversible.  Infusion al reactions . Routine premedication is not required for the first dose of 
bevacizumab. If infusional reactions occur, acetaminophen, diphenhydramine, steroids or other medications may be given for symptom control and for premedication as needed. Anaphylactic precautions should be observed during bevacizumab administration.  Hypertension . Patients should have BP monitored prior to each infusion of bevacizumab. 
Hypertensive medi cation should be initiated or increased for optimal BP control 
according to Appendix D. Specific guidelines for the management of hypertension are provided for children 6 through 17 years old enrolled on this trial (Sections 6.3 and Appendix D ). 
 
Proteinuria . Proteinuria should be monitored by urine protein: creatinine (UPC) ratio and  
dipstick as indicated in study calendar.  If urine dipstick ≤ 2+ protein, bevacizumab can 
be infused.  If urine dipstick > 2+, infusion can be provided once the UPC ratio is reported to be < 3.5.  Surgery and wound complication issues. The appropriate interval from discontinuation of bevacizumab to subsequent elective surgery required to reduce the risk of impaired wound healing has not been determined. Decision on such an interval should take into consideration the half- life of bevacizumab. It is generally recommended that 
bevacizumab should be discontinued at least 4-8 weeks prior to major elective surgery. In addition, bevacizumab should not be restart ed until at least 4 weeks after major surgery 
provided that the wound has adequately healed; in cases of high-risk procedures such as 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
23 liver resection, thoracotomy or neurosurgery, it is recommended that bevacizumab be 
resumed no earlier than 8 weeks after surgery.  NOTE : If bevacizumab is interrupted for 
ANY reasons for > 12 weeks, the patient should discontinue bevacizumab therapy on protocol. 
 
Bony toxicity . Children 6 through 17 years old will be carefully monitored for the 
development of bony toxicity (Sections 6.3 and Appendix E ). 
 For patients with open growth plates on tibial radiographs at baseline , measurements of 
stature (height) will be measured at visits on  week s 13, 25, 49, 73, and 91.  Bevacizumab 
will be discontinued if: 
 
• <1 cm growth is noted prior to week 25  
• <2.5 cm growth is noted prior to week 49 
• Subsequently, <2cm/year annualized growth velocity noted every 24 weeks ( for 
patients with open growth plates only)  
5.2 Bevacizumab Administration   
 
Bevacizumab is administered  by IV infusion at a dose of 10 mg/kg every 2 weeks  
(dose level +1)  for 24 weeks  (induction therapy) followed by a dose of 5 mg/kg every 3 
weeks (dose level 0) for 72 weeks (maintenance therapy).  During induction therapy, 
one cycle lasts 28 days  and includes two infusions of bevacizumab; during 
maintenance therapy, one cycle lasts 42 days and includes two infusions.  The dose should be based on the patient’s actual body weight.   The first dose of bevacizumab should be given over 90 minutes.  If well- tolerated, the second dose can be given over 
60 minutes. If this dose is well tolerated, then all subsequent infusions can be administered over 30 minutes. If an infusion reaction occurs, subsequent doses of bevacizumab should be administered over the shortest period that was well tolerated.   
 
5.3 Definition of Dose -Limiting Toxicity  
 
N/A 
 
5.4 General Concomitant Medication and Supportive Care Guidelines  
 
There is no known interaction of bevacizumab with other concomitantly administered drugs. Prophylactic low-dose (81 mg or 325 mg/day) acetylsalicylic acid and systemic anticoagulation is allowed (LMWH preferred relative to warfarin). Other medication considered necessary for the subject’s safety and well being may be given at the discretion of the investigator.  Prolonged systemic corticosteroid treatment should not be given during the study, except for topical applications ( e.g., rash), inhaled sprays ( e.g., obstructive airways 
diseases), eye drops or local injections ( e.g., intra- articular). A short duration (≤ 15 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
24 days) of systemic corticosteroids is allowed ( e.g., for sudden hearing loss, chronic 
obstructive pulmonary disease, or as an anti- emetic).   
 
Cases of sudden hearing loss during treatment (defined as hearing loss with onset over a period of less than 72 hours) may be treated with a  short course of high dose 
glucocorticoids ( e.g., prednisone 60 mg daily for 10 days followed by a taper of 10 mg 
every day ).  These patients should have repeat audiology performed during the episode 
at the discretion of the treating physician to document hearing function (see section 5.5 for guidance on continuing therapy).  
 
5.5 Duration of Therapy  
 
In the absence of treatment delays due to adverse event( s), treatment may continue for 2 
years (96  weeks) or until one of the following criteria applies (whichever occurs first): 
  
• Hearing decline at the 10 mg/kg every 2 week dose during induction therapy .  NOTE:  Patients with episodes of sudden hearing loss (Section 5.4) or 
hearing loss related to other causes (e.g., otitis media, allergic symptoms, or other infectious causes) should remain on treatment provided their word recognition score returns to the 95% cri tical difference compared with baseline [Appendix A] 
within 14 days of the start of the event.) 
• Hearing decline  at the 10 mg/kg every 2 week dose during maintenance 
therapy (hearing decline  is defined as a d ecline in word recognition score below 
the 95% cr itical difference interval from word recognition score leading subject to 
receive 10 mg/kg dose [Appendix A] ) after receiving bevacizumab 10 mg/kg every 2 weeks  for at least 12 weeks .  NOTE:  Patients with episodes of sudden 
hearing loss ( Section 5.4) or h earing loss related to other causes (e.g., otitis media, 
allergic symptoms, or other infectious causes) should remain on treatment provided their word recognition score returns to  the 95% critical difference  
compared with baseline [Appendix A] within 14 da ys of the start of  the event.) 
• Radiographic progression of NF2- associated tumors (target VS, contralateral VS, 
meningiomas, or ependymomas) that require additional or alternate therapies  
(Section 10.1.4); ( NOTE : Growth of NF2- associated tumors that is consistent 
with the natural history of the disease is not a criterion for discontinuing protocol therapy .) 
• Intercurrent illness that prevents further administration of treatment; 
• Unacceptable adverse event(s), including, but not limited to:  
o Grade 4 hypertension or Grade 3 hypertension not controlled with medication  
o Nephrotic syndrome  
o Grade ≥ 2 pulmonary or CNS hemorrhage; any Grade 4 hemorrhage  
o ≥ Grade 2 venous thromboembolic event  
o Any grade arterial thromboembolic event  
o ≥ Grade 2  congestive heart failure  
o Gastrointestinal perforation or new gastrointestinal fistula (any Grade)  
o Tracheoesophageal fistula (any grade) or Grade 4 fistula  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
25 o Grade ≥ 2 bowel obstruction  
o Wound dehiscence requiring medical or surgical intervention  
o Pregnancy during the study period (for female participants)  
o All Grade 4 events thought to be related to bevacizumab by the 
investigator  (NOTE:  Patients who have an ongoing bevacizumab-
related Grade 4 or serious adverse event at the time of discontinuation from study treatment will continue to  be followed until resolution of 
the event or until the event is considered irreversible [S ee Section 
7.1.3].) 
• Participant decides to withdraw from the study ; or 
• General or specific changes in the participant's condition render the participant  
unacceptable for further treatment in the opinion of the treating investigator . 
 
Withdrawal of full consent for a study means that the subject does not wish to receive  
further investigational treatment and does not wish to or is unable to continue further  
study participation; subject data up to withdrawal of consent will be included in the  
subject’s study data. Any subject may withdraw full consent to participate in the study at any time during the study. The investigator will discuss with the subject appr opriate  
procedures for withdrawal from the study.  
Withdrawal of partial consent means that the subject does not wish to take protocol- speci fied product any longer but is still willing to collaborate in providing  
further data by continuing on study (eg, pa rticipate in any or all subsequent study visits or 
procedures). Subjects may decline to continue receivi ng protocol -specified product  at any 
time during the study. If this occurs, the investigator will discuss with the subject  
appropriate procedures for wi thdrawal from protocol- specified therapy . These  subjects, as 
well as those who have stopped receiving protocol -specified product(s) for other reasons 
(eg, investigator or sponsor concern) should continue the schedule of  study observations  
at the discretion  of the principal investigator . 
 
NOTE : A course of high dose glucocorticoids (typically prednisone 60 mg daily for 10 
days followed by a taper of 10 mg every day ) is permitted at the discretion of the treating 
physician in cases of sudden hearing loss during treatment (defined as hearing loss with onset over a period
 of less than 72 hours).  
 
5.6 Duration of Follow- Up  
 
Participants will be followed  in person or by telephone  for 12 weeks after 
removal from study . Participants removed from study for unacceptable adverse 
events will be followed until resolution or stabilization of the adverse event.  
  
5.7 Criteria for Removal from Study  
 
Participants will be removed from study when any of the criteria listed in Section 5.5 applies. The reason for study removal and the date the participant was 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
26 removed must be documented in the data entry system . Alternative care options 
will be discussed with the participant.  
 
In the event of unusual or life -threatening complications, participating investigators 
must immediately notify the Principal Investigator (or Protocol Chair), Scott 
Plotkin, MD, PhD at 617- 726- 2000 (pager #34635) and Bruce Korf, MD, PhD, at 
205- 934-9411  (UAB Operations Center  Office ) or Liz Davis at 205- 934-5376  
(Research Nurse  Manager ) or email: nfconsortium@uab.edu . 
 
6. EXPECTED TOXICITIES AND DOSING DELAYS/DOSE MODIFICATIONS  
 
A number of measures will be taken to ensure the safety of patients participating in this trial.  These measures will be addressed through exclusion criteria (see Section 3.2) and routine 
monitoring as follows. 
Patients enrolled in this study will be evaluated clinically and with standard laboratory tests 
before and at regular intervals during their participation in this study.  Safety evaluations will consist of medical interviews, recording of adverse events, physical examinations, blood pressur e, and laboratory measurements.  Patients will be evaluated for adverse events 
(all grades), serious adverse even ts, and adverse events requiring study drug interruption or 
discontinuation at each study visit for the duration of their participation in the study.  Patients discontinued from the treatment phase of the study for any reason will be evaluated ~30 days (28–42 days) after the decision to discontinue treatment (see Section 5.5).   
Specific monitoring procedures are as follows: 
• Hypertension will be monitored through routine evaluation of blood pressure prior to 
each bevacizumab treatment.  Optimal control of blood pressure is recommended for 
patients on treatment with or without bevacizumab. Blood pressure monitoring during 
study drug administration should be performed according to institutional guidelines. 
• Proteinuria will be monitored by urine protein:creatinine (UPC) ratio and  
urinalysis/ dipstick at least every 6 weeks.  
• If patients on treatment with bevacizumab require major surgery, it is recommended that bevacizumab be held for 4-8 weeks prior to the surgical procedure. Patients 
undergoing a major surgical procedure should not begin/restart bevacizumab until 4 weeks after that procedure. In the case of high risk procedures ( such as liver 
resection, thoracotomy, or neurosurgery) , it is recommended that chemotherapy be 
restarted no earlier than 6 weeks and b evacizumab no earlier than 8 w eeks after 
surgery.  
 
Dose delays and modifications will be made using the following recommendations. Toxicity assessments will be done using the CTEP Version 4.03 of the NCI Common Terminology Criteria for Adverse Events (CTCA E) which is identified and located on the CTEP website 
at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
 
 
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
27 Dose Level  Bevacizumab  Dose  
-2 3 mg/kg IV every 3 weeks  
-1 4 mg/kg IV every 3 weeks  
0 5 mg/kg IV every 3 weeks  
+1 10 mg/kg IV every 2 weeks 
If possible, symptoms should be managed symptomatically. In the case of toxicity, 
appropriate medical treatment should be used (including anti -emetics, anti -diarrheals, etc.).  
 
All adverse events experienced by participants will be collected from the time of the first dose of study treatment, through the study and until the final study visit. Participants continuing to experience toxicity at the off study visit may be contacted for additional assessments until the toxicity has resolved or is deemed irreversible. 
 
6.1 Anticipated Toxicities  
  
Toxicities with a possible association to bevacizumab treatment include:  
 
Frequent (Chance of 10- 50% that this will happen) 
• Fatigue  
• Headaches  
• High blood pressure, with increased risk of heart problems, headache and stroke.  
• Pain 
• Abdominal pain 
• Shortness of breath 
• Mouth sores  
• Weakness  
• Upper respiratory infection  
• Chills  
• Loss of appetite 
• Bleeding (including in  stomach or intestines) 
• Runny nose or increase in tears in your eyes  
• Kidney damage, found by testing your urine 
• Irregular menstrual period  or loss of menstrual period 
• Loss of function of the ovaries (female sex glands), that can lead to menopause.  
Studies in humans have shown a decrease in the function of ovaries during treatment with bevacizumab with chemotherapy.  This condition results in difficulty becoming pregnant.  In some participants, the function of the ovaries returned to normal after treatment  with bevacizumab and chemotherapy was 
stopped.  
 
Occasional (Chance of 5- 10% that this will happen)  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
28 • Hoarseness  
• Nosebleeds 
• Low levels of potassium in the blood (can cause an irregular heartbeat)  
• Hair loss  
• Dry Skin  
• Hole in your intestine; requires hospitalization and/or surgery; could be fatal.  
• Blood clots in your veins and arteries.  These can cause chest pain, heart attack, or 
stroke.  A blood clot in your eye might cause vision loss.  Clots can be serious and 
life threatening.  
• Allergic reaction when infusion is given.  Serious allergic reaction may result in 
death.  
• Slowed growth in height and development (for children and young adults who are 
still growing).  Laboratory studies have shown a decreased in growth during treatment with bevacizumab  .   
 
Rare (Chance < 5% that this will happen)  
• Congestive heart failure (fluid that builds up in your lungs because your heart isn’t 
working properly). 
• Bevacizumab might affect the ability of your wounds to heal.  This can lead to 
infections, hospitalization , or could possibly be fatal. 
• A very rare problem in your brain that may cause confusion, blindness, and coma has been seen in some patients that were given Bevacizumab.  This is associated with very high blood pressure and is not thought to be a permanent condition. 
• Confusion 
• Abdominal abscess or infection in your abdomen 
• Fistula or hole in your bowel.  This is an abnormal connection between two different organs and may lead to life threatening complications including serious infections, bleeding, or dysfunction of the organs. 
• Dehydration  
• Abnormal bleeding in your body or from the tumor, which may be fatal. 
• Laboratory studies of bevacizumab showed abnormal bone growth.  These and other effects of bevacizumab could possibly cause problems with growth and development.  Abnormal changes in the bones after treatment with bevacizumab 
have been seen in young children with growing bones.  This side effect appeared to be reversible after the drug was stopped, but has not been studied with long- term 
use of the drug.  All participants in this study who receive bevacizumab and are still growing will be monitored for changes to bones by the use of x-rays performed throughout the study treatment. 
• Fistula or hole in your gallbladder (part of the intestines that helps with digestion).  This may require surgery and be serious or life threatening. 
• Osteonecrosis of the jaw.  A severe bone disease in which the jaw bone becomes visible (exposed) inside the mouth. This can be associated with pain and infection.    
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
29 6.2 Toxicity Management 
  
Any toxicities associated or possibly associated with bevacizumab treatment should be 
managed according to standard medical practice. Discontinuation of bevacizumab will have no immediate therapeutic effect. Bevacizumab has a terminal half -life of 21 days; 
therefore, its discontinuation results in slow elimination over several months. There is no available antidote for bevacizumab.  
 
6.3 Dose Modifications/Delays 
  
A list of the adverse events and potential risks associated with the agents administered 
in this study appear below . 
NOTE  1: Treatment should be interrupted or discontinued for certain adverse events, 
as described below. Doses missed while recovering from toxicity will not be made up.  The AEs will be defined based on CTCAE term (AE description) and grade.  The descriptions and grading scales found in the CTEP Version 4.03 of the NCI Common Terminology Criteria for Adverse Events (CTCAE) will be utilized for AE reporting.   
The CTEP Version 4.03 of the CTCAE is identified and located on the CTEP website at: http://ctep.cancer.gov/.  All appropriate treatment areas will have access to a copy of the CTEP Version 4.03 of CTCAE.  Details of actions to be taken based on a particular AE (using the most active CTCAE version) are provided below.  
 
NOTE  2: If bev acizumab is interrupted for ANY reasons for > 12 weeks, the patient 
should discontinue bevacizumab therapy on protocol. 
 
NOTE  3: Subjects will be allowed to increase their bevacizumab dose to 10 mg/kg 
every 2 weeks during maintenance therapy if they experience hearing decline during maintenance therapy (defined as decrease in word recognition score below the 95% critical difference  compared with the word recognition score at baseline, Appendix A ).  
Subjects will be taken off of study if their word recognition score does not remain within the 95% critical difference (determined from word recognition score leading subject to receive 10  mg/kg dose) after receiving bevacizumab 10 mg/kg every 2 weeks  
for at least 3 months.   
 Subjects should be assessed clinically for toxicity prior to, during, and after each infusion. If unmanageable toxicity occurs because of bevacizumab at any time duri ng 
the study (T able 1) , treatment with bevacizumab should be discontinued.  
 
Infusion Reaction : Infusion of bevacizumab should be interrupted for subjects who 
develop dyspnea or clinically significant hypotension. Subjects w ho experience a NCI 
CTCAE v. 4.3  Grade 3 or 4 allergic reaction / hypersensitivity, adult respiratory 
distress syndrome, or bronchospasm (regardless of grade) will be discontinued from bevacizumab treatment. 
 The infusion should be slowed to 50% or less or interrupted for subjects who experience any infusion -associated symptoms not specified above. When the subject’s 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
30 symptoms have completely resolved, the infusion may be continued at no more than 
50% of the rate prior to the reaction and increased in 50% increments every 30 minutes if wel l tolerated. Infusions may be restarted at the full rate during the next 
cycle.  
 Adverse events requiring delays , dose reductions, or permanent discontinuation of 
bevacizumab are listed in Table 1 .  
  
Table  1:  Bevacizumab Dose Management Due to Adverse Events  
 
Event  Action to be Taken  
Hypertension  (in adults only)  
No dose modifications for grade 1  or 2 events  
Grade 3  If not controlled to 150/100 mmHg with medication, reduce 
one dose level.  For second occurrence, reduce a second 
dose level.  For third occurrence, discontinue bevacizumab.  
Grade 4 (including 
hypertensive 
encephalopathy)  Discontinue bevacizumab.  
*Specific guidelines for the management of hypertension are provided for adults and children  6 
through 17 years (Appendix D).  
Hemorrhage  
No dose modifications for grade 1 or 2 non -pulmonary and non -CNS events  
  Grade 3   
  Non -pulmonary 
and     non- CNS 
hemorrhage  Subjects who are also receiving full -dose anticoagulation 
will be discontinued from receiving bevacizumab.   
All other subjects will have bevacizumab held until all of the following criteria
  are met:  
• The bleeding has resolved and hemoglobin is stable. 
• There is no bleeding diathesis that would increase the risk 
of therapy. 
• There is no anatomic or pathologic condition that 
significantly increases the risk of hemorrhage recurrence.  
Subjects who experience a repeat Grade 3 hemorrhagic 
event will be disconti nued from receiving bevacizumab.  
  Grade 4  
     non-pulmonary or  
    non- CNS 
hemorrhage  Discontinue bevacizumab.  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
31    Grade 1  
pulmonary or CNS 
hemorrhage  Subjects who are also receiving full -dose anticoagulation 
will be discontinued from receiving bevacizumab.   
All other subjects will have bevacizumab held until all of the following criteria
  are met:  
• The bleeding has resolved and hemoglobin is stable. 
• There is no bleeding diathesis that would increase the risk 
of therapy. 
• There is no anatomic or pathologic condition that 
significantly increases the risk of hemorrhage recurrence.  
 
Grade 2, 3, or 4 
pulmonary or CNS 
hemorrhage  Discontinue bevacizumab . 
Venous Thrombosis  
No dose modifications for grade 1 events  
 
Grade 2, 3, or 4 Discontinue bevacizumab . 
 
Arterial Thromboembolic event  
(New onset, worsening, or unstable angina, myocardial infarction, transient ischemic attack, 
cerebrovascular accident, and any other arterial thromboembolic event)  
 Any grade  Discontinue bevacizumab.  
Congestive Heart Failure (Left ventricular systolic dysfunction)  
No dose modifications for grade 1 events  
Grade 2, 3, and 4 Discontinue bevacizumab.  
Proteinuria  
No dose modifications for grade 1/2 events  
Grade 3  
(UPC> 3.5, urine collection > 3.5 g/24 hr)   
 Hold bevacizumab treatment until ≤ Grade 2, as determined by 
either UPC ratio ≤ 3.5 or 24 hr collection ≤ 3.5 g , and reduce by 
one dose level.  For second occurrence,  reduce by a second dose 
level.  For third occurrence, discontinue bevacizumab. 
 
Grade 4 (nephro tic 
syndrome)  Discontinue bevacizumab . 
GI Perforation  
 Discontinue bevacizumab.  
Fistula    
Any grade (TE or 
gastrointestinal 
fistula)  Discontinue bevacizumab.  
Grade 4 fistula  Discontinue bevacizumab.  
Bowel Obstruction  
Grade 1  
Continue patient on study for partial obstruction NOT requiring 
medical intervention.  
  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
32 Grade 2, 3, or 4 Discontinue bevacizumab . 
 
Wound dehiscence 
Any grade 
(requiring medical 
or surgical therapy)  Discontinue bevacizumab.  
Reversible Posterior Leukoencephalopathy Syndrome  (RPLS)   
Any grade  
(confirmed by MRI)  Discontinue bevacizumab.  
Ovarian function  
Follicle stimulating 
hormone (FSH)  > 
20 Units/L  Hold  bevacizumab  and refer patient to qualified practitioner 
(eg., reproductive endocrinology specialist) to assess ovarian function.  Subject should have measurement of anti-Mullerian hormone (AMH) and ultrasound of ovaries  for determination of 
antral follicle count by q ualified practitioner . If assessment 
reveals evidence of premature ovarian failure, consider 
discontinuation of bevacizumab after discussion with subject, medical monitor, and study PI.  No additional actions are 
required for subsequent occurrences.  
Other  Unspecified Bevacizumab -Related Adverse Events  
Grade 3  
Grade 4  Hold bevacizumab until recovery to ≤ Grade 1  
Discontinue bevacizumab.  
 Hypertension in children aged 6 - 17 years: 
Any patient with a diastolic blood pressure greater than 25 mmHg above the 95
th% for age 
and gender (Appendix D) confirmed by repeated measurements will result in reduction of one dose level.  For a second occurrence, discontinue bevacizumab. (See Appendix D for assessment of blood pressure recordings and for management.)    In children on antihypertensive therapy, a diastolic blood pressure ≥25 mmHg above the 95
th 
% for age and gender for >14 days will result in reduction of one dose level.  For a second occurrence, discontinue bevacizumab (see Appendix D ).   
 
Dose limiting bony changes in children aged 6 - 17 years 
 
Children 6 - 17 years old will be carefully monitored for the development of bony toxicity (Sections 6.3 and Appendix E ). 
 For patients with open growth plates on tibial radiographs at baseline , measurements of 
stature (height) will be measured at  week s 13, 25, 49, 73, and 91.  Bevacizumab will be 
discontinued if: 
 
• <1 cm growth is noted prior to week 25  
• <2.5 cm growth is noted prior to week 49 
• Subsequently, <2cm/year annualized growth velocity noted every 24 weeks for patients with open growth plates only  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
33 7. DRUG FORMULATION AND ADMINISTRATION  
 
7.1 Bevacizumab  
 
7.1.1 Description  
 
Other Names. rhuMAb VEGF, Avastin® 
 Classification. Recombinant humanized monoclonal antibody  
 
Molecular Weight. Approximate molecular weight is 149,000 daltons  
 
Mode of Action. Bevacizumab blocks the binding of vascular endothelial growth factor (VEGF) to its receptors resulting in inhibition of angiogenesis.  
 Description. Bevacizumab is a recombinant humanized anti- VEGF monocl onal 
antibody consisting of 93% human and 7% murine amino acid sequences. The agent is composed of human IgG framework and murine antigen-binding complementarity -determining regions 
 
Route  of Administration. Intravenous 
 
Terminal half -life.  21 days 
 
For f urther details and molecule characterization, see the bevacizumab 
Investigator Brochure. 
 
7.1.2 Form  
 
Bevacizumab is a clear to slightly opalescent, colorless to pale brown, sterile liquid concentrate for solution for intravenous (IV) infusion.  Bevacizumab may be supplied in 5-cc (100- mg) and 20 -cc (400 -mg) glass vials containing 4 mL or 
16 mL bevacizumab, respectively (all at 25 mg/mL).   Vials contain bevacizumab 
with phosphate, trehalose, polysorbate 20, and Sterile Water for Injection (SWFI), USP.   Vials contain no preservative and are suitable for single use only. 
 
7.1.3 Storage and Stability  
 
Upon receipt of the study drug, vials are to be refrigerated at 2°C–8°C  
(36°F–46° F) and should remain refrigerated until just prior to use.  DO NOT 
FREEZE.  DO NOT SHAKE.   Vials should be protected from light. 
Opened vials must be used within 8 hours.  VIALS ARE FOR SINGLE USE ONLY.  Vials used for 1  subject may not be used for any other subject.  Once 
study drug has been added to a bag of sterile saline, the solution must be administered within 8 hours. 
  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
34 7.1.4 Compatibility  
 
Bevacizumab will be diluted in a total volume of 100mL of 0.9% Sodium Chloride Injection, USP.  
7.1.5 Handling  
 
Qualified personnel, familiar with procedures that minimize undue exposure to 
themselves and the environment, should undertake the preparation, handling, and safe disposal of the chemotherapeutic agent in a self -contained and protective 
environment.  
7.1.6 Availability  
 
Distribution:  Bevacizumab will be supplied free of charge by Genentech, Inc. 
and will be distributed to investigators by a designated central pharmacy  (UAB  
Pharmacy ).  
 
7.1.7 Preparation  
 
Bevacizumab will be diluted in a total volume of 100mL of 0.9% Sodium 
Chloride Injection, USP.   Opened vials must be used within 8 hours.  VIALS 
ARE FOR SINGLE USE ONLY.  Vials  used for 1 patient may not be used for 
any other patient.  Once study drug has been added to a bag of sterile saline, the solution must be administered within 8 hours.     
7.1.8 Administration  
 
Anaphylaxis precautions should be observed during study drug administration.   
The initial dose will be delivered over 90± 15 minutes.  If the first infusion is 
tolerated without infusion- associated adverse events ( e.g., fever and/or chills), 
the second infusion may be delivered over 60± 10 minutes.  If the 60- minute 
infusion is well tolerated, all subsequent infusions may be delivered over 30±10 minutes.  If a subject experiences an infusion- associated adverse event 
with the 60 -minute infusion, all subsequent doses should be given over 
90±15 minutes.  Similarly, if a subject experiences an infusion -associated 
adverse event with the 30 -minute infusion, all subsequent doses should be given 
over 60±10 minutes.   
 
If a subject experiences a n infusion– associated adverse event, he or she may be 
premedicated for the next study drug infusion; however, the infusion time may 
not be decreased for the subsequent infusion.  If the next infusion is well tolerated with premedication, the subsequent inf usion time may then be 
decreased by 30 ±10 minutes as long as the subject continues to be premedicated.   
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
35 It is not necessary to correct dosing based on ideal weight.  
 
To insure complete delivery of bevacizumab, flush the IV infusion line with 0.9% sodium chloride. The following are two recommended methods for flushing the bevacizumab IV infusion line:  
• When the bevacizumab infusion is complete, add an additional 50mL of 0.9% 
sodium chloride for injection to the bevacizumab infusion bag. Continue the infusion until a volume equal to that of the volume contained in the tubing has been administered.  
 
• Replace the empty bevacizumab infusion bag with a 50mL bag of 0.9% sodium chloride for injection and infuse a volume equal to the volume contained in the tubing. NOTE : the flush is not included in the total 
recommended infusion times. 
 
7.1.9 Ordering  
 
(See Appendix B for Bevacizumab Supply Request Form)  
 
Initial Shipments (new patients registered to study)  
When a site has received Sponsor IRB approval and has identified potential patients to screen, the study site will complete a  ‘Drug Order Request Form’ 
and submit this request to UAB  Pharmacy .   
 After faxing to  the request , study site will:  
• Place a call UAB Pharmacy confirming the faxed order was received, and 
confirm  estimated  day and time of arrival for the study drug.   
• UAB will p ack and ship the required number of bevacizumab vials to the 
site for the patient to complete treatment for 24 weeks  based on the 
patient’s weight (kg).   Initially, 20 vials will be sent.  
 Subsequent Shipments (active patients requiring additional bevacizumab 
supply)  
When additional bevacizumab is required for a subject , the study site will 
complete a ‘Bevacizumab Supply  Request ’ and submit to UAB  by calling 205 -
975- 6647.  
 After faxing to UAB, site  will:  
• Place a call to UAB to conf irm the order was received, and arrange day and 
time of arrival for the study drug.   
• UAB will p ack and ship the required number of bevacizumab vials to the 
site. 
• UAB Pharmacy will pack and ship the additional vials of bevacizumab vials for 24 weeks based on the subject’s weight (kg). 
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
36 For all drug shipments from UAB:  
 
• Bevacizumab will be shipped in original manufacturers packaging.   Boxes 
are placed in a ZipLock bag.  Subject -specific labeling will be added at t he 
clinical study site.  
 
• A complete accountability record ( including date of dispense, site name, 
quantity dispensed, and balance forward) will be recorded.  Study 
accountability records are documented in electronic 21 CFR format and are 
kept in a secured area for duration of the study.  
 
• Require  a Pharmacist review; a licensed pharmacist checks off package for 
accuracy of contents, authorizing order via 21 CFR compliant trial accountability log. 
 
• Each shipment includes the following information:  
• Study number   
• IND caution statement and/or local regulatory statements  
• Drug identification  
• Lot number and expiration  
• Storage conditions  
• Dosing instructions (Take as Directed per Protocol)  
(Subject ID number, initials and date dispensed will be provided by the st udy site pharmacy.)  
 
• Enclose a packing slip that includes the quantity of drug provided with a 
section to be completed once received by the site coordinator. This section includes confirmation of drug receipt, verification of package contents, and instruct ion to fax the completed packing slip to UAB.   
 
• Process and ship authorized and completed orders “same day” of patient randomization if received  Monday through Thursday. Authorized and completed orders received after 12N CST  Thursday , will be sent on the  
following Monday or Tuesday if Monday is a Holiday.  Orders  will be 
processed and shipped the next business morning.  
 All drug orders are shipped via FedEx for Priority Overnight delivery. 
Bevacizumab is shipped with a gel pack  to maintain temperature stability.   
 Packages are tracked until confirmed delivered and delivery exceptions are managed with the highest level of urgency to ensure therapy start date adherence.  Packing slips with the shipment tracking number included will be faxed to the designat ed site coordinator for all shipments.  
   
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
37 Once study drug is received at the clinical trial site:  
 
• The designated site coordinator or Investigational pharmacy  representative 
validate s that contents of package matches information provided on 
packing slip, s igns off on the packing slip, and contacts UAB  to validate 
shipment has been received and is accurate.  
 
The order transaction is completed by entering the receipt confirmation and 
signed packing slip into the study file.  
 Drug Destruction and Transfer of Study Drug  
Sites will be instructed to destroy unused/returned drug per institution policy and note in the accountability record  after site Pharmacy Drug Destruction 
Policy is sent to Operations Center and policy is placed in the regulatory files . 
Drug destruction policy should also be maintained in Pharmacy.  
 Since study drug vials are sent to study sites, Bevacizumab may be used for all consented subjects. Use of all study drug vials will be documented on study drug accountability records.  
 Central Pharmacy – UAB  
Rebecca Quinn, PharmD Senior Pharmacist - Investigational Drug Service  
UAB Hospital  
North Pavilion, room 3470 1802 6th Avenue South Birmingham, AL   35249 
205-934-7191 (phone) 205-975-6647 (fax) UAB paging: 205-934-3411, pager 4295 
 
7.1.10  Accountability  
 
The investigator, or a responsible party designated by the investigator, must 
maintain a careful record of the inventory and disposition of the agent (investigational or free of charge) using the NCI Drug Accountability Record or another comparable drug accountability form. (See the CTEP website at http://ctep.cancer.gov/protocolDevelopment
  for the “Policy and Guidelines for 
Accountability and Storage of Investigational Agents” or to obtain a copy of the drug accountability form.)  
 Sites will be required to send site drug accountability records to Operations Center on a quarterly basis.  The site study drug accountability records will be checked against UAB Pharmacy study drug administration data accountability records.  
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
38 Drug accoun tability records should be submitted quarterly to UAB:  
 
Roy McDonald, MPH  
Research Compliance Manager   
Department of Genetics  
Univ ersity  of Alabama at Birmingham  
1720 20th Street South, MCML 262A   
Birmingham, AL  35294 -0024  
     205-975-4075 (phone)  
     205-975-3543 (fax)  
     Email: rmcdonald@uab.edu   
  
7.1.11  Destruction and Return  
 
At the end of the study, unused supplies of bevacizumab should be destroyed 
according to institutional policies. Destruction will be docume nted in the Drug 
Accountability Record Form. 
8. CORRELATIVE/SPECIAL STUDIES  
8.1 Pharmacokinetic Studies  
 
N/A 
8.2 Pharmacodynamic Studies  
 
N/A 
8.3 Laboratory correlative markers  
8.3.1 Markers of angiogenesis and tumor growth  
 Recent development in understanding the molecular basis of cancer has dramatically advanced the field in cancer drug discovery and development. Now it is clear that the translation of molecularly targeted cancer therapy into useful and practical therapeuti c approaches is highly complex. The discovery of 
mechanism -based biomarkers can facilitate the efficient development of new anti-
tumor medicines and potentially serve as true intermediate or surrogate end point biomarkers for future clinical trials. Biomar kers can also help guiding rational 
selection of therapeutic agents for patient likely to respond to therapy . Two recent 
studies show that collagen IV structure was modified after VEGFR2 blockade. These data together with other data on different biomarkers indicate that it is important to include measurement on the serum levels of biomarkers in future clinical practices.  
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
39 To measure numerous biomarkers simultaneously with exceptional sensitivity but 
only small amount of plasma proteins, the MSD (Meso Scale Discovery, Maryland) platform will be used. MSD technology utilizes electrochemiluminescence detection to detect binding events on patterned arrays.  By customizing the Multi -
Array, multiple serum molecules can be tested. We will collect blood samples from  
the patients before and during the course of treatment (see study table). Analysis will be performed for VEGF -A, VEGF -C, sVEGFR1, sVEGFR2, sVEGFR3, Col 
IV, SDF1a, IL -1beta, IL -6, IL -8, TNFalpha, G -CSF, Ang1, Ang2, sTie2, s -cKIT, 
MMP -1, MMP -2, MMP -3, MMP -9, MMP -10, PlGF, and bFGF using the Meso-
Scale Discovery multiplex array reader and custom multiplex plates and R&D Systems ELISA kits for collagen IV and SDF1 α. This assay provides a sensitivity 
of 0.001 ng/mL and low variability. The level of these biomar kers during treatment 
with bevacizumab will be compared to the baseline level.  
8.3.2 Collection of specimen(s)  
 
Sample Collection Time Points  
 Blood samples will be obtained for protein analysis of potential biomarkers for anti -angiogenic therapy ~3 hours prior to bevacizumab infusion (i.e., when 
baseline labs are drawn) at the following time points: 
• Prior to initiating therapy  
•Week s 3, 5, and 25 
 
Blood collection (needed for each time point sample) 
 
o Collect 16 ml of blood in 2 polypropylene tubes (8 mL in each tube) 
containing the anticoagulant EDTA. Tubes should be pre-cooled in an ice bath.  
 SARSTEDT Monovette® EDTA KE (9 ml), Part # 02.1333.001 
or 
 Becton -Dickinson VacutainerTM K2E (10 ml), Part # 367525 
or 
 Greiner Bio -One Vacuette® K3E EDTA K3 (9 m l), Part 
455036 
o Blood tubes must be gently inverted several times after collection to 
ensure thorough mixing of EDTA with the sample to prevent clotting. 
o Cool all tubes in an ice bath immediately after collection.  
o Glass tubes MUST NOT be used as they may b reak during transport 
and freeze- thaw cycles.  
Heparin must not be used as an anticoagulant as it may interfere with downstream genotyping methodology. 
8.3.3 Handling of specimens  
Centrifuge tubes collected at 700 G for 20 minutes at 4C° with no breaks within 30 minutes of collection.  
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
40 Prepare two labels  each printed with Study-No., patient ID, initials and 
day/time of sample collection (24 -hour clock format, i.e ., 6:30 pm = 18:30). A 
label example is provided below: 
 
 
Study -No.:  NFCTC104  Investigator:   
Patient -ID:  Sample Type:  Plasma   
Date of sampling: (mm/dd/yy)  Time of Sampling:  (hh:mm) (24 -hr format)  
 
• Plasma is pipetted in 1 ml aliquots into two red -labeled Nalgene 
cryovials.  
• Clearly label tubes as “plasma” and store at -80°C.  
• When samples from all time -points have been collected (after the 
patient goes off trial) the plasma samples should be shipped to the Steele Laboratory at Massachusetts General Hospital on DRY ICE in a Styrofoam box (Thermo Safe shippers, Fisher Scientific, cat# :11-676-14; 12/case; $122.30). If a deep freezer is not available on site, the plasma sample should be kept and shipped on dry ice on the same day. 
• Specimens should be shipped Monday to Wednesday only by 
overnight FedEx to the Testing Core Facility. 
 
8.3.4 Shipping and anal ysis of specimen(s)  
 
Ship all specimens to the following Testing Core Facility address : 
 
Attn : Julia Kahn or Anna Khachatryan or Ms. Sylvie Roberge 
100 Blossom St. MGH, Cox -734 
Boston, MA 02114 Tel. (617) 724-1353 Fax (617) 724-5841 Pager 14082 (617-726-2000)  
 
On the day of shipment, the study coordinator will notify the Testing Core Facility via email: jakahn@partners.org  or AKHACHATRYAN@PARTNERS.ORG
 or 
Sylvie@steele.mgh.harvard.edu  to expect the upcoming shipment and include the 
estimated date of arrival and FedEX tracking number.  
 All analysis will be performed within the Steele Laboratory under the direction of Dr. Dan Duda. The Steele Laboratory has 6 years experience in analyzing and understanding variation in circulating angiogenic markers in various clinical trials 
19, 
45, 46.  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
41 8.3.5 Future use  of specimen(s)  
Blood specimens will be stored for future use in NF studies approved by the IRB. 
Specimens will be labeled as noted above (see 8.3.3) and stored indefinitely in the Steele Laboratory at MGH .  Neither cell lines nor commer cial pro ducts will be 
developed from the blood specimens.  Specimens will be banked under the current study protocol.  Access to specimen samples will be limited to research personnel approved by the IRB.  Subjects who wish to have their samples removed fr om storage 
(e.g., withdraw consent for biomarker storage)  should contact the study PI who will work with  the Steele Laboratory to have the sample destroyed. 
 
9.  STUDY CALENDAR 
Baseline evaluati ons are to be conducted within 2 week s prior to start of protocol 
therapy. Scans must be done < 4 weeks prior to the start of therapy. In the event that the 
participant's condition is deteriorating, laboratory evaluations should be repeated within 48 hours prior to initiation of the next cycle of therapy.  
Appropriate  study  assessments must be performed prior to administration of study 
medication. All study assessments should be administered within + 7 days of the 
protocol -specified date, unless otherwise noted.   Audiology and MRI scans should be 
performed on day 1 of appropriate cycles  (see table below) .  Bevacizumab  should be 
provided on days 1 and 15 of each induction cycle and on days 1 and 22 of each 
maintenance cycle (window: -1 to +3 days).
Bevacizumab for children and adults with NF2    
Protocol Version Date:  May 13, 2016 Version 1.4  
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
 
42  Induction Therapy  
Cycle = 4 weeks  Maintenance  Therapy  
Cycle = 6  weeks   
 
Study week  Pre-
Study  1 3 5 9 13 17 21 25 31 37 43 49 55  
61  
67  
73  
79  
85  
91 Off 
Studyf 
 
Cycle number  Pre-
Study  1 1 2 3 4 5 6 7 8 9 10 11 12  
13  
14  
15  
16  
17  
18 Off Study
f 
 
Bevacizumab   
X X-------------------------------- X a X ------------------------------------------------------------------------- X b  
 
 
Informed consent   
X  
  
  
  
  
  
  
  
  
  
  
  
  
        
 
 
Demographics   
X  
  
  
  
  
  
  
  
  
  
  
  
  
        
 
 
Medical history   
X  
  
  
  
  
  
  
  
  
  
  
  
  
        
 
 
Concurrent meds  
  Interval history  
X X -----------------------------------------------------------------------------------------------------------  X  
X 
 
Physical exam   
X  
X  
  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X X X X X X X  
X 
 
Vital signs   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X X X X X X X  
X 
 
Height   
X  
  
  
  
  
  
  
  
  
  
  
  
  
        
X 
 
Weight   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X X X X X X X  
X 
 
Performance status   
X  
  
  
  
X  
  
  
  
X  
  
X  
  
X  
 X  X  X   
X 
 
CBC w/diff, plts   
X X X X X X X X X X X X X X X X X X X X  
X 
Coagulation 
studies  
(PT/PTT/INR) X        X    X    
X    
X 
 
Serum chemistry
c X X X X X X X X X X X X X X X X X X X X X 
 
Urinalysisd  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X 
 
EKG   
X  
  
  
  
  
  
  
  
  
  
  
  
  
        
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
43  
Adverse event 
evaluation   
X X -----------------------------------------------------------------------------------------------------------  X  
X 
 
B-HCG  e  
X  
  
  
   
X  
  
  
X  
  
X  
 X  X  X  X   
X 
 
FSHi  
X  
  
  
   
X  
  
  
X  
  
X  
 X  X  X  X   
X 
 
Radiologic evaluation  
j  
X  
  
  
   
X  
  
  
X  
  
X  
 X  X  X  X   
X 
 
Tumor volume 
measurements   
X  
  
  
   
X  
  
  
X  
  
X  
 X  X  X  X   
X 
 
Hearing assessment
g  
X  
  
  
   
X  
  
  
X  
  
X  
 X  X  X  X   
X 
 
Tinnitus Assessments
h  
X  
  
  
   
X  
  
  
X  
  
  
 X    X     
X 
 
NFTI -QOLk  
X  
  
  
  
  
  
  
  
X  
  
  
 X    X     
X 
 
Plasma biomarkers 
  
  
 X  
X  X 
  
  
  
  
  
X  
  
  
          
 
 
a: Bevacizumab 10 mg/kg by vein (IV) every 2 weeks .  Doses should be provided on days 1 and 15 of each cycle (window: -1 to +3 days) . 
b:    Bevacizumab 5 mg/kg by vein (IV) every 3 weeks  starting on week 25.  Doses should be provided on days 1 and 22 of each cycle (window: 
-1 to +3 days) .  For subjects on dosing every 2 weeks (dose level +1), doses should be provided on days 1, 15, and 29 of each 6 week cycle 
(window: -1 to +3 days).  
c: Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, phosphorus, potassium, total 
protein, SGOT[AST], SGPT[ALT], sodium.  
d:   Proteinuria will be m onitored by urine dipstick and by urine protein:creatinine (UPC) ratio at least every cycle. If urine dipstick ≤ 2+ 
protein, bevacizumab can be infused.  If urine dipstick > 2+, infusion can be provided once the UPC ratio is reported 
to be < 3.5.  If UPC ra tio is > 2, collection of 24 hour urine for measurement of urine protein level is recommended but not required.    
UPC ratio of spot urine is an estimation of the 24 urine protein excretion – a UPC ratio of 1 is roughly equivalent to a 24- hour urine 
protein  of 1 gm.   UPC ratio is calculated using one of the following formulas:  
- [urine protein]/[urine creatinine] – if both protein and creatinine are reported in mg/dL  
- [(urine protein) x0.088]/[urine creatinine] – if urine creatinine is reported in mmol/L  
e: Serum pregnancy test (women of childbearing potential).  
f:     Off -study evaluation.  Patients who have an on- going study agent -related serious adverse event upon study completion or at discontinuation 
from the study should be contacted by the investigator or his/her designee periodically until the event is reso lved or determined to be 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
44 irreversible.   Patients who continue with off -label bevacizumab after c ompletion of the study will be  contacted by the investigator or his/her 
designee for 30 days after removal from the study.  Adverse events during this time peri od will be assessed as part of the study.  Patients 
who do not receive off -label bevacizumab after completion of the study will be be contacted by the investigator or his/her designee for 12 
weeks after removal from study.  Adverse events during this time period will be assessed as part of the study.   
g:  Audiology will include measurement of pure tone thresholds and determination of word recognition scores as described in Appendix F .  
Audiograms should be performed on day 1 of each  designated cycle (win dow: -5 days to day of infusion).  Audiograms must be reviewed 
prior to bevacizumab infusion.  
h:  Tinnitus reaction questionnaire is given in Appendix H.   Children 11 and younger on day 1 of the protocol should not complete NFTI -QOL 
during trial participation.  
i:    Follicle stimulating hormone (FSH) should be measured in post- pubescent /pre-menopausal women only.  The day of the menstrual cycle 
(the onset of menses is day 1) on which the labs are drawn should be recorded (if the subject is menstruating).  O ff-study levels should be 
drawn 30 days (+/ -2 days) after discontinuing bevacizumab (can be drawn locally).  
j:   MRI scans should be performed on day 1 of each designated cycle (window: - 5 days to day of infusion).  
k:  See Appendix B for NFTI -QOL questionnaire .  Children 11 and younger on day 1 of the protocol should not complete NFTI -QOL during 
trial participation.   
 
 
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
45 Additional Evaluations for Bony Toxicity for Children only  (age s 6 to 17) 
 
 Induction Therapy  
Cycle = 4 weeks  Maintenance  Therapy  
Cycle = 6  weeks   
 
Study week  Pre-
Study  1 3 5 9 13 17 21 25 31 37 43 49 55  
61  
67  
73  
79  
85  
91 Off 
Studyb 
 
Cycle number  Pre-
Study  1 1 2 3 4 5 6 7 8 9 10 11 12  
13  
14  
15  
16  
17  
18 Off Study
b 
 
Height   
X  
  
  
  
  
X  
  
  
X  
   
  
X  
   X   X  
X 
 
Radiograph of tibial growth plate   
X  
  
  
  
  
X a  
  
  
X a  
   
  
X a  
   X a   X a  
X a 
a:      Radiographs of tibial growth plates will be repeated if  growth plates are open at baseline.   
b:     Off-study evaluation.  Patients who have an on- going study agent-related serious adverse event upon study 
completion or at discontinuation from the study should be contacted by the investigator or his/her designee periodically 
until the event is resolved or determined to be irreversible.  Patients who continue with off- label bevacizumab after 
completion of the study will be contacted by the investigator or his/her designee for 30 days after removal from the study.  Adverse events during this time period will be assessed as part of the study.  Patients who do not receive off -
label bevacizumab after completion of the study will be be contacted by the investigator or his/her designee for 12 weeks after removal from study.  Adverse events during this time period will be assessed as part of the study.   
 
 
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
46 10. MEASUREMENT OF EFFECT  
10.1 Antitumor Effect – Solid Tumors  
 
For the purposes of this study, patients should be re- evaluated for response every 
12 weeks .  Response and progression will be evaluated in this study using the 
criteria proposed by Widemann and colleagues15 for neurofibromatosis- associated 
lesions. Response and progression will not be evaluated using the Response 
Evaluation Criteria in  Solid Tumors (RECIST)47 or by MacDonald Criteria48, since 
they may underestimate progression in these irregularly shaped tumors. However, 
linear measurements will be collected as part of the trial for comparison with volumetric measurements.  
10.1.1  Definitions  
 
Evaluable for toxicity .  All patients will be evaluable for toxicity from the time 
of their first treatment with bevacizumab.  
 
Evaluable for objective response.  Only those patients who have received at 
least one cycle of therapy, and have had their disease re- evaluated will be 
considered evaluable for response.  These patients will have their response classified according to the definitions stated below .   
10.1.2  Disease Parameters  
 
Measurable disease.  Measurable lesions are defined as those that can be 
accurately measured using volumetric analysis of cranial MRI scans.  All study MRI scans should include standard brain imaging sequences as well as fine cuts through the internal auditory canal (3 mm slice, no gaps) to image small tumors.  In patients who have had surgery for tumors in the cerebellopontine angle, fat -saturation should be performed with the post- contrast sequences to 
compensate for the possible presence of post -operative fat packing.    
 
NOTE :  Tumor lesions that are situated in a previously irradiated area are 
considered measurable.   
 
Non-measurable disease.  Non -measurable lesions include skull- base lesions 
that are obscured by artifact from auditory brainstem implants (ABIs) or lesions whose margins are completely obscured by neighboring tumors ( i.e., 
“collision” tumors).  
  
Target lesions .   Investigators should identify a single target lesion in all 
subjects. The target lesion in this study is the  progressive VS ( e.g., the lesion 
that is enlarging or is associated with hearing loss) that le d to enrollment in the 
protocol. In cases where subjects have a single ear with hearing, the target lesion should be the enlarging VS ipsilateral to the hearing ear.   In cases where 
subjects have hearing in both ears, the target lesion should be the tumor associated with word recognition score < 85% and is growing the fastest or is 
causing the most rapid hearing loss.  In rare cases where both VSs are 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
47 associated with word recognition < 85% and progressing equally rapidly, the 
target lesion should be the larger of the two tumors on imaging. Target lesions should be identified at baseline and measured using volumetric analysis of the baseline MRI scan. The baseline volumetric  MRI scan will be used as reference 
for comparison of all future MRI scans to character ize the objective tumor 
response.
 
 
Non-target lesions .  Non- target lesions in this study include VSs  contralateral to 
the target lesion (if present) .  The baseline contralateral VS will be used as 
reference by which to characterize the objective tumor resp onse.   
 NOTE : Histologic confirmation of tumor type is not required. Designation of 
tumor type will be determined by the radiographic appearance by the study radiologist.  
10.1.3  Methods for Evaluation of Measurable Disease  
All measurements should be taken and recorded in metric notation [ i.e., cubic 
centimeters (cm3) and in millimeters (or decimal fractions of centimeters )] for 
linear measures.  All baseline evaluations should be performed as closely as possible to the beginning of treatment and never more than 8 weeks before the beginning of the treatment. 
The same method of assessment and the same technique should be used to 
characterize each identified and reported lesion at baseline and during follow -
up.  
Cranial MRI.  Volumetric analysis of MRI scans should be performed on 
sequences with fine cuts through the internal auditory canal (3 mm slices, no gap; Appendix G ). 
10.1.4  Response Criteria  
10.1.4.1 Evaluation of Target Lesions 
 
For the purpose of this study, radiographic response will be defined by 
the change in tumor volume compared to baseline, as previously defined in previous studies in NF1.
15   Hearing will be measured in 
standardized fashion as described in Appendix F.  Hearing response (Section 10.3) will be defined by the change in word recognition scores, taking as reference the baseline word recognition score (Appendix A and S ection 1 0.3). 
 
Radiographic Response (RR): At least a 20% decrease in the volume of 
the ta rget lesions, taking as reference the 
baseline volume. 
 
Progressive Disease (PD) : A t least a 20% increase in the volume of 
the target lesion, taking as reference the lower  volume during treatment 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
48  
Stable Disease (SD) : Does not meet crit eria for radiographic 
response or for progressive disease.   
Unknown (UN):  Assessment of target lesions cannot be made due to 
insufficient or unevaluable data.  In this case, a concise explanation 
must be given. 
10.1.4.2 Evaluation of Non- Target Lesions  
  Radiographic evaluations should be calculated separately for non -target 
lesions (contralateral  VS).   
 
Radiographic  Response (RR) :At least a 20% decrease in the non- target 
lesions, taking as reference the baseline volumes. 
 
Stable Disease (SD) : Does not meet criteria  for radiographic 
response or progressive disease.  
 
Progressive Disease (PD) : At least a 20% increase in the volume of 
the non- target lesions, taking as reference 
the baseline volume 
 
Although a clear progression of “non- target” lesions only is exceptional, 
the opinion of the treating physician should prevail in such circumstances, and the progression status should be confirmed at a later time by the review panel (or Principal Investigator).  
10.1.4.3 Evaluation of Best Overall Response 
 The best overall response is the best response for the target vestibular schwannoma recorded from the start of the treatment until disease progression (taking as reference for progressive disease the hearing measurements recorded at baseline and the minima l tumor volume 
during treatment ).   
 
Note :  Patients with a global deterioration of health status requiring 
discontinuation of treatment without objective evidence of disease progression at that time should be reported as “ symptomatic 
deterioration” .  Every effort should be made to document the objective 
progression even after discontinuation of treatment. 
10.1.5  Duration of Response  
 Hearing evaluations should be performed for non- target (contralateral) VS if 
present and if hearing is present in the ipsilater al ear.  
 
Duration of hearing response:  The duration of hearing  response (HR) is 
measured from the time that measurement criteria are met for HR  until the first 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
49 date that the word recognition score decreases beneath the upper limit of the 
95% critical difference of the baseline word recognition score.. 
 
Duration of stable hearing :  Stable disease is measured from the start of the 
treatment until the criteria for progression are met, taking as reference the word 
recognition score recorded at baseline.  
 
Duration of radiographic response:  The duration of radiographic response is 
measured from the time measur ement criteria are met for RR  until the first date 
that progressive disease is objectively documented (taking as reference for progressive disease the lowest tumor volume during treatment ). 
 
Duration of stable disease :  Stable disease is measured from the start of the 
treatment until the criteria for progression are met, taking as reference the measurements recorded at baseline.  
10.1.6  Progression -Free Surviv al: Freedom from hearing loss and freedom from tumor 
progression  
 The proportion of patients alive and free from progressive hearing loss at 24, 48, 72, and 96 weeks from the start of treatment will be determined.  The 
proportion of patients alive and free from progressive tumor growth at 24, 48, 72, and 96 weeks from the start of treatment will be determined.   
10.1.7  Response Review  
Central review of audiologic and radiologic data will be performed at MGH/MEEI.  Audiograms collected during the study period will be sent to the Operations Center and then forwarded to the team at MGH/MEEI for analysis.  A study member (under the guidance of lead study audiologist Chris Halpin, 
PhD) will extract data for review by the Principal I nvestigator and lead 
audiologist.  The expected time to review audiologic data is ≤ 2 business days once it is received at MGH/MEEI.  
MRI images from enrolled subjects will transmitted by the “MedCommons On Demand” platform t o the Dana-Farber/Harvard Cancer Center Tumor Imaging 
Metric Core (TIMC)  for central analysis of tumor volume .    The procedure for 
clinical sites to upload MRI scans are provided in Appendi x G.  MedCommons 
On Demand is a HIPAA -compliant and customizable web service that 
provides secure communications for document management and storage of medical images. The application allows users to conveniently upload DICOM CDs to cloud standards. The system requirements to launch MedCommons include 1) Windows, Mac, or Linux system with access to the internet 2) modern web browsers such as Internet Explorer, Firefox, Safari, or Chrome and 3) Java. All activities are monitored by MedCommons and full suppor t 
team is available for problem resolution.  
Enhancing lesions will be outlined using a volumetric approach that includes outlining each enhancing voxel on post- contrast scans and then summing the 
voxels to calc ulate an overall lesion volume .  A report will  be generated and 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
50 then sent to the P rincipal Inves tigator at each study site within 2 business days 
of receiving the files.  
10.2 Antitumor Effect – Hematologic Tumors  
N/A 
10.3 Other Response Parameters: Hearing R esponse  
 
Hearing Response (HR) : Improvement in word recognition score above the 95% 
critical difference , taking as reference the baseline word recognition score 
(Appendix A).  
 
Stable Hearing (SH) : Persistence of word recognition score within the 95% critical 
difference, taking as reference the baseline word recognition score (Appendix A ). 
 
Progressive Hearing Loss (PHL):  Decline in word recognition score below the 
95% critical difference, taking as reference the baseline word recognition score 
(Appendix A ). 
11. ADVERSE EVENT REPORTING REQUIREMENTS  
11.1 Definitions  
11.1.1  Specification of Safety Variables  
Safety assessments will consist of monitoring and reporting adverse events (AEs) 
and serious adverse events (SAEs) that are considered related to bevacizumab , all 
events of death, and any study specific issue of concern.  
11.1.2  Adverse Events  
 
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution.  This includes the following:  
• AEs not previously observed in the subject that emerge during the protocol-specified AE reporting period, including signs or symptoms associated with neurofibromatosis 2 that were not present prior to the AE reporting period. 
• Complications that occur as a result of protocol-mandated interventions (e.g., invasive procedures such as cardiac catheterizations).  
• If applicable, AEs that occur prior to assignment of study treatment 
associated with medication washout, no treatment run-in, or other protocol-mandated intervention. 
• Preexisting medical conditions (other than the condition being studied) judged by the investigator to have worsened in severity or frequency or changed in character during the protocol-specified AE reporting period. 
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
51 Abnormal laboratory values or diagnostic test results constitute adverse events 
only if they  are accompanied by clinical symptoms , result in a change in study 
treatment  or require a medical intervention, or are considered to be clinically 
significant in the investigators judgment.    Abnormal vital signs constitute adverse events only if they are accompanied by clinical symptoms, results in a change in study treatment, or require a medical intervention, or are considered to be clinically significant in the investigators 
judgment.   In the event of an adverse event the first concern will be for the safety of the subject . 
11.1.3  Serious A dverse Event (SAE)  
 Investigators are required to report to Operations Center ANY serious treatment emergent ad verse event  as soon as possible.  Operations Center will report 
ANY serious treatment emergent adverse to Genentech Drug Safety and the Protocol Chair.   An AE should be classified as an SAE if the following criteria are met:  
• It results in death ( i.e., the AE actually causes or leads to death).  
• It is life threatening ( i.e., the AE, in the view of the investigator, places 
the subject at immediate risk of death. It does not include an AE that, had it occurred in a more severe form, might have caused death.). 
• It requires or prolongs inpatient hospitalization. 
• It results in persistent or significant disability/incapacity ( i.e., the AE 
results in substantial disruption of the subject’s ability to conduct normal life functions). 
• It results in a congenital anomaly/birth defect in a neonate/infant born to 
a mother exposed to the IMP. 
• It is considered a significant medical event by the investigator based on medical judgment ( e.g., may jeopardize the subject or may require 
medical/surgical intervention to preve nt one of the outcomes listed 
above). 
 Events not considered to be serious adverse events are hospitalizations for: 
• routine treatment or monitoring of the studied indication, not associated with any deterioration in condition, or for elective procedures; 
• elective or pre- planned treatment for a pre -existing condition that did 
not worsen; 
• emergency outpatient treatment for an event not fulfilling the serious 
criteria outlined above and not resulting in inpatient admission ; and/or 
• respite care  
11.1.4  Expectedness  
 
Adverse events can be 'Expected' or 'Unexpected.'  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
52 11.1.4.1 Expected adverse event  
 
Expected adverse events are those that have been previously identified 
as resulting from administration of the agent. For the purposes of this study, e xpected adverse events are those adverse events that are listed 
or characterized in the Package Insert or current Investigator Brochure.  
 
Refer to Section 6.1 for a listing of expected adverse events associated with the study agent(s).  
11.1.4.2 Unexpected adverse e vent 
  
For the purposes of this study, unexpected adverse events are those not listed in the Package Insert (P.I.) or current Investigator Brochure (I.B.) or not identified. This includes adverse events for which the specificity or severity is not consistent with the description in the  P.I. 
or I.B. For example, under this definition, hepatic necrosis would be unexpected if the P.I. or I.B. only referred to elevated hepatic enzymes or hepatitis.  
11.2 Methods and Timing for Assessing and Recording Safety Variable  
 The investigator is responsible for ensuring that all AEs and SAEs that are observed or reported during the study, are collected and reported to the FDA, appropriate IRB(s), and Genentech, Inc. in accordance with CFR 312.32 (IND Safety Reports) and with the most recent approved protocol document. 
11.2.1  Adverse Event Reporting Period  
 
The study period during which all AEs and SAEs must be reported begins after informed consent is obtained and initiation of any study procedures and ends 30 days following the last administration of study treatment or study discontinuation/termination, whichever is earlier. After this period, investigators should only report SAEs that are attributed to prior study treatment.  
11.2.2  Assessment of Adverse Events  
 
All AEs and SAEs whether volunteered by the subject, discovered by study personnel during questioning, or detected through physical examination, laboratory test, or other means will be reported in the participant’s medical record and on the appropr iate study -specific case report forms and entered into 
the NF Consortium’s web- based data entry system.  Each reported AE or SAE 
will be described by its duration ( i.e., start and end dates), regulatory 
seriousness criteria if applicable,  suspected relatio nship to the bevacizumab 
(see following guidance), and actions taken.  To ensure consistency of AE and SAE causality assessments, investigators should apply the following general guideline: 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
53 Yes:  There is a plausible temporal relationship between the onset of th e AE 
and administration of bevacizumab; and the AE cannot be readily explained by 
the subject’s clinical state, intercurrent illness, or concomitant therapies; and/or the AE follows a known pattern of response to bevacizumab ; and/or the AE 
abates or resolves upon discontinuation of the bevacizumab  or dose reduction 
and, if applicable, reappears upon re- challenge.  
 No : Evidence exists that the AE has an etiology other than the bevacizumab  
(e.g., preexisting medical condition, underlying disease, intercurrent illness, or 
concomitant medication); and/or the AE has no plausible temporal relationship to bevacizumab  administration ( e.g., cancer diagnosed 2 days after first dose of 
study drug).  
11.3 Procedures for Eliciting, Recording, and Reporting Adverse Events  
11.3.1  Eliciting Adverse Events  
A consistent methodology for eliciting AEs at all subject evaluation time points  
should be adopted. Examples of non-directive questions include:    • “How have you felt since your last clinical visit?”  
 • “Have you had any new or changed health problems since you were 
last here?”  
 
11.3.2  Specific Instructions for Recording A dverse Events  
Investigators should use correct medical terminology/concepts when reporting AEs or SAEs. Avoid colloquialisms and abbreviations.  The descriptions and grading scales found in the CTEP Version 4.03 of the NCI Common Terminology Criteria for Adverse Events (CTCAE  v. 4.03) will be utilized for 
AE reporting. The CTEP Version 4.03 of the CTCAE is identified and located on the CTEP website at:   
 http://ctep.cancer.gov/  All appropriate treatment areas should have access to a copy of the CTEP Version  4 of CTCAE.  
11.3.2.1 Diagnosis vs. Signs and Symptoms If known at the time of reporting, a diagnosis should be reported rather than individual signs and symptoms ( e.g., record only liver failure or 
hepatitis rather than jaundice, asterixis, and elevated transaminases). However, if a constellation of signs and/or symptoms cannot be medically characterized as a single diagnosis or syndrome at the time of rep orting, it is ok to report the information that is currently 
available. If a diagnosis is subsequently established, it should be reported as follow-up information. 
11.3.2.2 Deaths  
All deaths that occur during the protocol- specified AE reporting 
period, regardless of attribution, will be reported to the appropriate parties. When recording a death, the event or condition that caused or 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
54 contributed to the fatal outcome should be reported as the single 
medical concept. If the cause of death is unknown and cannot be ascertained at the time of reporting, report “Unexplained Death”.  
11.3.2.3 Preexisting Medical Conditions  
A preexisting medical condition is one that is present at the start of the study. Such conditions should be reported as medical and surgical history. A preexisting medical condition should be re- assessed 
throughout the trial and reported as an AE or SAE only if the frequency, severity, or character of the condition worsens during the study. When reporting such events, it is important to convey the concept that the p reexisting condition has changed by including 
applicable descriptors ( e.g., “more frequent headaches”).  
11.3.2.4 Hospitalizations for Medical or Surgical Procedures Any AE that results in hospitalization or prolonged hospitalization should be documented and reporte d as an SAE. If a subject is 
hospitalized to undergo a medical or surgical procedure as a result of an AE, the event responsible for the procedure, not the procedure itself, should be reported as the SAE. For example, if a subject is hospitalized to undergo coronary bypass surgery, record the heart condition that necessitated the bypass as the SAE.  
    Hospitalizations for the following reasons do not require reporting: 
• Hospitalization or prolonged hospitalization for diagnostic or 
elective surgical procedures for preexisting conditions; 
• Hospitalization or prolonged hospitalization required to allow 
efficacy measurement for the study ; or 
• Hospitalization or prolonged hospitalization for scheduled therapy 
of the target disease of the study.  
11.3.2.5 Pregnancy  
If a female subject becomes pregnant while receiving investigational 
therapy or within 30 days after the last dose of study drug, a report should be completed and expeditiously submitted to the Genentech, Inc as an SAE . Follow -up to obtain the outcome of the pregnancy 
should also occur. Abortion, whether accidental, therapeutic, or spontaneous, should always be classified as serious, and expeditiously reported as an SAE. Similarly, any congenital anomaly/birth defect in a child born to a female subject exposed to the bevacizumab  should be 
reported as an SAE.  
11.3.2.6 Post-Study Adverse Events 
The investigator should expeditiously report any SAE occurring after 
a subject has completed or discontinued study participation if attributed to prior bevacizumab  exposure. If the investigator should 
become aware of the development of cancer or a congenital anomaly in a subsequently conceived offspring of a female subject who participated in the study, this should be reported as an SAE. 
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
55 11.3.2.7 Reconciliation/Genentech  
The Sponsor agrees to conduct reconciliation for the product.  
Genentech and the Sponsor will agree to the reconciliation periodicity 
and format, but agree at minimum to exchange monthly line listings of cases received by the other party.  The responsible in dividuals for each 
party shall handle the matter on a case- by-case basis until satisfactory 
resolution. 
 
11.3.2.8 AEs of Special Interest (AESIs)/Genentech  
AEs of Special Interest are defined as a potential safety problem, identified as a result of safety monitorin g of the product. The Avastin 
AESIs are:  
• Hypertension  ≥ Gr 3  
• Proteinuria ≥  Gr 3  
• GI Perforation, abscesses and fistulae (any grade)  
• Wound healing complications ≥  Gr 3  
• Hemorrhage ≥  Grade 3 (any grade CNS bleeding;  > Gr 2 
hemoptysis 
• Arterial thromboembolic e vents ( any grade)  
• Venous thromboembolic events ≥  Gr 3  
• RPLS (any grade)  
• CHF ≥  Gr 3  
• Non-GI fistula or abscess ≥  Gr 2  
 
11.3.2.9 SAE Reporting /Genentech  
All SAEs  should be recorded on a MedWatch 3500a Form and SAE 
CRF and sent to NF Consortium Operations Center (A ttn: Research 
Nurse Manager ) within 24 hours. 
   The NF Consortium Operations Center must report all SAEs  reported 
by a clinical site and entered into the electronic data entry system  to 
Genentech within the timelines described below. The completed MedWatch/case report should be faxed immediately upon completion 
to Genentech Drug Safety at :  (650) 225-4682 or (650) 225-5288. 
 
• Relevant follow-up information should be submitted to Genentech Drug Safety as soon as it becomes available.    
• Serious AE reports that are related to bevacizumab  will be 
transmitted to Genentech within fifteen (15) calendar days of the Awareness Date.    
• Serious AE reports that are unrelated to the bevacizumab  will 
be transmitted to Genentech within thirty (30) calendar days of the Awareness Date.   
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
56 • Serious AE reports that are related to the study drug and AEs 
of Special Interest (regardless of causality) will be transmitted to Genentech within fifteen (15) calendar days of the Awareness Date.  
   
The Operations Center will complete Gene ntech Drug Safety fax 
cover sheet with contact information for appropriate follow-up.   The NF Consortium is also responsible for notifying the NF Consortium IRB, DSMB and appropriate Regulatory agencies.  Because this is an IND study, the IND holder, Dr. Bruce Korf, will submit the report to the FDA.   
MedWatch 3500a Reporting Guidelines: 
 
In addition to completing appropriate patient demographic and suspect medication information, the report should include the following information within the Event Description ( Section 5) of the 
MedWatch 3500a form:  
• Treatment regimen (dosing frequency, combination therapy) 
• Protocol description (and number, if assigned) 
• Description of event, severity, treatment, and outcome, if known 
• Supportive laboratory results and diagnostics 
• Investigator’s assessment of the relationship of the adverse event to each investigational product and suspect medication  Follow-up information:    Additional information may be added to a previously submitted report by any of the following methods:  
• Adding to the original MedWatch 3500a report and submitting it as follow-up; 
• Adding supplemental summary information and submitting it as follow-up with the original MedWatch 3500a form; or 
• Summarizing new information and faxing it with a cover le tter 
including subject identifiers ( i.e., D.O.B. initials, subject number), 
protocol description and number, if assigned, suspect drug, brief adverse event description, and notation that additional or follow-up information is being submitted .  (The subject  identifiers are important 
so that the new information is added to the correct initial report.) 
 
Occasionally Genentech may contact the reporter for additional information, clarification, or current status of the subject for whom and adverse event was reported.  For questions regarding SAE 
reporting, you may contact the Genentech Drug Safety representative 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
57 noted above or the MSL assigned to the study. Relevant follow-up 
information should be submitted to Genentech Drug Safety as soon as it becomes available and/or upon request. 
 
MedWatch 3500A (Mandatory Reporting) form is available at: http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM048334.pdf
 
  
Additional reporting requirements   
 
 All pregnancies whether reported by the participant, discovered during questioning, 
directly observed, or detected by physician examination, laboratory test(s) or by other means, will be recorded in the participant’s medical records and on the appropriate study-specific case report form and entered into the data- base subject record.  The 
pregnancy will also be recorded on a MedWatch 3500a Form and SAE CRF and the NF Consortium Operations Center will be notified within 24 hours.  The NF Consortium Operations Center is resp onsible for notifying Genentech of any reports 
of pregnancy following the start of administration with  bevacizumb will be 
transmitted to Genentech within thirty (30) calendar days of the Awareness Date. The NF Consortium Operations Center is also responsible for notifying the NF Consortium IRB (UAB and the DOD), DSMB , the FDA,  and all other appropriate 
regulatory agencies.  
11.4 Adverse Event Reporting to the US Army  
 
This trial receives funding by a Grant of the U.S. Army. Per US Army request, adverse events will therefore also be reported by the NF Consortium Operations 
Center to the US Army as follows: All adverse events, which require prompt reporting (as defined in Section 10.5), will be immediately reported by telephone to the USAMRMC Deputy C hief of Staff for Regulatory Compliance and Quality 
(301-619-2165) (non-duty hours call 301-619- 2165 , email or  by facsimile to (301 -
619-7803).  A written report will follow the initial contact within three working 
days to the NF Consortium Operations Cente r.  The NF Operations Center will 
notify all appropriate study regulatory personnel and send a written report to the U.S. Army Medical Research and Materiel Command within seven working days of the initial contact to ATTN: MCMR -RCQ, 504 Scott Street, Fort Detrick, Maryland 
21702- 5012  or email.  
11.5 Reporting Requirements  
 The study must be conducted in compliance with FDA regulations, local safety 
reporting requirements, and reporting requirements of the P rincipal Investigator.  
 
Each investigative site will be  responsible for report ing SAEs that occur at that 
institution to their respective IRB. It is the responsibility of the Operations Center  to 
report serious adverse events  (SAEs) to the study sponsor and/or others as previously 
described and according to the schedule below.     
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
58 11.6 Reporting to the Study Sponsor  
11.6.1  Serious Adverse Event Reporting  
All serious adverse events that occur after the initial dose of study treatment, 
during treatment, or within 30 days of the last dose of treatment must be reported to the NF Consortium Research Nurse Manager using the appropriate SAE reporting forms, MedWatch Form 3500a. This includes events meeting the criteria outlined in Section 11.1.2, as well as the following:  
• Grade 2 (moderate) and Grade 3 (severe) events that are unexpected and at least possibly related/associated with the intervention.  
• All Grade 4 (life -threatening or disabling) events that are unexpected or 
not specifically listed in the protocol as not requiring reporting. 
• All Grade 5 (fatal) events while the participant is enrolled and actively participating in the trial OR when the event occurs within 30 days of the last study intervention.  
 
Note : If the participant is in long term follow up, report the death at the 
time of continuing review.  
 Participating investigators must report each serious adverse event to the NF Consortium Operations Center Research Nurse Manager  (Liz Davis)  within 24 
hours of learning of the occurrence. In the event that the participating investigator does not become aware of the serious adverse event immediately (e.g., participant sought treatment elsewhere), the participating investigator is 
to report the event within 24 hours after learning of it and document the time of his or her first awareness of the adverse event. Report serious adverse events by email to:  NF Consortium Operations Center Research Nurse Manager  
Attn: Liz Davis, RN, MPH, CCRC 
Email: lvdavis@uab.edu
 
 and 
 
  Scott R. Plotkin, MD, PhD    Telephone: 617-724-8770     Email: splotkin@partners.org
  
  F ax: 617-724-8769 
 
Within the following 24-48 hours, the participating investigator must provide follow-up information on the serious adverse event. Follow-up information should describe whether the event has resolved or continues, if and how the event was treated, and wheth er the participant will continue or discontinue 
study participation.  
   
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
59 11.6.2  Non-Serious Adverse Event Reporting  
 
Non-serious adverse events will be reported to the NF Consortium via the UAB  
web-based data entry  system  on the adverse event screen(s).   All non-serious 
adverse events will be forwarded, at most, on a quarterly report to Genentech. 
11.7 Reporting to the Institutional Review Board (IRB) 
 All participating study sites will report all serious adverse events directly to their institutional regulatory agencies according to their institutional policies and procedures.   
A copy of the submitted institutional SAE documentation should be forwarded to: 
 NF Consortium Operations Center  Attn: Roy  McDonald   
Phone: (205) 975-4075 Email: rmcdonald@uab.edu
 
 
All SAE reports will be reported to Study PI  by the Operations Center.  
11.8 Reporting to the Food and Drug Administration (FDA)  
 
For Investigator -Sponsored IND Studies, some additional reporting requirements for 
the FDA apply in accordance with the guidance set forth in 21 CFR § 600.80.  All related adverse events that are both serious and unexpected will be sent to the FDA on Form FDA 3500A MedWatch Form (http://www.fda.gov/medwatch/getforms.htm
) by Dr. Bruce Korf and the Operations 
Center.   MedWatch Form will be sent by mail or fax to:  
 MedWatch  
5600 Fisher s Lane  
Rockville, MD 20852-9787 Fax: 1 -800- FDA -0178 
 Events meeting the following criteria need to be submitted to the Food and Drug Administration (FDA) as expedited IND Safety Reports by Dr. Bruce Korf according 
to the following guidance and timelines: 
• 7 Calendar Day via Telephone or Fax Report 
The IND-holder is required to notify the FDA of any fatal or life -
threatening adverse event that is unexpected and assessed by the investigator to be possibly related to the use of bevacizumab. An unexpected adverse event is one that is not already described in the bevacizumab Investigator Brochure. Such reports are to be telephoned or 
faxed to the FDA and Genentech within 7 calendar days of first learning of the event. 
• 15 Calendar Day via Written Report 
The IND-holder with support of Protocol Chair is also required to notify 
the FDA and all participating investigators, in a written IND Safety 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
60 Report, of any serious, unexpected AE that is considered reasonably or 
possibly related to the use of bevacizumab . An unexpected adverse event 
is one that is not already described in the bevacizumab  investigator 
brochure. 
 
Written IND Safety Reports should include an Analysis of Similar Events in accordance with regulation 21 CFR § 312.32. All safety reports previously fi led by 
the investigator with the IND concerning similar events should be analyzed and the significance of the new report in light of the previous, similar reports commented on.  Written IND safety reports with Analysis of Similar Events are to be submitted  to the 
FDA, Genentech, and all participating investigators within 15 calendar days of first learning of the event. The FDA prefers these reports on a Med Watch 3500 form, but 
alternative formats are acceptable ( e.g., summary letter).    
   FDA Fax number  for IND Safety Reports :  
1 (800) FDA 0178 
 
All written IND Safety Reports submitted to the FDA by the Investigator must also be faxed to Genentech Drug Safety  at:   
 (650) 225-4682 or (650) 225-5288 
   
and to the Site IRB s:  
(see contact information about Consortium Participating Sites  at 
the beginning of the document) 
     For questions related to safety reporting, please contact Genentech Drug Safety:  
Tel: (888) 835-2555 Fax: (650) 225-4682 or (650) 225-5288  
IND Annual Report  
 
Copies to Genentech :  All IND annual reports submitted to the FDA by the 
Sponsor-Investigator should be copied to Genentech. Copies of such reports should 
also be faxed to Genentech Drug Safet y: 
 Fax: (650) 225-4682 or (650) 225-5288 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
61 11.9 Reporting to the NIH Office of Biotechnology Activities (OBA)  
 
N/A  
11.10 Reporting to the Institutional Biosafety Committee (IBC)  
 
N/A.  
11.11 Reporting to Hospital Risk Management 
 Participating investigators will report to their local Risk Management office any subject safety reports or sentinel events that require reporting according to institutional policy.  
11.12 Monitoring of Adverse Events and Period of Observation 
 
All adverse events attributable to study drug, both serious and non-serious, and deaths that are encountered from initiation of study intervention, throughout the study, and within 30 days of the last study intervention should be followed to their resolution, or until the participating investigator assesses them as stable, or the participating investigator determines the event to be irreversible, or the participant is lost to follow -up. The presence and resolution of AEs and SAEs (with dates) should 
be documented on the appropriate written or electronic  case report form and recorded 
in the participant’s medical record to facilitate source data verificat ion.  
 For some SAEs, the study sponsor or designee may follow-up by telephone, fax, and/or monitoring visit to obtain additional case details deemed necessary to appropriately evaluate the SAE report ( e.g., hospital discharge summary, consultant 
report, or autopsy report).   Participants should be instructed to report any serious post-study event(s) that might reasonably be related to participation in this study. Participating investigators should notify the Study PI and Operations Center and their respective IRB of any 
unanticipated death or adverse event occurring after a participant has discontinued or terminated study participation that may reasonably be related to the study.   
12. DATA AND SAFETY MONITORING  
12.1 Data Reporting 
12.1.1  Method  
The NF Consortium Data Management and Analysis Center (DMAC) will 
collect, manage, and monitor data for this study.  
 
DMAC Director: Gary Cutter , PhD  
Phone: 205- 975-5048  
Email: cutterg@ ms.soph. uab.edu  
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
62 DMAC Deputy Director : Joan Hilner , MPH, MA  
Phone:  205- 934-4943  
Email:  jhilner@uab.edu  
 
DMAC Program Manager: Steve Powell, PhD  
Phone:  205- 934-6741  
powells@uab.edu  
 DMAC Fax:  205-975- 2540 
12.1.2  Data Submission  
The schedule for completion and submission of electronic case report  forms 
(paper or electronic) to the NF Consortium via a web -based data entry system as 
follows : 
 
Form  Submission Timeline  
Eligibility Checklist  Complete prior to registration and 
enrollment with NF DMAC  
On Study Form  Within 14 days of registration  
Baseline Assessment Form  Complete prior to enrollment  
Treatment Form  Within 10 days of the last day of the 
treatment  
Adverse Event Report Form Within 10 days of the last day of the evaluation  
Serious Adverse Event 
Reporting  Initial reporting within 24 hours of awareness of occurrence  
Response Assessment Form 
(i.e., audiology and MRI 
assessment forms)  Within 10 days of the completion of the 
cycle required for response evaluation  
Off Treatment/Off Study 
Form  Within 14 days of completing treatment or 
being taken off study for any reason 
Follow up/Survival Form  Within 14 days of the protocol defined follow up visit date or call 
The NF Consortium D MAC  is responsible for compiling and providing the 
data to the Principal Investigator for review.  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
63 12.2 Safety Meetings  
 
The trial PI and clinical coordinator will review the study progress regularly. Patients entered on the trial and adverse events will be reviewed to ensure that the study is implemented as outlined in the protocol. Monthly reports will be generated by the NF Consortium to assess completeness and timeliness of data. There will be monthly phone conferences between the NF Consortium and the Principal Investigator to address QA issues.  A Data Safety Monitoring Board has been established for the purpose of ensuring data compliance and regular monitoring of this trial.   A medical monitor has be en selected for this study (Dr. Christopher Moertel, see 
roster at beginning of protocol). The medical monitor is  a qualified physician and is 
not associated with this particular protocol.  The monitor  will work closely with the 
DSMB and Protocol Chair to monitor the participants’ treatment while on this study.  
 The medical monitor is required to review all unanticipated problems involving risk to subjects or others, serious adverse events and all subject deaths associated with the protocol and provide an unbiased written report of the event.  At a minimum, the medical monitor should comment on the outcomes of the event or problem, and in the case of a serious adverse event or death, comment on the relationship to participation in the study.  The medical monitor should also indicate whether he/she concurs with the details of the report provided by the study investigator.  Reports for events determined by either the investigator or medical monitor to be possibly or definitely related to participation and reports of events resulting in death should be promptly forwarded to the USAMRMC ORP HRPO. 
12.3  Monitoring  
Involvement in this study as a participating investigator implies acceptance of potential audits or inspections, including source data verification, by representatives designated by the Protocol Chair or NF Consortium Operations Center. The purpose of these audits or inspections is to examine study- related activities and 
documents to determine whether these activities were conducted and data were recorded, analyzed, and accurately rep orted in accordance with the protocol, 
institutional policy, Good Clinical Practice (GCP), and any applicable regulatory requirements and to ensure subject safety.   
 
All data will be monitored for timeliness of submission, completeness, and adherence to pr otocol requirements.  
 
12.4 Privacy  
Data provided must be treated in strictest confidence.  No information provided from individual subject’s records may be discussed with anyone other than those individuals mentioned in the collaborative research agreement.  D ata may not be 
released in any form except as provided in the agreement.  
 
  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
64 12.5 Confidentiality  
Each subject enrolled will, from that point forward, be identified by a unique 
identifier (study number).  This study number will also be used for any research specimens collected and shipped to analysts outside of the NF Consortium. All records generated will be stored in a locked office area, only accessible to study personnel.  Clinical information will be accessed, according  to HIPAA 
requirements, by study personnel to complete study documents, as needed . For 
standard of care procedure reimbursement, clinical information may be shared with insurers.  
 
13. REGULATORY CONSIDERATIONS  
13.1 Protocol Review and Amendments  
This protocol, the proposed informed consent and all forms of participant 
information related to the study ( e.g., advertisements used to recruit participants) 
and any other necessary documents must be submitted, reviewed and approved by a properly constituted IRB governing each study location.  
Any changes made to the protocol must be submitted as amendments and must be 
approved by the DSMB, Genentech, and the UAB IRB prior to implementation. 
Any changes in study conduct must be reported to the IRB. The NF Consortium Operations Center will disseminate protocol amendment information to all participating investigators.  
All decisions of the IRB concerning the conduct of the study must be made in writing.  
13.2 Informed Consent  
 
All participants must be provided a consent form describing this study and providing sufficient information for participants to make an informed decision about their participation in this study. The formal consent of a participant, using the IRB approved consent form, must be obtained before the participant is involved in any study -related proce dure. The consent form must be signed 
and dated by the participant or the participant’s legally authorized representative, and by the person obtaining the consent. The process of informed consent should also be documented in the subject research record. Th e 
participant must be given a copy of the signed and dated consent document. The original signed copy of the consent document must be retained in the 
medical record or research file.  
13.3 Ethics and Good Clinical Practice (GCP)  
This study is to be conducted according to the following considerations, which represent good and sound research practice:  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
65 • E6 Good Clinical Practice: Consolidated Guidance 
www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129515.p
df  
• US Code of Federal Regulations (CFR) governing clinical study conduct 
and ethical principles that have their origin in the Declaration of Helsinki 
o Title 21 Part 11 – Electronic Records; E lectronic Signatures 
www.access.gpo.gov/nara/cfr/waisidx_02/21cfr11_02.html  
o Title 21 Part 50 – Protection of Human Subjects 
www.access.gpo.gov/nara/cfr/waisidx_02/21cfr50_02.html   
o Title 21 Part 54 – Financial Disclosure by Clinical Investigators 
www.access.gpo.gov/nara/cfr/wais idx_02/21cfr54_02.html   
o Title 21 Part 56 – Institutional Review Boards 
www.access.gpo.gov/nara/cfr/waisidx_02/21cfr56_02.html   
o Title 21 Part 312 – Investigational New Drug Applic ation 
www.access.gpo.gov/nara/cfr/waisidx_02/21cfr312_02.html   
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
66 State laws  
It is understood that deviations from the protocol should be avoided, except when 
necessary to eliminate an immediate hazard to a research participant. In such case, the deviation must be reported to the IRB according to the local reporting policy.  
13.4 Study Documentation 
 
The investigator must prepare and maintain adequate and accurate case histories designed to record all observations and other data pertinent to the study for each research participant , including all protocol deviations. This information enables the 
study to be fully documented and the study data to be subsequently verified.  
 
Original source documents supporting entries in the electronic data entry system  
include but are not limited to hospital records, clinical charts, laboratory and pharmac y records, recorded data from automated instruments, microfiches, 
photographic negatives, microfilm or magnetic media, and/or x- rays. To standardize 
data collection and entry, study staff can complete a hard copy of the eCRFs prior to entry into the web- based data collection system.  
13.5 Records Retention  
 
All study -related documents must be retained for the maximum period required by 
applicable federal regulations and guidelines or institutional policies.  
13.6 Multi -center Guidelines  
This protocol will adhere to the policies and requirements of NF Consortium IRB and the Sponsor . The specific responsibilities of the Protocol Chair, NF 
Consortium Coordinating Center, and Participating Institutions  are presented in the 
Multi- Center Data and Safety Monitoring Plan.  
• The Protocol Chair  and NF Consortium Coordinating Center are  responsible 
for distributing all IND Action Letters or Safety Reports to all participating 
institutions for submission to their individual IRBs for action as required.  
• Mechanisms will be in place to ensure quality assurance, protocol compliance, and adverse event reporting at each site.  
• Except in very unusual circumstances, each participating institution will order 
the agent from a licensed drug distribution vendor. A participating site 
may order the  agent(s) only after the initial IRB  approval for the site has been 
forwarded to the drug distribution center at UAB.   
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
67 13.7 Cooperative Research and Development Agreement (CRADA)/Clinical Trials 
Agreement (CTA)  
 
N/A  
14. STATISTICAL CONSIDERATIONS  
 
14.1 Study Design/Endpoints  
 
The primary endpoint for the study is hearing response at 24 weeks, defined as an improvement in word recognition score above the 95% critical difference, taking as reference the baseline word recognition score (Appendix A).  We will use a  Simon 
two stage MinMax design with a one sided significance level of .05 and 90% power for a null response rate of .03 vs. an alternative of .23.  This design calls for accruing 14 patients in the first stage.  If none respond, the study will be terminated with the conclusion that bevacizumab  is not effective.  Otherwise we will accrue 8 additional 
patients for a total of 22.  Bevacizumab  will be considered effective if and only if 3 
or more of the 22 respond.   
14.2 Sample Size/Accrual Rate  
 
 A maximum of 22 e valuable s ubjects will be accrued into the trial.  Allowing for 
10% inevaluable, we may need to accrue a total of 24.  We believe this 10% ra te is 
reasonable since no patients discontinued treatment due to toxicity in the previous study using bevacizumab.  Similarly, no patients have discontinued treatment in an ongoing study of PTC299 in adult patients with NF2.  The estimated accrual rate is 2 subjects per month with an expected accrual period will be about 12 months.  If the true response rate for bevacizumab  is .03 then the probability of stopping after 
only 14 patients is .65 and the expected sample size is 16.78.   
14.3 Stratification Factors  
 
None 
14.4 Analysis of Secondary Endpoints  
 
The secondary endpoints include :  
 
• Frequency of adverse events (possibly, probably, or definitely) related to bevacizumab use in this patient population;  
• Proportion of patients with a radiographic response at 24, 48, 72, and 96 weeks; 
• Proportion of patients with a hearing response at weeks 48, 72, and 96  (response defined as a statistically significant improvement in word recognition score compared with baseline score—Appendix A );  
• Proportion of patients free from progressive hearing loss at 24, 48, 72, and 96 
weeks  (response defined as a statistically significant decline in wo rd 
recognition score compared with baseline score);  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
68 • Proportion of patients free from tumor progression at weeks 24, 48, 72, and 96  
(progression defined as an increase in VS volume by ≥ 20% );  
• Durability of hearing response in patients with a hearing respo nse at 24 weeks, 
as measured freedom from hearing loss  at weeks 48, 72, and 96  (progression 
defined as a decrease in word recognition score below the 95% critical difference compared with values at 24 weeks, Appendix A );  
• Durability of radiographic response in patients with a radiographic response at 24 weeks , as measured by freedom from tumor progression at  weeks 48, 72, 
and 96  (progression defined as an increase in VS volume by ≥ 20%  compared 
with volume at 24 weeks, Appendix A );  
• Change in 4-tone pure tone average compared to baseline.  The proportions above will be estimated from our data and exact 95% confidence intervals will be constructed.  Changes in 4-tone pure tone average will be described descriptively by means, medians, and standard deviations.    
• Change in tinnitus as measured by the Tinnitus Questionnaire (Appendix H).  The proportions above will be estimated from our data and exact 95% confidence intervals will be constructed.  Changes in tinnitus will be described descriptively by me ans, medians, and standard deviations.    
 
Radiographic response rate 
The secondary endpoint of change in target tumor size  will be assessed by 
volumetric analysis of MRI scans.  In a longitudinal study of plexiform neurofibromas in 49 patients, no patients experienced spontaneous tumor regression, as assessed by volumetric MRI scanning.
49  Similarly , the proportion of 
patients with spontaneous tumor regression of vestibular schwannoma in the international Natural History of NF2 Study  was < 5 %.
50  The radiologic response 
rate will be reported for all patients in the study and for all patients who complete at least 12 weeks of treatment.  Radiologic response rates will be reported with exact 95% confidence limits.  The durability of radiographic response over time will estimated using the Kaplan -Meier method.  The median of the duration of 
response time with 95% confidence limits will be reported.  The proportion of patients free from tumor progression at weeks 24, 48, 72, and 96 will be reported with 95% confidence limits.  
 
Audiometric outcomes 
Secondary endpoints will include changes in word recognition scores, pure-tone averages (PTAs), and tinnitus questionnaire scores.  These tests will be performed at baseline and every 24 weeks . 
 
o Word recognition score:  A hearing response will be defined as 
improvement in word recognition score above the 95% critical difference (Appendix A ) in the affected ear.  The hearing response rate will be 
reported for all patients in the study and for all patients who complete at least 12 weeks of treatment.  Hearing response rates at weeks 24, 72, and 96 will be reported with exact 95% confidence limits.  The durability of hearing response over time will be estimated using the Kaplan -Meier 
method.  The median time with 95% confidence limits will be reported.  The proportion of patients free from hearing decline at weeks 24, 48 72, and 96 will be reported with 95% confidence limits.  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
69 o Pure tone average : A 12 dB change in 4- frequency Pure T one Average will 
be considered clinically significant. The proportion with this change will be 
estimated and an exact 95% confidence interval computed.  
o Tinnitus:  In the analysis of the Tinnitus Questionnaire data, compliance 
with questionnaire administra tion (defined as the proportion of 
questionnaires actually received out of the expected number) will be calculated. Questionnaires will be scored as recommended in the user manual for the instrument.  
 
14.5 Reporting and Exclusions  
 
14.5.1  Evaluation of toxicity.  All patients will be evaluable for toxicity from the time 
of their first treatment with bevacizumab.  
 14.5.2  Evaluation of response.  Only those patients who have received at least one 
cycle of therapy, and have had their disease re -evaluated will be considered 
evaluable for response.  Each participant should be assigned one of the following 
categories: 1) hearing response, 2) stable hearing, 3) progressive hearing loss, 4) early death from NF2 -related condition, 5) early death from toxicity, 6) early 
death because o f other cause, or 9) unknown (not assessable, insufficient data). 
By arbitrary convention, category 9 usually designates the "unknown" status of any type of data in a clinical database.  
 All of the participants who met the eligibility criteria (with the po ssible 
exception of those who received no study medication) should be included in the main analysis of the response rate. Participants in response categories 5- 9 should 
be considered to have a treatment failure (disease progression). Thus, an 
incorrect treatment schedule or drug administration does not result in exclusion from the analysis of the response rate.  
 All conclusions should be based on all eligible participants. Subanalyses may then be performed on the basis of a subset of participants, excluding 
those for whom major protocol deviations have been identified ( e.g., early death 
due to other reasons, early discontinuation of treatment, major protocol 
violations, etc.). However, thes e subanalyses may not serve as the basis for 
drawing conclusions concerning treatment efficacy, and the reasons for excluding participants from the analysis should be clearly reported. The 95% confidence intervals should also be provided. 
15. PUBLICATION PLAN  
The results of this study will be made public within 24 months of the end of data collection. If a report is planned to be published in a peer-reviewed journal, then that initial release may be an abstract that meets the requirements of the International Committee of  Medical Journal Editors. A full report of the outcomes should be made 
public no later than three (3) years after the end of data collection.  
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
70 16. REFERENCES  
 
Reference List  
 
 1.  CBTRUS. Statistical report: primary brain tu mors in the United States, 1998-2002. 2005 
 2.  Otsuka G, Saito K, Nagatani T, Yoshida J. Age at symptom onset and long- term survival 
in patients with neurofibromatosis Type 2. J Neurosurg 2003;99(3):480-483. 
 3.  Badie B, Pyle GM, Nguyen PH, Hadar EJ. Elevation of internal auditory canal pressure 
by vestibular schwannomas. Otol Neurotol 2001;22(5):696-700. 
 4.  Evans DGR, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and 
new primary tumours after therapeutic radiation for benign diseas e: substantial risks in 
certain tumour prone syndromes. J Med Genet 2006;43(4):289-294. 
 5.  Mathieu D, Kondziolka D, Flickinger JC et al. Stereotactic radiosurgery for vestibular 
schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, 
complications, and hearing preservation rates. Neurosurgery 2007;60(3):460-468. 
 6.  Plotkin SR, Stemmer -Rachamimov AO, Barker FG et al. Hearing improvement after 
bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361(4):358-367. 
 7.  Mahmud MR, Khan AM, Nadol JB, Jr. Histopathology of the inner ear in unoperated 
acoustic neuroma. Ann Otol Rhinol Laryngol 2003;112(11):979-986. 
 8.  Thornton AR, Raffin MJ. Speech- discrimination scores modeled as a binomial variable. 
J Speech Hear Res 1978;21(3):507-518. 
 9.  Halpin C, Rauch SD. Using audiometric thresholds and word recognition in a treatment 
study. Otol Neurotol 2006;27(1):110-116. 
 10.  Hornigold R, Golding JF, Lechziner G et al. The NFTI -QOL: A new disease -specific 
quality of life score for NF2. Children's Tumor Foundation Conference , 22. 2011.  
Ref Type: Abstract  
 11.  Committee on Hearing and Equilibrium guidelines for the evaluation of hearing 
preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology-Head and Neck Surgery Foundation, INC. Otolaryngol Head Neck Surg 1995;113(3):179-180. 
 12.  Harris GJ, Plotkin SR, MacCollin M et al. Three- dimensional volumetrics for tracking 
vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery 2008;62(6):1314-1319. 
 13.  Solomon J, Warren K, Dombi E, Patronas N, Widemann B. Automated detection and 
volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance im aging. Comput Med Imaging Graph 2004;28(5):257-265. 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
71  14.  Babovic-Vuksanovic D, Ballman K, Michels V et al. Phase II trial of pirfenidone in 
adults with neurofibromatosis type 1. Neurology 2006;67(10):1860-1862. 
 15.  Dombi E, Solomon J, Gillespie AJ et al. NF1 plexiform neurofibroma growth rate by 
volumetric MRI: relationship to age and body weight. Neurology 2007;68(9):643-647. 
 16.  Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti- vascular endothelial 
growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57(20):4593-4599. 
 17.  Avastin
™ (bevacizumab) Investigator's Brochure. 2007 
 18.  Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced 
angiogenesis suppresses tumour growth in vivo. Nature 1993;362(6423):841-844. 
 19.  Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF -specific 
antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10(2):145-147. 
 20.  Borgstrom P , Gold DP, Hillan KJ, Ferrara N. Importance of VEGF for breast cancer 
angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999;19(5B):4203-4214. 
 21.  Kabbinavar F, Wong JT, Ayala RE. The effect of antibody to vascular endothelial 
growth factor and cisplatin on the growth of lung tumors in nude mice. Proc.Am.Assoc.Cancer Res. 36, A488. 1995.  
Ref Type: Abstract  
 22.  Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both 
pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111(9):1287-1295. 
 23.  Shaheen RM, Ahmad SA, Liu W et al. Inhibited growth of colon cancer ca rcinomatosis 
by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001;85(4):584-589. 
 24.  Cobleigh MA, Langmuir VK, Sledge GW et al. A phase I/II dose- escalation trial of 
bevacizumab in previously treated metastatic br east cancer. Semin Oncol 2003;30(5 
Suppl 16):117-124. 
 25.  Allegra CJ, Yothers G, O'Connell MJ et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011;29(1):11-16. 
 26.  Glade Bender JL, Adamson PC, Reid JM et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2008;26(3):399-405. 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
72  27.  Benesch M, Windelberg M, Sauseng W et al. Compassionate use of bevacizumab 
(Avastin) in children and young adults with refractory or recurrent solid tumors. Ann 
Oncol 2008;19(4):807-813. 
 28.  Bender JL, Adamson PC, Reid JM et al. Phase I trial and pharmacokinetic study of 
bevacizumab in  pediatric patients with refractory solid tumors: a Children's Oncology 
Group Study. J Clin Oncol 2008;26(3):399-405. 
 29.  Packer RJ, Jakacki R, Horn M et al. Objective response of multiply recurrent low- grade 
gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009;52(7):791-795. 
 30.  Gururangan S, Chi SN, Young PT et al. Lack of efficacy of bevacizumab plus irinotecan 
in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol 2010;28(18):3069-3075. 
 31.  Reismuller B, Azizi AA, Peyrl A et al. Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatr Blood Cancer 2010;54(5):681-686. 
 32.  Narayana A, Kunnakkat S, Chacko- Mathew J et al. Bevaci zumab in recurrent high- grade 
pediatric gliomas. Neuro Oncol 2010;12(9):985-990. 
 33.  Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and 
bevacizumab. N Engl J Med 2006;354(9):980-982. 
 34.  Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and 
bevacizumab. N Engl J Med 2006;354(9):980-982. 
 35.  Hambleton J, Skillings JR, Kabbinavar F, Bergsland E, Holmgren E, Holden SN. Safety 
of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology 23[Suppl 16s], 3554. 2005.  
Ref Type: Abstract  
 36.  Scappaticci FA, Fehrenbacher L, Cartwright T et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab . J Surg 
Oncol 2005;91(3):173-180. 
 37.  Miller KD, Wang M, Gralow J, Dickler M. E2100: a randomized phase III trial of 
paclitaxel versus paclitaxel plus bevacizumab as first -line therapy for locally recurrent or 
metastatic breast cancer. Journal of Clinical Oncology 23. 2005.  
Ref Type: Abstract  
 38.  Karp JE, Gojo I, Pili R et al. Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1 -beta-d-
arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res 2004;10(11):3577-3585. 
 39.  Sandler A, Gray R, Perry MC et al. Paclitaxel -carboplatin alone or with bevacizumab for 
non-small- cell lung cancer. N Engl J Med 2006;355(24):2542-2550. 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
73  40.  Baser ME, Friedman JM, Aeschliman D et al. Predictors of the risk of mortality in 
neurofibromatosis 2. Am J Hum Genet 2002;71(4):715-723. 
 41.  Duda DG, Willett CG, Ancukiewicz M et al. Plasma soluble VEGFR -1 is a potential 
dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 2010;15(6):577-583. 
 42.  Willett CG, Duda DG, Xu L et al. Correlation of blood and physiologic markers with effect of bevacizumab (BV) with chemoradiation therapy in rectal cancer (RC). Journal of Clinical Oncology 26[May 20 suppl.], 202s. 2008.  
Ref Type: Abstract  
 43.  Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R. NIH 
conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 1990;113(1):39-52. 
 44.  Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG. Evaluation of 
clinical diagnostic criteria for neurofibromatosis 2. Neurology 2002;59(11):1759-1765. 
 45.  Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan- VEGF receptor 
tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11(1):83-95. 
 46.  Willett CG, Boucher Y, Duda DG et al. Surrogate markers for antiangiogenic therapy and dose- limiting toxicities for bevacizumab with radiation and chemotherapy: 
continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23(31):8136-8139. 
 47.  Therasse P, Arbuck SG, Eisenhauer EA et al . New guidelines to evaluate the response to 
treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216. 
 48.  Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase 
II studies of supratentorial malignant glioma. J Clin Oncol 1990;8(7):1277-1280. 
 49.  Dombi E, Solomon J, Gillespie AJ et al. NF1 plexiform neurofibroma growth rate by 
volumetric MRI: relationship to age and body weight. Neurology 2007;68(9):643-647. 
 50.  Slattery WH, III, Fisher LM, Iqbal Z, Oppenhiemer M. Vestibular schwannoma growth 
rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol 2004;25(5):811-817. 
 51.  Kopke RD, Hoffer ME, Wester D, O'Leary MJ, Jackson RL. Targeted topical steroid 
therapy in sudden sensorineural hearing loss. Otol Neurotol 2001;22(4):475-479. 
 52.  Sorensen AG, Patel S, Harmath C et al. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol 2001;19(2):551-557. 
  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
74 17. APPENDICES  
Appendix A: Hearing Response Guidelines  
 
Clinical criteria for definition of hearing response based on a 50-word hearing test.  Upper and 
lower limits for the 95% critical differences for percentage scores are adapted from Thornton.8 
 
Baseline word 
recognition  
score (%) 95% critical  
difference (%)  Hearing 
Response (%)  Progressive 
hearing loss (%) 
0 0–4 ≥ 6 n/a 
2 0–10 ≥ 12 n/a 
4 0–14 ≥ 16 n/a 
6 2–18 ≥ 20 0 
8 2–22 ≥ 24 0 
10 2–24 ≥ 26 0 
12 4–26 ≥ 28 ≤ 2 
14 4–30 ≥ 32 ≤ 2 
16 6–32 ≥ 34 ≤ 4 
18 6–34 ≥ 36 ≤ 4 
20 8–36 ≥ 38 ≤ 6 
22 8–40 ≥ 42 ≤ 6 
24 10–42 ≥ 44 ≤ 8 
26 12–44 ≥ 46 ≤ 10 
28 14–46 ≥ 48 ≤ 12 
30 14–48 ≥ 50 ≤ 12 
32 16–50 ≥ 52 ≤ 14 
34 18–52 ≥ 54 ≤ 16 
36 20–54 ≥ 56 ≤ 18 
38 22–56 ≥ 58 ≤ 20 
40 22–58 ≥ 60 ≤ 20 
42 24–60 ≥ 62 ≤ 22 
44 26–62 ≥ 64 ≤ 24 
46 28–64 ≥ 66 ≤ 26 
48 30–66 ≥ 68 ≤ 28 
50 32–68 ≥ 70 ≤ 30 
52 34–70 ≥ 72 ≤ 32 
54 36–72 ≥ 74 ≤ 34 
56 38–74 ≥ 76 ≤ 36 
58 40–76 ≥78 ≤ 38 
60 42–78 ≥ 80 ≤ 40 
62 44–78 ≥ 80 ≤ 42 
64 46–80 ≥ 82 ≤ 44 
66 48–82 ≥ 84 ≤ 46 
68 50–84 ≥ 86 ≤ 48 
70 52–86 ≥ 88 ≤ 50 
72 54–86 ≥ 88 ≤ 52 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
75 74 56–88 ≥ 90 ≤ 54 
76 58–90 ≥ 92 ≤ 56 
78 60–92 ≥ 94 ≤ 58 
80 64–92 ≥ 94 ≤ 62 
82 66–94 ≥ 96 ≤ 64 
84 68–94 ≥ 96 ≤ 66 
86 70–96 ≥ 98 ≤ 68 
88 74–96 ≥ 98 ≤ 72 
90 76–98 100 ≤ 74 
92 78–98 100 ≤ 76 
94 82–98 100 ≤ 80 
96 86–100 n/a ≤ 84 
98 90–100 n/a ≤ 88 
100 96–100 n/a ≤ 94 
 
  
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
76 Appendix B:  NFTI -QOL (Neurofibromatosis 2 impact on quality of life) 
 
SUBJECT IDENTIFIER: _____________________________________ 
 
 INSTRUCTIONS FOR COMPLETING THE NFTI-QOL  
 
Please complete the following information:  
 
Age:              years  
 
Gender: Male     1   Female    2           (please tick) 
 
 
For each of the questions on the next page, please tick the one box that 
describes how you feel today 
 
Usual activities include: work; housework; study; sport; social; family or leisure activities  
 
 
Guy’s  NFTI-QOL  
 
Q1. Do balance or dizziness problems stop you performing your usual  activities?  
No balance problems or dizziness                                          □0 
Balance or dizzi ness pr oblems but no di fficultie s                 □1 
Balance or dizziness problem s cause m e some difficulties   □2 
Balance or dizziness problem s stop my usual activities        □3 
 
Q2. Do hearing problems stop you perfo rming your  usual  activities? 
No hearing  problem s                                                              □0 
Hearing problems but no difficulty                                        □1 
Hearing problem s cause me some difficulty                          □2 
Hearing problem s stop my usual activities                            □3 
 
 
Q3. Does facial weakness stop you performing  your  usual  activities? 
No facial weakness                                                                □0 
Facial weakness, but no difficulty                                         □1 
Facial weakness causes so me difficulty                                 □2 
Facial weakness stops my usual ac tivities                             □3 
 
 
 
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
77 Q4. Do problems with your sight stop you performing your us ual activities?  
No problems with sight                                                          □0 
Sight problems, but no difficulty                                           □1 
Sight problem s cause m e some difficulty                              □2 
Sight proble ms stop my usual ac tivities                                 □3 
 
Q5. Do you have any  problems  in mobility and walking? 
No problems in m obility  and walking                                   □0 
Some diffi culty but can manage on my own                         □1 
Unable to walk around without som e help                            □2 
Unable to walk at  all                                                              □3 
 
Q6. Has your medical condition affected your  role and outlook on life?  
(e.g., confidence, vulnerability, relationships, caring for family, career, having children) 
No e ffect or positive effect                                                    □0 
Small negative effect                                                              □1 
Moderately  negative effect                                                    □2 
Large negative effect                                                              □3 
 
Q7. Pain; t hroughout  our lives, most of us have had pain from time to time such as mild 
headaches, sprains and toothaches. Have you had pain other than this in the last week? 
None                                                                                       □0 
Mild p ain                                                                                □1 
Moderate pain                                                                        □2 
Severe pain                                                                             □3 
 
Q8. Do you currently suffer fr om anxiety or depression?  
No                                                                                           □0 
Mild anxiety or depression                                                     □1 
Moderate anxiety or depression                                             □2 
Extre me anxiety or depression                                               □3 
Bevacizumab for children and young adults with NF2    
Protocol Version Date:  April 15, 2015    Version 1.3  
1CONFIDENTIAL  
This document is confidential. Do not disclose or use except as authorized.  
 
78  
Guy's  NFTI -QOL  
 
If you have any further  comments  regarding the impact  of NF2 on your  quality 
of life, please write  them here:  
 
 
 
  
 
 
 
  
 
  
 
 
You have now completed  the  NFTI- QOL.  Thank you for your  input.  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 79 Appendix C : Performance Status Criteria  
 
 
ECOG Performance Status Scale 
  
Karnofsky Performance Scale 
Grade  Description  Percent  Description  
0 Normal activity. Fully active, able 
to carry on all pre-disease 
performance without restriction.  100 Normal, no complaints, no 
evidence of disease.  
90 Able to carry on normal activity; 
minor signs or symptoms of 
disease.  
1 Symptoms, but ambulatory. 
Restricted in physically strenuous 
activity, but ambulatory and able to carry out work of a light or sedentary nature ( e.g., light 
housework, office work).  80 Normal activity with effort; 
some signs or symptoms of 
disease.  
70 Cares for self, unable to carry on 
normal activity or to do active 
work.  
2 In bed < 50% of the time. 
Ambulatory and capable of all self -
care, but unable to carry out any work activities. Up and about more than 50% of waking hours.  60 Requires occasional assistance, 
but is able to care for most of 
his/her needs.  
50 Requires considerable assistance 
and frequent medical care.  
3 In bed >50% of the time. Capable 
of only limited self -care, confined 
to bed or chair more than 50% of waking hours.  40 Disabled, requires special care 
and assistance.  
30 Severely disabled, 
hospitalization indicated. Death 
not imminent.  
4 100% bedridden. Completely 
disabled. Cannot carry on any self -
care. Totally confined to bed or chair.  20 Very sick, hospitalization 
indicated. Death not imminent.  
10 Moribund, fatal processes 
progressing rapidly.  
5 Dead.  0 Dead.  
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 80  Appendix D :  Grading and management of hypertension for adults and for children 6 
through 17 years old. 
 
 
Suggested management of hypertension for adults 
 
Hypertension*  
 Treat with anti-hypertensive medication as needed.  The goal of BP control should be 
consistent with general medical practice, including confirming that BP is elevated across 
three separate measurements on three separate days and all other contributing factors have 
been addressed ( i.e., pain, anxiety).  
     Grade 1  
(SBP 120 -139 mmHg or 
DBP80 -89 mm Hg)  Consider increased BP monitoring; start anti -hypertensive 
medication , if appropriate . 
Grade 2 asymptomatic  
(SBP 140 -159 mmHg or 
DBP 90 -99 mm Hg)  Begin anti-hypertensive therapy and continue bevacizumab . 
   Grade 3 
(> SBP 160 mmHg or > 
DBP 100 mmHg  If not controlled to 150/100 mmHg with medication, reduce 
one dose level.  For second occurrence, discontinue 
bevacizumab.  
Grade 4  Discontinue bevacizumab.  
  
Grading of hypertension for children 6 through 17 years old 
  Diastolic blood pressure levels for BOYS aged 6-17 years   
 1 2 3 4 
Age 
(years)  ULN* 
DBP 
mmHg  DBP ≤10 
mmHg above 
ULN  DBP >10 or ≤25 
mmHg above ULN DBP>25 
mmHg 
above ULN  
6 73 74-83 84-98 99 
7 75 76-85 86-100 101 
8 77 78-87 88-102 103 
9 78 79-88 89-103 104 
10 79 80-89 90-104 105 
11 79 80-89 90-104 105 
12 80 81-90 91-105 106 
13 80 81-90 91-105 106 
14 81 82-91 92-106 107 
15 82 83-92 93-107 108 
16 83 84-93 94-108 109 
17 86 85-94 95-111 112 
* ≤95th percentile for age and 50% height percentile 
 
   
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 81  
 Diastolic blood pressure levels for GIRLS aged 6-17 years  
 1 2 3 4 
Age 
(years)  ULN* 
DBP 
mmHg  DBP ≤10 
mmHg above 
ULN  DBP>10 or ≤25 
mmHg above ULN DBP>25 
mmHg 
above ULN  
6 73 74-83 84-98 99 
7 74 75-84 85-99 100 
8 75 76-85 86-100 101 
9 76 77-86 87-101 102 
10 77 78-87 88-102 103 
11 78 79-88 89-103 104 
12 79 80-89 90-104 105 
13 80 81-90 91-105 106 
14 81 82-91 92-106 107 
15 82 83-92 93-107 108 
16 83 84-93 94-108 109 
17 83 84-93 94-108 109 
* ≤95th percentile for age and 50% height percentile 
 
These c harts list DBP levels within the ULN (1), within 10 mmHg above the ULN (2), within 
11-25 mmHg above the ULN (3), and >25 mmHg above the ULN ( taken from “The Fourth 
Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents” PEDIATRICS Vol. 114 No. 2 August 2004, pp. 555-576).   Instructions for using this BP c hart: 
1. Measure the patient’s blood pressure using an appropriate size cuff. 
2. Select appropriate chart for a female or male patient.  Age should be rounded to the nearest year.  
3. Using the “age” row determine if the DBP is within the ULN (1) or elevated (2, 3, 4).  
4. See Section 6 for definition of dose limiting hypertension.  
 
Manageme nt of Bevacizumab -related Hypertension  in Children   
The algorithm outline below will be used to grade and manage bevacizumab- related 
hypertension. A diastolic blood pressure (DBP) equal to the 95th % for age and gender will be 
defined as the upper limit of normal (ULN).   
 Patients with elevated DBP at any time should have blood pressure measurements performed twice weekly until DBP is within the ULN.  
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 82  
 Monitor DBP†
DBP†>25 mm Hg 
above ULN§for age 
or Grade 4 HTN*10< DBP†≤25 mm Hg 
above ULN§for age
Discontinue 
drug
Continue drug 
at same doseDBP†≤ULN§
forage
DBP ≤ULN for 
age within 14dDBP >25 mm Hg 
above ULN for 
age*
DBP ≤25 mm Hg 
above ULN for 
age for >14d*Start anti -HTN therapy
†Elevated diastolic blood pressure (DBP) measurements should be r epeated on the same day to confirm the elevation
§ULN (Upper Limit of Normal) is a DBP ≤ the 95thpercentile from age and gender -appropriate normal values (Appendix G)
*If DBP >25 mm Hg above ULN for age (verified) or grade 4 HTN at any time, discontinue drug.  Antihypertensive agents can be 
used to control hypertension as clinically indicated after study drug is discontinued.Hold drug; continue 
anti-HTN until DBP 
<10 mm Hg above 
ULN for age x 2; 
then discontinue 
anti-HTNDBP†≤10 mm Hg 
above ULN§for age
Continue drug at same 
dose; recheck BP 
within 72 h
DBP ≤ULN 
for age on 
recheckDBP†>ULN§
on recheckArm 1 Arm 2 Arm 3 Arm 4
Grade 4 HTN*
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 83 Arm 1 of algorithm: 
• If DBP ≤95% for age and gender, continue bevacizumab at the same dose.   
Arm 2 of algorithm: 
• If DBP ≤10 mm Hg above the ULN for age and gender, continue bevacizumab at same 
dose. 
• If the DBP ≤ 95% for age and gender on recheck, continue bevacizumab at same dose.  
• If the DBP remains above the ULN for age and gender on recheck, then start single agent antihypertensive therapy (consider a calcium channel blocker such as amlodipine or nifedipine) and follow arm 3 of the algorithm from the point that anti- hypertensive 
therapy is started.  
Arm 3 of algorithm: 
• If DBP is 11 to 25 mm Hg above the 95% for age and gender on ≥2 of 3 measurements, start single agent anti- hypertension therapy (consider a calcium channel blocker such as 
amlodipine or nifedipine), continue bevacizumab at the same dose and monitor blood pressure at least every 3 days.  
o If the DBP remains elevated ≤25 mm Hg above 95% for age and gender for more 
than 14 days after the institution of single agent anti-hypertensive therapy, reduce 
bevacizumab  one dose level and continue the antihypertensive agent until the 
DBP is ≤10 mm Hg above the 95% for age and gender on 2 measurements at least 3 days apart.   If the DBP remains elevated ≤25 mm Hg above 95% for  age and 
gender for more than 56 days after the institution of single agent anti-hypertensive 
therapy, discontinue bevacizumab. 
o If the DBP increases to ≥25 mm Hg above the 95% for age and gender despite antihypertensive therapy or the participant develops grade 4 hypertension (CTCAE ),  discontinue bevacizumab permanently, but continue the 
antihypertens ive agent until the DBP is ≤10 mm Hg above the 95% for age and 
gender on 2 measurements at least 3 days apart.  
Arm 4 of algorithm: 
• If DBP is >25 mm Hg above the 95% for age and gender or the participant develops a grade 4 hypertension (CTCAE), discontinue bevacizumab permanently and monitor blood pressure at least every 3 days.  Antihypertensive agents can be used until the DBP is <10 mm Hg above the 95% for age and gender on 2 measurements at least 3 days apart.  
• The cycle remains 28  consecutive days in patients who have dose interruptions.   
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 84 Appendix E : Management of B one R elated Toxicity. 
 
Potential bone related toxicity is of great concern for this study based on pre- clinical data and 
because bevacizumab will be used in a pediatric population.   Theref ore, we will carefully 
monitor for it, utilizing multiple serial measurements of height (in patients with open growth plates at baseline).   
 For patients with open growth plates on tibial radiographs at baseline , measurements of stature 
(height) will be measured at  week s 13, 25, 49, 73, and 91.  Bevacizumab will be discontinued if: 
 
• <1 cm growth is noted prior to week 25  
• <2.5 cm growth is noted prior to week 49 
• Subsequently, <2cm/year annualized growth velocity noted every 24 weeks for patients with open growth plates only 
  
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 85  Appendix F : Audiology Procedures  
 
1.0    INTRODUCTION 
The purpose of this appendix is twofold: In the first section, procedures for local 
audiologists will be outlined. In the second section, procedures for transfer of the audiometr ic 
data from the local audiogram to the data form will be specified.  
 
2.0   AUDIOLOGY PERSONNEL   
The primary source of reliability and validity will be the qualifications of the clinical 
audiologists performing the tests, and their adherence to standard pr actices.  These practices will 
be specified in this section.  A secondary source of reliability and validity will be the oversight of the local Lead Audiologist appointed for each c linical s ite.  T he Lead Audiologist will compile 
information assuring standard calibration, installation of reference -calibrated equipment, etc.  
1  
The local Lead Audiologist will also act as a stable contact on behalf of their center.  Finally, the Senior Study Audiologist (MEEI) will provide a final layer of assurance by developing and updating the procedures in this manual in response to any problems and by maintaining regular contact with each site's Lead Audiologist.  
 
2.1 Lead Audiologist 
Each Clinical Site will designate a Lead Audiologist who will be the contact for 
study- related issues with the Senior Study Audiologist.  This audiologist will oversee local 
audiology operations and also communicate with the site PI.  The lead audiologist may train other audiologists at the site for testing.  
2.2 Qualifications  
Each evaluation will be performed by a fully qualified audiologist.  The precise 
definition of qualification can vary from state to state depending on licensure laws, etc.  For the purposes of this study, full qualification is defined as the highest local level of qualification, certification or licensure. Basic requirements for Lead Audiologist will be no different, but only one audiologist per center will be designated for this duty.  
2.3 Training  
Each site's Lead Audiologist will be responsible for local tra ining of any audiologist 
performing assessments for this protocol.  This training will be based on this appendix, and the a ppendix will remain available to all trained audiologists as a resource. All Lead 
Audiologists will be contacted in advance of the initiation of participant enrollment at the site, and the Senior Study Audiologist will discuss and demonstrate the procedures contained in this Appendix.  These will include personnel, test protocols, data cross checking, procedures for correcting or completing evaluations, and reporting results. 
  2.4 Contacts 
A system of regular contact between the Senior Study Audiologist and each Lead 
Audiologist will be initiated before any participant's enrollment.  This will take place 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 86 primarily by e -mail, with documents faxed as necessary.   As audiologic issues arise, the 
local audiologists will be asked to contact the Lead Audiologist, who will act as liaison 
with the Senior Study Audiologist.  Other local issues are expected to be addressed by contact among  the clinical site PIs, their Lead Audiologists, and the CRCs.  
 
3.0 AUDIOLOGY FILES  
Each c linical s ite's Lead Audiologist will, at the commencement of the study, create a filing 
system for audiology facility records and correspondence. System features will be at the 
discretion of the Lead Audiologist, incorporating the local filing protocols.  However, at minimum this system will contain three recognizable sections: general information, correspondence, and worksheets. 
3.1 General Information Section 
This sect ion will include site -specific information as to the identification of the PI, the 
Lead Audiologist, Senior Study Audiologist, and others associated with the study, along with extensive contact and coverage information. This section will also include the l ocal 
location of this appendix, and the data reporting protocol along with copies of calibrations and other equipment records sufficient to document validity. Finally, the g eneral section 
will include a comment log, in which dated and initialed entries by any audiologist may make note of any events or concerns. 
3.2 Correspondence Section  
This section will include records of conference calls and other correspondence 
regarding procedural issues, changes in equipment or personnel, and any adverse events. 3.3 Audiogram Section  
This section will include a udiograms generated for each audiologic evaluation related 
to this study.  
 
4.0 AUDIOLOGY TESTING PROTOCOL OVERVIEW   
Participants will be referred for each evaluation by the local s ite PI or CRC, who will 
determi ne the timing of return visits.  At minimum, the referral will include designation of the 
target ear.   When the participant arrives for each test, the audiologist will greet the participant 
and accompanying persons and briefly and privately discuss progress if the participant wishes. 
Study questions may  be referred to the local PI or CRC.  Audiologists will not be formally 
blinded to any aspect of the study.  
The audiologist will seat the participant in a sound -treated room . 
2 No more than one 
person will be allowed to accompany the participant to this area and this person will not be allowed to sit in the booth or to be in the line of sight of the participant.  As much as possible, light levels in the participant and the tester sides will be adjusted to prov ide a good view of the 
participant and a poorer view of the audiologist ( i.e.,  participant side bright, tester side dark). 
The participant should be seated perpendicular to the audiologist to minimize cues.  The room door will be fully closed.  The participant will be asked to respond by hand raise or by button push, whichever is c ustomary at the clinical site.  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 87 The Lead Audiologist at each site will ensure that threshold tests are performed in the 
standard manner.  This includes the Hughson- Westlake bracketing procedure 3, 4. A 200 ms.  ON 
versus 200 ms.  OFF duty cycle for tone presentation is recommended with an opportunity to 
appreciate 4 tones per trial.  Narrow band noises or FM modulated tones will not be substituted for standard pure tones.  Thresholds will be transcribed on the Clinical Site’s standard audiogram, using standard symbols.
5  At the conclusion of the evaluation, the audiologist may 
briefly discuss the result with the participant and accompanying persons, again referring most study questions to the PI or CRC where possible.  Discussion of helpful strategies and devices as indicated by the case is expected.   
4.1 The Sound Pathway  
The testing audiologist will perform a visual inspection of both ears using an 
otoscope.  If there is sufficient access to the tympanic membrane to allow testing, the audiologist will proceed. If there are concerns as to cerumen or other factors, the audiologist may elect to perform tympanometry.  When complete, the outcome of tympanometry will be noted on the audiogram in the customary manner for that site. If  occluding cerumen or similar factors cannot be resolved, testing will not proceed. The local PI has overall responsibility to ensure unoccluded ears if referrals are required.  
4.2 Pure Tone Thresholds  
Pure tone thresholds will be found in the standard manner by bone conduction at 250, 
500, 1000, 2000 and 4000 Hz. Air conduction thresholds will be found at 250,500, 1000, 2000, 3000, 4000 and 8000 Hz. Masking will be used in any case where it is considered necessary to establish which ear is responding.
6 Air-bone gaps larger than 10 dB will be 
masked. For air conduction, masking will be applied for each threshold where the possibility of crossover exists. The possibility of overmaskin g will be evaluated by the 
audiologist and may be addressed, for example, by using insert phones. A masking plateau procedure will be performed at the discretion of the audi ologist.
7 The local audiologists 
have discretion to test other frequencies or to repeat testing to ensure validity. In addition, further testing (Stenger’s test; SRT; OAE) is at the discretion of the local audiologist to ensure validity. Auditory brainstem response testing is not indicated in these patients because their retrocochlear diagnosis is established prior to entry.  
4.2.1 Transducer 
Air conduction thresholds may be evaluated using both standard headphones 
(TDH -39, 49, 50) or calibrated insert phones (Etymotic ER -3A), as long as specific 
correction factors are in place.8 The transducer type ( i.e., TDH -49, ER 3-A) should be 
entered on the local clinical audiogram form  reflecting the method by which the final 
recorded threshold was obtained.   
4.3 Vibrotactile and Responses at Limits  
Vibrotactile responses will never be reported  as thresholds. On discussing the nature 
of the percept with the participant and determining that they are vibrotactile, the audiologist will mark the response as “out at limits”  at the vibrotactile response level. Other “out at 
limits” responses will be noted at the highest actual stimulus level with the standard “down arrow” notation. None of the study frequencies should ever be left blank.  
  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 88 4.4 Word Recognition  
Speech  intelligibility will be evaluated for each ear using standard word recognition 
of monosyllables.9 All tests will use recorded lists (CID -W22, Ira Hirsh recording, 
Q/MASS v 2)   from a compact disk supplied by the Senior Study Audiologist, 10 including 
standardized score sheets. Each disk contains a calibration reference 1 KHz tone (track 1) 
which will be used to set the input sensitivity (V.U. meter) to “0” before each set of tests.  
The recording and list must be noted on the clinical audiogram. This is nec essary to verify 
the list used in all cases when the report of this study is made.   Since the results are 
analyzed as repeated measures, a participant may be evaluated using English materials if the loc al audiologist decides that the results reasonably ref lect comparative (test to test) 
performance.  In such a case, the participant may be instructed to produce the sounds of the words, even if they do not necessarily recognize the meaning. All lists will be recorded (no live voice tests) and 50 items always given. 
4.4.1 Setting the “High” and “Low” speech test level s 
The principal guiding the initial level setting for speech tests is: The level 
should be set where maximum performance is expected for each ear.  P erformance 
has been shown to exhibit “rollover” in some NF2 cases,11,51 so an empirical search 
using at least two  levels  will also be used. These will be designated the “High” and 
the “Low ” levels. The “High ” level will be the level calculated for maximum audibility, as in the standard method for level setting in non -tumor cases. The “Low” 
level will be the maximum level minus 10 -15 dB as chosen by the audiologist to 
reflect a level with less chance of rollover.  
  Fletcher’s Articulation Index
12 will be used to assist in calculation of the initial 
(“High”) presentation level .  This formula can be used to draw a cumulative (ogive) 
optimum performance/intensity (P/I) function for any audiogram (Figure 1, below ).  
If rollover was not a factor, t he maximum performance would be expected at levels   
Figure 1.   Cumulative optimum performance/intensity (P/I) function.  
 

Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 89 on the asymptote of the curve. 13 Using software developed for this purpose14, Table 1 
was created for setting “High” speech levels:  
 
Table 1.   High Speech Level Settings:  
 
PTA2  Monosyllable level  
30 - 
35 - 
40 70 
45 75 
50 80 
55 85 
60 90 
65 95 
 
 
The PTA2 parameter designates Fletcher’s 2 -frequency average.  15  PTA2 is the 
average of the two best (lowest) thresholds of the set 500 Hz, 1 KHz and 2 KHz.  This 
value is easy to calculate and delivers better performance predicting speech reception threshold (SRT) and other speech level values than the more inclusive PTAs .
16  The 
levels were developed Monte Carlo  fashion by submitting a representative sample of 
audiograms to the P/I function generator and relating the PTA2 to the lower levels of the asymptotic portion of the curve.  The step size is 5 dB.  Smaller gradations are available on some audiometers and m ay be used at the discretion of the audiologist.  
No “High” level list will ever be given lower than 70 dB HL.  The advantage of this 
minimum level is that normal, mild, and moderate loss cases can all be tested at the same physical level .
17 
Table 1 is designed to replace rule -based level setting schemes since they may 
not be optimal, especially given severe losses (PTA ≥ 50 dB HL).  For example, a common rule requires a further test (SRT) to allow levels set at SRT + 40 dB.  While this provides reasonable maximum performance for milder cases, with severe losses 
the dynamic range is reduced below the 40 dB constant.  On the other hand, no rule or table can replace good clinical sense when very high levels are required. In abandoning the table values, the audiologist will be asked to decrease lev els 
minimally below the participant’s Uncomfortable Level (UCL) rather than set the level at a determined Most Comfortable Level (MCL).  No levels should exceed 95 dB HL.  
As described above, after performing a word lis t at the “High” level, the 
Audiologist will reduce the intensity by 10-15 dB and present a 50- item list at the 
“Low ” level.  If the speech stimulus exceeds most frequencies at a level 15 dB below 
the “High” level then that level should be used. If, on the other hand, many important frequencies are no longer audible, then the level 10 dB below should be used. This procedure will be used for the target and the contralateral ear, with the exception that  
the “High” level may be used alone for the contralateral  ear if there is no vestibular 
schwannoma on that side. 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 90 4.4.2 Participant responses  
Participants with poor speech intelligibility are expected to initially report no 
intelligibility  (i.e., “I can’t get it”).  The audiologist is required to explain that 
guessing is very helpful and that, in order for the test to proceed, the participant must 
guess a monosyllable each time the carrier phase is heard.  Instead of reporting no recognition, a “wild guess” should be substituted.  This strategy will optimize responses in cases of low speech intelligibility and is surprisingly effective with 
participants who are really only uncertain.  Dropped plurals are to be scored wrong.  If the participant responds with several options, the first one said will be scored.  Items will not be repeated.  Small variations in regional dialect ( i.e., vowel 
boundaries) are scored at the discretion of the audiologist.  Fifty items will be given unless the audiologist is convinced that the participant has no speech- like percept at 
all.  Fifty wrong guesses will be scored as 0% and this represents an optimal test by 
both the participant and the audiologist.  If there is no speech- like percept at all, the 
test can be scored CNT (could not test).  Skipping the word recognition test and entering the notation “DNT” (did not test) is never acceptable. The audiology 
evaluation will be considered incomplete if the notation DNT appears.  Under no circumstances will half -lists or screening lists be accepted . 
4.4.3 Masking for word recognition  
Masking will be applied to the contralateral ear during speech tests if there exists 
a possibility of significant contribution due to crossover. 18 To facilitate this 
application for this study, the Articulation Index was again used to calculate the maximu m score possible by crossover given the difference in PTA2 and the effective 
masking required to reduce this contribution to zero
19 (Table 2 ). 
Table 2.  Calculation/Crossover Scores 
 
Speech Level minus  
Non-test PTA2  Speech Noise TDH  Speech Noise Inserts  
50 15 - 
55 20 - 
60 25 - 
65 30 - 
70 35 10 
75 40 15 
80 45 20 
85 50 25 
90 55 30 
95 60 35 
100 65 40 
 
Table 2 includes values based on published interaural attenuation values for both TDH phones
20 and insert phones.21  Standard speech -shaped noise is assumed in this 
calculation and will be the masker used at the study centers.  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 91 4.5 Validity  
If the audiologist determines that the test is valid she/he will indicate this in the 
space used for this purpose on the local audiogram form and need not enter any further 
information regarding validity.  If the audiologist decides to perform other tests (for example SRT, to rule out functional loss) this will be noted along with the outcome in the text section. In most cases, the principles an d procedures outlined above will allow 
reliable and valid data.  One example of an exception requiring different tests would be when functional hearing loss (pseudohypoacusis) is suspected.  Hesitant threshold responses or a history of litigation for loss are some of the many warning signs audiologists use to initiate tests to rule out functional loss.  In this study, audiologists, supported by their local Lead Audiologist will rule out functional loss on a case- by-case 
basis.  For example, SRTs may be done to evaluate the match with the pure tones. 
22 
Stenger’s test  23 may be performed.  The text section of the local audiogram  will also be 
used to convey any testing issues such as participant cooperation, noise, equipment issues, etc., which mig ht adversely affect validity.   
4.6 The Target Ear  
  All referrals to the local audiologist from the local investigator site must include a 
designation of the target ear. Designation of the target ear is noted to occur redundantly on many forms of document ation in this study. The local audiologist will ensure that the 
special “High” and “Low” level word recognition testing is performed on the target ear at minimum during the evaluation. This strategy should also be applied to the contralateral ear if that ear is known to have a vestibular schwannoma or its status is unknown. The audiologist will specify the target ear on their audiogram at every evaluation.   
4.7 Example Audiogram 
  Figure 2 shows an example audiogram which satisfies the needs of this study 
protocol. It is for example only and local variation is expected. 
 
          
 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 92  

Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 93 5.0 DATA CROSS CHECKS  
This section will describe data cross check activities performed by the testing audiologist 
and the Lead Audiologist, as well as the mechanism for reporting unforeseen problems or 
concerns.   
5.1 Testing Audiologist 
The primary data cross checks will be th e responsibility of the testing audiologist.  
Specifically, equipment and training will be maintained which will allow such procedures as masking plateau verification, tympanometry, SRT, Stenger’s test, etc.  These tests will be applied at the discretion of the testing audiologist to verify results and to rule out functional or retrocochlear hearing loss.  None of these tests will be used as data, but will be noted on the local audiogram form along with the overall judgment of the audiologist as to validity .   
5.2 Lead Audiologist 
The audiogram will then be given to the Lead Audiologist or placed in the study 
“Audiograms” file section for data awaiting review.  The Lead Audiologist will verify the 
audiologic aspects of the data.  The Lead Audiologist will verify validity and completeness, or will contact the CRC for rescheduling for other testing if necessary.  The completed form will be faxed or emailed (scanned) to  the NF Consortium Operations Center.  
5.3 Problems and Concerns  
The Senior Study Audiologist will be responsible for resolution of problems in 
audiology data interpretation.  If these arise at the office of the PI, they will be communicated to the Senior Study Audiologist ( i.e., not the local Lead Audiologist 
directly), who will have discretion as to resolution study- wide or site -specific.  If problems 
arise at an individual site, they will be communicated by the local Lead Audiologist to the Senior Study Audiologist, who will again be responsible for resolution either study-wide or site-specific.  The anticipated mechanism for resolution of study- wide issues will be 
communication with all local Lead Audiologists and changes or additions to this Appendix.  The Senior Study Audiologist will be responsible for informing and receiving advice and approval from the Study Chair as appropriate.   
 
6.0  AUDIOGRAM ACCEPTANCE  
After the audiogram is faxed (or emailed) to the NF Consortium Operations Center, i t 
will be forwarded to the Senior Audiologist in the office of the overall study PI for review 
and approval  for use in the study . This is particularly critical in the case of the initial 
audiometric evaluation. All subsequent evaluations and outcomes will be compared to this initial audiometric evaluation and, following intent -to-treat principles, patients will not be 
removed from the study after the fact if the audiogram is found to be invalid. If the audiogram is not accepted, it must be re-scheduled by the study local PI’s office, re-done and re-submitted for acceptance. The Senior Study Audiologist will be responsible for providing any required materials and advice in order to ensure audiogram acceptance before the fact. It is necessary that each site make contact with the Senior Study Audiologist (C. Halpin, chris_halpin@meei.harvard.edu
,  617-573-3266) when they are 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 94 contacted by referral sites in order to initiate this support. The following sections will 
describe some factors which will cause the audiogram not to be accepted.  
6.1 Improper Referral  
If a patient arrives at the audiologist’s office without that office being previously 
contacted about the study, or provided full materials and adequate time to have questions addressed, this evaluation is not expected to be possible and the result will be a request by the Senior Audiologist and the Study PI to the referring center for adequate referral procedures. 
 6.2 Ear O ccluded W ith Cerumen  
If the audiologist finds the ear occluded with cerumen (it is recommended that this be 
confirmed using tympanometry) , the patient’s audiologic evaluation cannot be performed 
and the patient should be returned to the referral source for remediation if the cerumen cannot be managed in the audiologists’ office. If a notation is found that either ear was occluded with cerumen, the audiogram will not be accepted. 
 6.3 Word Recognition 
If word recognition is recorded as “DNT” (Did Not Test) on either side, the 
patient’s audiologic evaluation cannot be accepted. This is also true if a half (25- item) or 
screening list was given,  or if the word recognition test was delivered using monitored live 
voice (MLV). Word recognition must be positively noted as having been done using the provided CD, 50 items and done at high and low levels as described in section 5.6.1 in order to be accepted. The software used to create Table 2 may be used to evaluate the potential for influence of the contralateral ear, though significant crossover is unlikely.  
6.4 Pure Tone Thresholds  
If pure tone thresholds do not include all frequencies specified in section 5.4, for 
example if bone conduction was not done, the audiogram cannot be accepted. With regard to masking, thresholds may be input to the Harvard Audiometry software for evaluation of crossover. If significant chance that the non- test ear was respo nding is found, the 
audiogram cannot be accepted.  
 
7.0 EQUIPMENT  
The following section contains specifications for equipment used in this study. 
7.1 Sound- treated Enclosure 
A single - or double-walled sound- treated enclosure that meets American National 
Standard Criteria for Maximum Permissible Ambient Noise Levels for Audiometric Test 
Rooms shall be used to conduct pure tone air and bone conduction thresholds and word recognition testing.   
An illuminated otoscope is used to examine a participant’s ear canals.   If any 
possible contraindications to audiometric testing (such as excess cerumen, eardrum abnormalities, etc.) are detected, the participant must be referred for medical evaluation before audiometric testing can proceed.  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 95 7.2 Audiometer  
Audiometers that meet the American National Standard Specifications for 
Audiometers1 and have two channels are used to conduct pure tone air and bone conduction 
threshold, SRT and word recognition testing.  One channel of the audiometer generates and 
delivers the test s ignals, either pure-tones or prerecorded speech.   The second channel 
delivers narrow- band or speech -band masking noise simultaneously with the test signal, but 
to the non- test ear whenever necessary.  The audiometer must have an input jack for 
external eq uipment such as a compact disc player or tape player, which will be used to 
present speech stimuli for word recognition testing. 
7.3 Audiometer Transducers  
Earphones mounted in supra- aural cushions and calibrated according to the American 
National Standard  Specification for Audiometers1 are used to deliver the test material from 
the audiometer to the participant.  The earphones are designated as “right” and “left” and 
will be placed comfortably over the participant’s right and left ears, respectively.  Bone vibrators calibrated according to the same standards are used to obtain bone conduction thresholds.   During the testing, the bone vibrator is positioned over the mastoid area of the participant’s test ear, taking care that it is not in contact with the p osterior part of the pinna. 
7.4 Compact Disc Player 
A compact disc player must be used to deliver pre- recorded speech material to the 
audiometer and subsequently to the transducers positioned over the participant’s ears.  A cable extends between the output jack of the compact disc player and the input jack of the audiometer.  
7.5 Acoustic Immittance Equipment  
Immitance is not required by this study protocol, but may be used at the audiologists’ 
discretion. An immittance device that meets the American Nationa l Standard Specifications 
for Instruments to Measure Aural Acoustic Impedance and Admittance is used to conduct tympanometry and acoustic reflex threshold testing.   Test results will be printed directly from the immittance device or recorded manually at t he conclusion of testing on each ear.  
Probe tips must be appropriate in size to seal the participant’s ear canal tightly during tympanometry and acoustic reflex testing.   Clinical centers must have an adequate variety of sizes of probe tips to accommodat e ear canals of varying dimensions.  
7.6 Maintenance  
Each clinical center is responsible for the proper operation and maintenance of its 
audiometric equipment.   Responsibility for proper maintenance is assumed by the Lead Audiologist, and all staff are instructed to report promptly any real or suspected equipment problems to that person.   All checks, inspections, and repairs are documented and recorded by date in a permanent log.  The Study PI  and Study Senior Audiologist may review this 
log at periodic site visits.  All study test equipment including audiometers and acoustic immittance devices must be calibrated according to the American National Standards Institute. Listening checks may help to identify problems that could influence participants’ test behavior and audiometric results in between scheduled physical calibrations.   Study audiologists should perform a listening check on any day when a participant enrolled in the protocol will be tested.  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 96 8.0 Data Reporting 
Audiograms done using the procedure s described above will be faxed or emailed 
from the NF Consortium Operations Center to the office of the Senior Study Audiologist 
(C. Halpin, PhD) and the Principal Investigator. The Senior Study Audiologist and others at the PI’s office, will have direct access to the eCRF software used for data collection in the study. The clinical audiograms will be checked and the data transferred to the study eCRF system. The PI’s office (Senior Study Audiologist) will keep copies of each of the study audiograms and records of the transfer process.  
 
  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 97 Appendix G : MRI Protocols  
 
Image Acquisition  
Each patient will be scanned on the same MRI system . Each scanning session must include the 
following sequences (although additional sequences can be performed per institutional protocol) :  
1) Scout sequence 
2) T2-weighted imaging  
3) Fluid -attenuated inversion recovery (FLAIR) imaging  
4) T1-weighted pre- contrast imaging  
5) Diffusion weighted  imaging  (DWI)  
6) Post- contrast T1 -weighted imaging  (including post- contrast T1 weighted imaging    
with fine cuts through the internal auditory canal ) 
 
NOTE:   The post-contrast T1 weighted imaging with fine cuts through the internal auditory 
canal (3 mm slices, no skip) and volumetric a nalysis will be used to assess the endpoint of 
radiographic response (defined as ≥ 20% decrease in tumor volume by MRI scan).  The total scan time for the required images for the primary endpoint is roughly 10 minutes.   
 
Image Analysis  
Enhancing lesions will be quantitatively analyzed by an experienced neuroradiologist blinded to 
the order of the scans, patient identity and treatment status of the patients. Bi-dimensional diameters will be created and outlined using electronic calipers in accordance with the Macdonald criteria 
48. The lesions will also be outlined using a volumetric approach described 
previously 52 that includes outlining each enhancing voxel on post-contrast scans and then 
summing the voxels to calculate an overall lesion volume.    
Secure File Transfer  
The procedure for uploading MRI scans to the Tumor Imaging Metrics Core are listed below.  
 MRI images from enrolled subjects should be de- identified and will be transmitted 
electronically to the Dana- Farber/Harvard Cancer Center Tumor Imaging Metric Core (TIMC) 
under the direction of Dr. Gordon Harris for central analysis of tumor volume. (see section 10.1.7). 
 
Welcome to the TIMC  
The TIMC provides standardized measurement of imaging scans for oncology clinical trials. 
TIMC’s web -based system ensures easy ordering and access with exceptionally fast 
turnaround. Tumor response assessment criteria include RECIST, RECIST 1.1, Cheson, irRC, SUV, and 3D volume.  
 
Getting Started  
This document provides step- by-step instructions to help you use the TIMC website. Topics 
covered include:  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 98 • New User Registration  
• Patient Registration  
• Scan Assessment Requests  
• Results Reporting  
• Resources  
 
Please contact the TIMC help desk at timc@nmr.mgh.harvard.edu  for any questions or 
concerns that are not addressed below.  
 
New User Registration:  
1. Please email the TIMC help desk at timc@nmr.mgh.harvard.edu  and provide the 
following information:  
• User Full name  
• Home inst itution  
• Study role  
• Disease group affiliation  
2. After account set -up, TIMC will notify you via email with your username and 
temporary password. Please go to www.tumormetrics.org  and click Client Login  or 
go to www.timclogin.org  to directly access the login page.  
3. Login with your TIMC username and password. The password can be changed by 
going to Main Menu → My Profile → Edit. You will be required to enter your current password and new password (alphanumeric, case sensitive, 6 -10 characters). 
Click OK.  
 
Patient Registration:  
1. After login, click on the link for the appropriate protocol number (12- 466).  
2. Select Patient Registration  from the Protocol Menu  pull-down.  
 
3. Click Add New  Record  to register a new research subject.  
 

Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 99  
 
Subject ID  • Enter the PID1 upon initial registration. Once the PID2 is issued, 
edit this field to reflect the PID2.  
Sponsor Prefix  • Enter your site’s code according to the chart below:  
CHLA, Children’s Hospital Los Angeles  CLA  
CHOP, Children’s Hospital of Philadelphia  CHP  
CHB, Children’s Hospital Boston  CHB  
UAB, University of Alabama at Birmingham  UAB  
MGH  MGH  
CNMC, Children’s National Medical Center  CHN  
UChicago, University of Chicago  UCH  
LCH, Lurie Children’s Hospital  LCH  
WU, Washington University  WAU  

Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 100 NYUMC, New York University Medical Center  NYU  
JHU, Johns Hopkins University  JHU 
CCHMC, Cincinnati Children’s Medical Center  CCH  
IU, Indiana University  INU 
 
Primary Disease  • Select Patient’s primary disease from pull -down.  
• Please email timc@nmr.mgh.harvard.edu  if the patient’s primary 
disease is not included in the list. 
Date Registered  • This date will auto -populate with the dat e the patient is registered 
in the system.  
Date Off 
Protocol  • Leave Date off Protocol field blank at this time.  
• Date off Protocol will auto -populate with the date of response 
assessment progression.  
• Please manually fill in Date Off Protocol if the patient comes off 
study for another reason (i.e., toxicity, etc ). 
Failed Screening  • Failed Screening should be checked if the patient does not meet 
enrollment criteria per imaging assessment.  
 
4. Click Submit . 
 
 
Making Changes:  
TIMC website has an audit trail which requires users to enter a reason for the change before 
they can edit.  
1. Please select the reason to change the data  from the pull -down highlighted in 
yellow near the top right hand side of the browser window.  
 
2. Click Edit  to make changes to data entry.  
 
Scan Assessment Requests:  
1. Click on the appropriate protocol number. (is automatically prepopulated)  

Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 101 2. Select Order Entry from the  Protocol Menu pull-down.  
 
3. Click Add New Order . 
 
 
 
Protocol  • Automatically populates the protocol for which the 
patient is registered to (12 -466).  
Patient  • Select the patient from the Patient pull-down.  
• Only registered patients will appear in this list.  

Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 102 Scan Institution  • Select the institution where the scan was performed.  
Radiation Date  • Select whether the patient has received radiation 
recently.  If yes, enter the date of radiation.  
Scan Date  • Enter date as MM/DD/YY or click the calendar button 
to select the scan date.  
Scan Time  • Round time to the nearest 30 minutes.  
Time Point  • Choose screening, baseline, or follow -up. 
Imaging Modality  • Select the scan modality from the pull -down (i.e., CT, 
MR, PT).  
Imaging Source  PACS  
• Select PACS if the scans were uploaded into the 
hospital’s imaging archive (PACS).  
CD 
• Select CD if the scan is from an outside institution and 
needs to be uploaded manually.  
Due Date  • Enter date as MM/DD/YY or click the calendar button 
to select the scan date.  
Due Time  • Round time to the nearest 30 minutes.  
Order Comment  • Indicate if left and/or right schwannoma should be 
assessed.  
• Enter information about the scan (i.e., scans to include in the assessment, lesion(s) of interest, etc).  
Reason for Urgent 
Request  • Select a reason for urgent request from the Reason  
pull-down.  
• This field is required for urgent scans.  
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 103 Treating Physician Email  • Enter the treating physician’s email address  
• This field is required for urgent scans  
Notify by Email Upon 
Assessment Completion  • Check the box if you would like to be notified by 
email when the scan assessment has been completed.  
• Add up to 3 additional email addresses to receive 
notifications  
Status  This field is not editable and refers to the scan assessment 
status.  
• Ordered = Scan request has been made by trial staff  
• Inquiry = Inquiry initiated by TIMC; email response required by trial staff.  
• Processed = TIMC has started scan analysis.  
• Complete = Preliminary results are complete but scan has not been reviewed by a radiologist.  
• Final = Radiologist has reviewed and approved the scan assessment.  
 
4. Click Submit.  
Note:  The online system has an audit trail. To change data, please select the reason 
to change the data from the pull -down highlighted in yellow near the top right hand 
side of the browser window. Once a reason has been selected, click on ‘Ed it’ to edit 
the patient information.  
 
Results Reporting:  
• Click on the appropriate protocol.  
• From the Patient List  page, click on the 
appropriate patient link.  
• Compare image captures across time points by clicking the lesion location link (left box).  
• View annotated images for a specific scan date by clicking on the measurement link (right box).  

Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 104  
• Click the Next Lesion  button located near the top right hand side of the screen to 
view the image capture for the next lesion or select the lesion of interest from the 
Select Lesion  pull-down located under the patient information.  
• Click the Next Scan  button located to the right hand side of the image capture (on 
the right) to go to the next scan or select the desired scan date from the pull -downs 
located above t he image captures.  
 
 
 
• Select Patient Summary  from the Patient Menu  pull-down to go back to results  
 
Longitudinal Graphs:  
• Click the graph button  to view graphs. This button is located near the bottom 
left hand side of the screen on the Patient Summary  page, or Select Response 
Graph  from the Patient Menu  pull-down  
• Compare time point and individual lesion measurement data to baseline, nadir (scan 
with the lowest measurement total), and prior scans.  

Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 105  
 
Request Re- Review : 
 
If the central review is felt to be discordant with the clinical assessment, trial staff has the option to request a re- review of the scan.   
 
• Click on the appropriate protocol. 
• From the Patient List  page, click on the appropriate patient link.  
• Click the Request Re- review  button. 
• Populate  all fields in the email template.  
Resources : 
 Click on the Resources button at the top right hand side of the website to go to our Resources website. This website provides: 
• Tutorials on imaging assessment criteria for clinical trials  
• Documents to incorpor ate imaging metrics in study protocols  
• Service and workflow requirement policies 
• "How to" documents for navigating the TIMC website 
• Imaging specific manuals and policies, only accessible to core staff  
For additional information about our services, please visit www.tumormetrics.org . 
 
 

Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 106 Appendix H : Tinnitus Reaction Questionnaire (TRQ) a 
 
SUBJECT  IDENTIFIER  :   ______________________________ 
  
 
Number  Item  Scoresb 
1 My tinnitus has made me unhappy.   0  1  2  3  4 
2 My tinnitus has made me feel tense.   0  1  2  3  4 
3 My tinnitus has made me feel irritable.   0  1  2  3  4 
4 My tinnitus has made me feel angry.   0  1  2  3  4 
5 My tinnitus has led me to cry.   0  1  2  3  4 
6 My tinnitus has led me to avoid quiet situations.   0  1  2  3  4 
7 My tinnitus has made me feel less interested in going out.   0  1  2  3  4 
8 My tinnitus has made me feel depressed.   0  1  2  3  4 
9 My tinnitus has made me feel annoyed.   0  1  2  3  4 
10 My tinnitus has made me feel confused.   0  1  2  3  4 
11 My tinnitus “driven me crazy”.   0  1  2  3  4 
12 My tinnitus interfered with my enjoyment of life.   0  1  2  3  4 
13 My tinnitus made it hard for me to concentrate.   0  1  2  3  4 
14 My tinnitus has made it hard for me to relax.   0  1  2  3  4 
15 My tinnitus has made feel distressed.   0  1  2  3  4 
16 My tinnitus has me feel helpless.   0  1  2  3  4 
17 My tinnitus has made me feel frustrated with things.   0  1  2  3  4 
18 My tinnitus has interfered with my ability to work.   0  1  2  3  4 
Bevacizumab for children and adults with NF2    
Protocol Version Date: May 13, 2016  Version 1.4      
 107 19 My tinnitus has led me to despair.   0  1  2  3  4 
20 My tinnitus has led me to avoid noisy situations .  0  1  2  3  4 
21 My tinnitus has led me to avoid social situations.   0  1  2  3  4 
22 My tinnitus has made me feel hopeless about the future.   0  1  2  3  4 
23 My tinnitus has interfered with my sleep.   0  1  2  3  4 
24 My tinnitus led me to think about suicide.   0  1  2  3  4 
25 My tinnitus has made me feel panicky.   0  1  2  3  4 
26 My tinnitus has made me feel tormented.   0  1  2  3  4 
a From Wilson et al, 1991 
b 0 = not at all, 1 = a little of the time, 2 = some of the time, 3 = a good deal of the time, and 4 = almost all of the time.  
 
  
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 1 of 17 
   Protocol Title:   Open -label, Phase 2 study of bevacizumab in children and adults with 
neurofibromatosis  2 and progressive vestibular schwannomas that are poor candidates for 
standard treatment with surgery or radiation    
IND Number : 112096 
SITE  IRB Protocol Number:   
Sponsor : US Army, Dept. of Defense and Genentech  
Principal Research Doctor/Institution:   SITE PI  
                                                                         
If you are a parent or guardian of a child under 19 years old, the word “you” refers to 
your child.  You, the parent, will be asked to read and sign this document to give permission for your child to participate.   
 
INTRODUCTION  
 
You are invited to take part in a clinical trial, a type of research study . You are invited to 
take part  because you have neurofibromatosis type 2 (NF2) and a tumor on your hearing 
nerve (vestibular schwannoma) that is causing you to lose hearing.  At this time, you may 
have been told that surgery to remove the tumor or radiation treatments are  not favorable 
options.  This r esearch study is a way of gaining new knowledge about vestibular 
schwannomas. If you decide to take part, you will be known as a “participant” rather than a “patient ”.  This research study is evaluating a drug  called bevacizumab as a possible 
treatment for vestibular schwannoma.  
 
It is expected that about 22 people will take part in this research study .  At SITE , we will 
enroll 2 to 5 participants.  Some research studies are supported in some way by an outside organization. Genentech, Inc. and the US Army, Department of Defense (DOD)  are 
supporting this research study by providing bevacizumab  (Genentech)  and by providing 
funds (DOD and Genentech) to cover the costs of running this clinical trial.  
 This research consent form explains why this research study is being done, what is involved in participating in the research study, the possible risks and benefits of the research study, alternatives to participation, and your rights as a research particip ant.  The 
decision to participate is yours.  If you decide to participate, please sign and date at the end of this form. We will give you a copy so that you can refer to it while you are involved in this research study. If you choose not to participate in this research study, t he 
research doctors will discuss other treatment options with you and/or refer you back to 
your regular doctor.  
 We encourage you to take some time to think this over, to discuss it with other people and your doctor, and to ask questions now and at any time in the future.  
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 2 of 17 
    
WHY IS THIS RESEARCH STUDY BEING DONE ?  
 
This research study is a Phase II clinical trial.  Phase II clinical trials test the effectiveness of an investigational drug  to learn whether it  works in treating a specific tumor.  
“Investigational” means that bevacizumab  is still being studied in NF2 and that research 
doctors are trying to find out more about it(such as the safest dose to use), the side- effects  
it may cause, and if it is effectiv e for treating different types of tumors.  Bevacizumab is 
an investigational agent that has been approved by the U.S. Food and Drug Administration (FDA) for use in cancers of the colon, breast, brain, pancreas, and kidneys.  However, bevacizumab is not approved to treat vestibular schwannomas.  The purpose of this study is to find out what effects, good and/or bad, bevacizumab has on you and your vestibular schwannoma.  Bevacizumab acts by preventing the growth of new blood vessels in tumors.  Because tumors need new blood vessels to grow and spread, bevacizumab may stop blood vessel growth and slow or reverse the growth of the vestibular schwannoma or improve your hearing.     
WHAT OTHER OPTIONS AR E THERE ? 
 Taking part in this research study is voluntary. Instead of being in this research study, you have other options which may include the following : 
 
• Radiation treatments to your vestibular schwannoma 
• Surgery to remove your vestibular schwannoma 
• Participate in another research study  
• No therapy specific to your tumor 
• Comfort care, also called palliative care.  This type of care may help to reduce pain, tiredness, appetite problems and other problems caused by the tumor .  It 
does not treat the tumor directly, but instead tries to treat the symptoms  
 
The study doctor will discuss with you alternate p rocedures or courses of treatment. 
Please talk to the research doctor about your options before you decide whether you want 
to take part in this research study.  
 
WHAT IS INVOLVED IN THE RESEARCH STUDY ? 
 Sometimes it is hard to keep track of all of the deta ils and procedures that are part of a 
research study. We will describe them in this consent form and you can refer to this at any time during the research study.  The study doctor will discuss with you your responsibilities as a participant.   
Before the research starts (screening) :  After signing this consent form, you will be 
asked to undergo some screening tests or procedures to find out if you can be in the research study.  Many of t hese tests and procedures are likely to be part of regular cancer 
care and may be done even if it turns out that you do not take part in the research study.   
 
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 3 of 17 
   If you have had some of these tests or procedures recently, they may or may not have to 
be repeated.   
 
• Physical exam , including measurement of vital signs (temperatu re, heart rate 
and blood pressure) 
• Medical history , including questions about your health, current medications, 
and any allergies  
• Blood tests . Blood will be drawn (about 4 tablespoons) for tests to monitor 
your health, including blood counts and clotting studies, chemistry, and liver and kidney function   
• Urine test  to measure the amount of protein 
• Pregnancy test .  If you are a woman who can have children, you will have a 
blood pregnancy test.  (If you are pregnant, you will not be able to participate in this research study ) 
• Electrocardiogram (EKG) . The function of your heart will be checked with 
an EKG, which traces the electrical activity of your heart  
• MRI scan  of the brain  to measure the size of your tumor 
• Hearing assessment  to measure your ability to hear sounds and words 
• Questionnaire s to measure any e ffect your treatment may have on your 
tinnitus  (“ringing” in the ears)  and other symptoms that affect quality of life  
• For participants less than 18 years of age: X-rays  of the leg to determine 
whether you are still growing 
 If these tests show that you are eligible to participate in the research study, you will begin the study treatment.  If you do not meet the eligibility criteria, you will not be able to participate in  this research study. 
 
After the screening procedures confirm that you are eligible to participate in the 
research study :   
 If you take part in this research study, you will come to the outpatient clinic for all of your evaluations and procedures over the course of 24 months.  A ll participants will 
receive treatment for 6 months  (the induction phase).  Participants  who benefit from 
treatment  will continue receiving treatment for an additional 18 months (t he maintenance 
phase).  Participants who do not benefit from treatment by 6 months will not be allowed to continue receiving treatment.  
 Treatment will be divided into time periods called cycles. Each cycle is 4 weeks ( 28 
days)  during the first 6 months . You will come to clinic  every 2 weeks to receive 
bevacizumab  by vein . After the first 6 months, you will come to clinic every 3 weeks to 
receive bevacizumab by vein as long as your hearing is stable or improving. Each cycle after the first 6 months is 6 weeks as long as your hea ring is stable or improves .   If your 
hearing gets worse, then you will come to the clinic every 2 weeks  to receive 
bevacizumab by vein . 
  
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 4 of 17 
   The following tests and procedures are part of regular tumor care and will be done 
throughout the study: 
• Physical exam , including measurement of vital signs (height, weight, 
temperature, heart rate and blood pressure) 
• Questions about how you are able to perform activities of daily living (performance status assessment)  
• Blood tests. Blood will be drawn (about 4 tablespoons) for tests to monitor 
your health, including blood counts, chemistry, and liver and kidney function 
• MRI scan to measure the size of your tumor 
 
You will need the following tests and procedures repeated throughout the study.  These tests are part of re gular tumor care, but are being done more often because you are in this 
study:  
• Urine test to measure the amount of protein 
• Hearing assessment to measure your ability to hear sounds and words 
• Pregnancy test.  If you are a female who can have children, you w ill have 
occasional blood pregnancy test  
• Blood tests for hormone levels.  If you are a woman who has reached puberty, blood will be drawn (about 1 tablespoon) for tests to monitor the function of your ovaries  
•  Questionnaires to measure any effect your tre atment may have on your 
tinnitus (“ringing” in the ears)  and other symptoms that affect quality of life  
 The following procedures will be done as part of the research trial to see how the study 
treatment is affecting your body:  
 
• Questionnaires to  measure any effect your treatment may have on your 
tinnitus  and other symptoms that affect quality of life  
• For participants less than 18 years of age that are still growing: X -rays of the 
leg to determine the effect of treatment on your growth 
• Blood samples (about 5 teaspoons) will also be collected to test if you have     
any biomarkers or special measurements to see if bevacizumab is working to preventing the growth of blood vessels into your tumor. This collection is done prior to the first treatment, a t week 3, week 5 and week 25. 
 The chart below shows what will happen to you during Cycle 1 and future treatment cycles , as previously explained.  The left -hand column shows the day in the cycle and the 
right -hand column tells you what to expect on that da y. 
 
  
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 5 of 17 
    
Cycle 1  
 
Day        Tests/Procedures  
 
Day 1  • Routine blood tests  (about 2 tablespoons) , urine test, and exams : 
• Medical History  
• Physical exam  
• Vital signs , height and weight 
• Performance status . 
• Receive first treatment of bevacizumab  
Day 15 • Routine blood tests (about 2 tablespoons), urine test, and exams:  
• Physical exam  
• Vital signs and weight  
• Research blood samples (about 5 teaspoons) will also be collected to test for 
biomarkers during week 3 
• Receive second treatment of bevacizumab  
Day 28 • Cycle 1 ends.  Return to clinic the following day (day 1 of cycle 2) for next 
infusion of bevacizumab  
  
 
Cycles  2 to 6 
 
Day  Tests/Procedures  
 
Day 1  • Urine test and physical exams every cycle (more if your doctor tells you to).  
• Routine blood tests (about 2 tablespoons)  
• Brain MRI scan and hearing assessments during cycle 4 
• Tinnitus Questionnaire and Quality of Life questionnaire during cycle 4 
• For participants under the age of 18 who are still growing: x- ray of the leg  during 
cycle 4 
• Research b lood samples (about 5 teaspoons) will also be collected to test for 
biomarkers during week 5 (cycle 2)  
• Receive treatment of bevacizumab  
Day 15  • Receive treatment of bevacizumab  
Day 28  • Cycle ends.  Return to clinic the following day (day 1 of next cycle) for infusion 
of bevacizumab  
 
  
 
  
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 6 of 17 
    
Future cycles  – after the first 6 months    
 
Day  Tests/Procedures  
 
Day 1  • Urine test and physical exams every cycle (more if your doctor tells you to)  
• Routine blood tests (about 2 tablespoons)  
• Brain MRI scan and hearing assessments during cycles 7, 9, 11, 13, 15, and 17. 
• Tinnitus Questionnaire and Quality of Life questionnaire during cycles 7, 11, and 
15 
• For participants under the age of 18 who are still growing: x- ray of the leg  during 
cycles 7 , 11, and 15 
• Research b lood samples (about 5 teaspoons) will also be collected to test for 
biomarkers at week 25 (cycle 6)  
• Receive treatment of bevacizumab  
Day 22 • Receive treatment of bevacizumab  
Day 42 • Cycle ends.  Return to clinic (day 1 of next cycle)  for infusion of bevacizumab  
 
After the final dose of the study drug:   After the final dose of bevaci zumab , you will 
have tests and procedures including urine test, physical exam, ro utine blood tests (about 2 
tablespoons), performance status, brain MRI, hearing assessment, t innitus Questionnaire 
and Quality of Life questionnaire , research blood tests for biomarkers (about 5 
teaspoons), and x -ray of the leg (f or participants under the age of 18 who are still 
growing ).  Afterwards, you will resume standard care for your neurofibromatosis 2 and 
vestibular schwannomas.  No research tests are scheduled after the final round of testing 
noted above.  However, we would like to keep track of your medical condition 12 weeks 
after you finish taking bevacizumab.  We wo uld like to do this by calling you on the 
telephone once a year to see how you are doing.   
 
HOW LONG WILL I BE IN THIS RESEARCH  STUDY ? 
 
You will be asked to take bevacizumab  for 2 years or until your tumor grows or your 
hearing gets worse .  After you are finished taking bevacizumab, the study doctor will ask 
you to visit the office or follow-up by telephone for at least 12 weeks.    
 
The research doctor may decide to take you off the research study for many reasons 
including if: 
• It is considered to be in your best interest 
• The study treatment or procedures are found to be unsafe or ineffective 
• There is any problem with following study treatments and procedures 
• Your condition worsens 
• Or for other unforeseen reasons that make it necessary to stop your participation 
in the research study  
  
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 7 of 17 
   If you are removed from the research study, the research doctor will explain to you why 
you were removed.  In addition, you can stop participating in the research study at any time. If you decide to stop particip ating in this research study, e it is very important that 
you talk  to the research doctor and your regular doctor first. 
 In addition, you can stop participating in the research study at any time; however, the FDA requires that any information collected up to the point of your withdrawal cannot be removed from the study.  If you decide to stop participating in this research study, we 
encourage you to talk to the research doctor and your regular doc tor first.  
 
WHAT ARE THE RISKS OR  DISCOMFORTS OF THE RESEARCH  STUDY ? 
 
There are risks to taking part in any research study. One risk is that you may get a drug 
that does not help treat your disease or that makes your condition or disease worse.  Another risk is that there may be side- effects .   
 All chemotherapy drugs have side- effects , which can range from mild and reversible to 
severe, long lasting and possibly life- threatening.  There is a wide range of side- effects  
between  different drugs and between individuals.  For investigational drugs, not all of the 
risks are known at this time. You need to tell your doctor or a member of the study 
team immediately if you experience any side -effects .  
 Since many drugs used to treat tumors are designed to cause the rapidly dividing tumor cells in your body to slow down or die, these drugs can also cause other rapidly dividing normal cells in your body to slow down or die.  These include the blood cells that help to fight infection (white blood cells), the blood cells that help the blood clot (platelets), and the blood cells that carry oxygen in your body (red blood cells).  When anticancer drugs cause a decrease in these blood cells, it is called bone marrow suppression.  While you are participating in this research study, your blood cell levels will be monitored closely.   Please notify your doctor if any of the following occur:  
• A fever of 100.5 or above.   
This could be a sign of an infection.  If you have a low white blood cell count, this can be serious, life-threatening or fatal. You m ay have to take 
antibiotics or be admitted to the hospital.  
 
• Low energy or shortness of breath. 
This could be a sign of anemia (not enough red blood cells).  If this becomes severe, you may need to come into the clinic or hospital to have a transfusion of red blood cells.    
• You bruise easily, or, when injured, you do not stop bleeding. 
This could be a sign that your platelets (blood cells that help with clotting) are low.  This can be serious or life-threatening.  You may need to come into the clinic or hospital for a transfusion of platelets.  
 
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 8 of 17 
   Many cancers are associated with an increased risk of blood clots forming that could lead 
to swelling in the legs and arms.  These clots may travel to the lungs causing shortness of breath or to the brain causing a stroke.  This may become serious and life threatening.  Some cancer drugs can increase this risk.  It is important to let your doctor know if you have increased shortness of breath or difficulty breathing.   Everyone in the research study will be watched carefully for side- effects .  You will be 
monitored during your chemotherapy to keep track of your blood counts and organ function, particularly your kidney and liver function.  If you experience side- effects , they 
may go away after you stop taking the study drug.  Some side- effects  can be mild; but 
others can be long lasting and may never go away.  Some may be life-threatening or fatal.   Since the effect of the study drug(s) taken with other medications may not be known, it is important that you tell the res earch doctor about all prescription and non-prescription 
drugs, herbal preparations and nutritional supplements that you are taking or planning to take.  There may also be some foods that you should avoid while on this research study 
and your research docto r will review this information with you.  
 During the research study, you will be notified of newly discovered side- effects  or 
significant findings, which may affect your health or willingness to participate.  You may be asked to sign a new consent form that shows that you have been informed of new information relating to this research study.  
 
Risks Associated with Bevacizumab : 
 Frequent (Chance of 10 -50% that this will happen)  
• Fatigue  
• Headaches  
• High blood pressure, with increased risk of heart problems, headache and stroke.  
• Pain 
• Abdominal pain 
• Shortness of breath 
• Mouth sores  
• Weakness  
• Upper respiratory infection  
• Chills  
• Loss  of appetite  
• Bleeding (including in stomach or intestines)  
• Runny nose or increase in tears in your eyes  
• Kidney damage, found by testing your urine 
• Loss of function of the ovaries (female sex glands), that can lead to menopause.  Studies in humans have shown a decrease in the function of ovaries during treatment with bevacizumab with chemotherapy.  This condition results in difficulty becoming pregnant.  In some participants, the 
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 9 of 17 
   function of the ovaries returned to normal after treatment with bevacizumab 
and chemotherapy was stopped.  
• Changes in menstrual period, including abnormally heavy menstrual bleeding, decreased menstrual bleeding, absent menstrual bleeding, or irregularity in time between the menstrual periods  
 
Occasional (Chance of 1- 10% that this will happen)  
• Hoarseness  
• Nosebleeds  
• Low levels of potassium in the blood (can cause an irregular heartbeat ) 
• Hair loss  
• Dry Skin  
• Hole in your intestine; requires hospitalization and/or surgery; could be fatal. 
• Blood clots in your veins and arteries.  These c an cause chest pain, heart 
attack, or stroke.  A blood clot in your eye might cause vision loss.  Clots can be serious and life threatening.  
• Allergic reaction when infusion is given.  Serious allergic reaction may result 
in death.  
• Slowed growth in height and development (for children and young adults who 
are still growing).  Laboratory studies have shown a decreased in growth during treatment with bevacizumab.  
 
Rare (Chance of less than 5% that this will happen)  
• Congestive heart failure (fluid that build s up in your lungs because your heart 
isn’t working properly). 
• Bevacizumab might affect the ability of your wounds to heal.  This can lead to 
infections, hospitalization, or could possibly be fatal. 
• A very rare problem in your brain that may cause confusion, blindness, and coma has been seen in some patients that were given Bevacizumab.  This is associated with very high blood pressure and is not thought to be a permanent condition. 
• Confusion 
• Abdominal abscess or infection in your abdomen 
• Fistula or hole in  your bowel.  This is an abnormal connection between two 
different organs and may lead to life threatening complications including serious infections, bleeding, or dysfunction of the organs. 
• Dehydration  
• Abnormal bleeding in your body or from the tumor, whi ch may be fatal.  
• Laboratory studies of bevacizumab showed abnormal bone growth.  These and other effects of bevacizumab could possibly cause problems with growth and development.  Abnormal changes in the bones after treatment with bevacizumab have been seen in young children with growing bones.  This side effect appeared to be reversible after the drug was stopped, but has not been studied with long- term use of the drug.  All participants in this study who 
receive bevacizumab and are still growing will b e monitored for changes to 
bones by the use of x-rays performed throughout the study treatment. 
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 10 of 17 
   • Fistual or hole in your gallbladder (part of the intestines that helps with 
digestion).  This may require surgery and be serious or life threatening. 
• Osteonecro sis of the jaw.  A severe bone disease in which the jaw bone 
becomes visible (exposed) inside the mouth. This can be associated with pain and infection.  
• Pulmonary hypertension.  Abnormally high blood pressure in the blood 
vessels in the lungs, which makes it harder to pump blood into the lungs.  May 
cause fatigue, shortness of breath, chest pain, and ankle swelling.  Can lead to loss of consciousness and could be serious and life threatening.   
 
Cancer research often included biopsies, scans, x-rays that are also provided as routine 
care.  The following describes the side effects of procedures down only for the purposes or research.  
  
Reproductive Risks :  
 
Because the drug in this study can possibly affect an unborn baby and infants, you should 
not become pregnant or father a baby or breast feed while you are on this study.  Also, because bevacizumab remains in your body for weeks to months, you should continue to use adequate contraceptive measures and avoid nursing a baby for at least 6 months after your last dose of bevacizumab, although the optimal or the maximal time required for drug clearance cannot be precisely predicted.  Let your doctor know immedi ately if you 
become pregnant or find out that you are going to be the father of a child. We can provide counseling about preventing pregnancy for either male or female study participants.  In 
addition, the effect of the study drug on the ability have child ren in the future is 
uncertain .  The study drug may make it more difficult or impossible to have children in 
the future.  
 
NON-PHYSICAL RISKS  
 
Because of side- effects or the time required for tests and clinic visits while you are on 
this research study, y ou may be unable to keep up with your normal daily activities.  
 
Questionnaires  
 The questionnaires used in this study may be upsetting. If you find the questionnaires upsetting, you may speak with the research doctor or ask to be referred for additional emotional support.  
WHAT ARE THE BENEFITS  OF THE RESEARCH STU DY? 
 Taking part in this research study may or may not make your health better.  We hope the information learned from this research study will help doctors learn more about bevacizumab  as a treat ment for vestibular schwannomas  in the future.   
 
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 11 of 17 
   CAN I STOP BEING IN THE R ESEARCH STUDY AND WHAT ARE MY RIGHTS ? 
 
You have the right to choose not to sign this form.  If you choose not to participate in this research study, do not sign this form. If you decide not to sign this form, you cannot participate in this research study.  
 You can stop being in the research study at any time.  Tell the research doctor if you are thinking about stopping or decide to stop.  He or she will tell you how to stop.  Leaving the research study will not affect your medical care outside of the research study.    If you choose not to participate, are not eligible to participate, or withdraw from this research study, this will not affect your present or future care and will not cause any penalty or loss of benefits to which you are otherwise entitled.    It is important to tell the r esearch doctor if you are thinking about stopping so your 
research doctor can evaluate the risks from stopping the study treatment with bevacizumab.   In some cases, the abrupt stopping of a drug can have risks in itself. 
Another reason to tell your research doctor that you are thinking about stopping is to discuss what follow-up care and testing could be most helpful for you.  
WHO IS CONDUCTING THE  RESEARCH STUDY ? 
 
The study is being conducted here at SITE  as part of the Neurofibromatosis Consortium.  
This group is dedicated to the treatment of NF -related tumors and other problems 
resulting from NF . It is made up of thirteen clinical centers within the United States and 
Australia and an Operations Center (University of Alabama at Birmingham, AL) . The 
Neurofibromatosis Consortium is a clinical cooperative group (a network of hospitals working together) funded by the Department of Defense (D oD). Each clinical site has NF 
specialists, health care providers, nurses, and other scientists who are dedicated to the development of new treatments and cures for the tumors of infants, children, adolescents, and young adults with NF. We also conduct research on the causes, prevention and treatment of tumors, and the long- term effects of treatment on patients.  
 This research study is also being supported by an outside organization called Genentech, 
Inc. They are supporting this research study by providing the study drug and modest monetary support.   
WILL I BE  PAID TO TAKE PART IN THIS RESEARCH STUDY ? 
 You will not be paid as part of this research study.    We may use your samples and information to develop a new product or medic al test to be 
sold.  The sponsor, hospital, and researchers may benefit if this happens. There are no plans to pay you if your samples are used for this purpose.  
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 12 of 17 
    
WHAT ARE THE COSTS ? 
 
Taking part in this research study might  lead to added costs to you or your insurance 
company.  The costs of your standard medical care will be billed to you and/or your 
insurance company in the usual manner.   You will not be charged for bevacizumab . 
 You or your insurance company will be charged for portions of your care during this research study that are considered standard care. Typical standard care for NF2 patients includes MRI scans and hearing tests.  Yo u may be responsible for co-payments and 
deductibles that are typical for your insurance coverage.  
 If you have questions about your insurance coverage, or the items you might be required to pay for, please call financial services for information.  The con tact information for 
financial services  are:   
 
• SITE: SITE PHONE NUMBER  
 The National Cancer Institute provides an online resource to help people participating in cancer clinical trials understand which services their insurance company is required by law t o pay.  This can be found at the website below or can be provided by the study team: 
 
http://www.cancer.gov/clinicaltrials/learning/insurance -coverage
 
 
WHAT HAPPENS IF I AM INJURED OR SICK BECAUSE I TOOK PART IN THIS R ESEARCH STUDY ? 
 We will offer you the care needed to treat injuries directly resulting from taking part in this research.  We may bill your insurance company or other third parties, if appropriate, for the costs of the care you get for the injury, but you may also be responsible for some of them.  
The SITE , Department of Defense and the Neurofibromatosis Consortium has made no 
provision for monetary compensation in the event of injury from the research, and in the event of such injury, treatment will be provided, but is not free of charge. 
 The Principal Investigator or his/her designee will assist you and your child in obtaining appropriate medical treatment if it is required.  If you have any questions, please d iscuss 
this issue thoroughly with the Principal Investigator or his/her designee before you enroll in this study.  This is not a waiver or release of your legal rights.    
What about confidentiality? 
 We will take measures to protect the privacy and securi ty of all your personal 
information, but we cannot guarantee complete confidentiality of study data.  
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 13 of 17 
    
Medical information created by this research study may become part of your hospital 
medical record  and may be forwarded to your primary doctor . Informati on that does not 
become part of your medical record will be stored in your study file.  It may also become 
part of a SITE  research database.  Representatives of the Department of Defense, the 
outside organization that is partly funding the study, are autho rized to review research 
records.  
 The results of this research study may be shared with the sponsor s and published. You 
will not be identified in publications without your permission.    Your information may also be shared with outside individuals or entities  that have a need 
to access this information to perform functions relating to the conduct of this research.  This may include, but not limited to, other research doctors and medical centers participating in this research, labs, insurance agencies, Federal and state regulatory agencies and safety monitoring boards.   A description of this clinical trial will be available on http://www.ClinicalTrials.gov
, as 
required by U.S. Law.  This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.  
 
WHOM DO I CONTACT IF I HAVE QUESTIONS ABOU T THE RESEARCH STUDY ? 
 
If you have questions about the study, pleas e contact the research doctor , SITE PI  at  
SITE PHONE NUMBER  .  She will be glad to answer any of your questions.  After 
hour number to call are: SITE PHONE NUMBER .  You may also use these numbers if 
you have questions about any part of this study or consent form either now or at any time in the future  or if you believe  you have been injured as a result of being in this study 
 
If you have any questions or concerns about your rights as a research participant, or 
concerns or complaints about the research, you may contact The SITE  Office of the IRB 
(OIRB) at  SITE PHONE NUMBER .  Regular hours for the Office of the IRB are 8:00 
a.m. to 5:00 p.m. Central Time Zone, Monday through Friday.  You may also call this number in the event the research staff cannot be reached or you wish to talk to someone else. 
 
Storage of Specimens for Future Use  
 
We will try to collect the blood used for this research at the same time as blood is drawn to monitor your health during your study treatment and at follow-up visits, in order not to increase the number of times you will have blood drawn.  If you agree, any blood sample that is left over after the research for this study is complete will be stored for future use.  Please read each sentence below and think about your choic e.  After reading each 
sentence, circle “yes” or “no” for each type of specimen and write your initials.  Then sign your name at the bottom of this section.  If you have any questions, please talk to 
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 14 of 17 
   your doctor or nurse, or call the Principal Investigator for this study ( SITE PI  at  SITE 
PHONE NUMBER ). 
  
No matter what you decide to do, it will not affect your care.   You may request at any time that your research samples be removed from storage and not be used for future research.  If you decide you want your samples removed, you may  
contact SITE PI  at  SITE PHONE NUMBER .  Once your request is received, and if your 
samples have not already been used for other research, they will be destroyed.  If you do not make such a request, your specimens will be stored indefinitely or until used.   
 
1. My blood specimens may be kept for use in future research to learn about, prevent, or treat neurofibromatosis 2: 
 
  ⁪ Yes   ⁪ No ___________________________    ___________ 
    Signature    Date  
  
2. My blood specimens may be kept for use in future research to learn about, prevent, or treat other health problems (for example, diabetes, Alzheimer’s disease, or heart disease):  
 
  ⁪ Yes   ⁪ No ___________________________    ___________ 
   Signature    Date  
  3. Someone may contact me in the future to ask me to take part in more research: 
 
  ⁪ Yes   ⁪ No ___________________________    ___________  
   Signature    Date  
          
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 15 of 17 
    
Document of Assent  
 
Signature of participant between age of 14 and 1 7: The person doing this research 
study has explained what will happen to me if I take part in this research study.  My 
signature below means that I want to be in this research study.  I can decide not to take part in this research study if I do not want to and nothing will happen to me if I decide I do not want to participate.      ____________________________________ __________________ Signature of Participant     Date  
 
Document of Consent  
 My signature below indicates  that I agree to participate in this study.  I am aware that I 
will receive a copy of this signed agreement : 
 
• I have had enough time to read the consent and think about participating in this study;  
• I have had all of my questions answered to my satisfaction; 
• I am willing to participate in this s tudy;  
• I have been told that my participation is voluntary and I can withdraw at any 
time 
 
 
             
Signature of Participant     Date  
Or Legally Authorized Representative   
  
             
Relationship of Legally Authorized Representative to Participant     
___________________________________  ______________________________ 
Signature of Witness      Date  
         
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 16 of 17 
    
Waiver of Assent   
 
The assent of ______________________________ (name of child/minor) was waived 
because of:  
 Age _________  Maturity ________  Psychological state of the child ________  
 
 
To be completed by person obtaining consent:  
 
The consent discussion was initiated on    (date).  
 A copy of this signed consent form will be given to the participant  or legally 
authorized representative, or, where the participant  is a minor, the participant ’s parent 
or legal guardian. 
For Adult Participant s 
 The participant  is an adult and provided consent to participate.  
  The participant is a non-English speaker and signed the translated Short Form in 
lieu of English consent document 
 The participant  is an adult who lacks capacity to provide consent and his/her legally 
authorized r epresentative:  
 gave permission for the adult participant  to participate  
 did not give permission for the adult participant  to participate  
or 
For Minor Participant s 
 The parent or legally auth orized representative gave permission for the minor to 
participate.  
  parent or legally authorized representative is a non-English speaker and signed 
the translated Short Form in lieu of English consent document 
 The parent or legally authorized representative did not give permission for the minor 
to participate  
 
 
Signature of Individual obtaining consent:   
 
Printed name of above:   
 
Date:    
 
 
Research Consent Form  
NF Consortium                 NF 2 Trial  Protocol  Version  1.4 dated   May 13, 2016    
Revised: January 30, 2017  
Page 17 of 17 
    
 
Medical Release of Information  
 
Permission is hereby given:  
 
______________________________________ Name  
 ______________________________________ Address  ______________________________________ City   State   Zip  
  
To release to the SITE , any and all medical information contained in the record of: 
 ______________________________________ Name of Patient  
 ______________________________________ Address  ______________________________________ City   State   Zip 
 ______________________________________ Date  
      Signed:  ______________________________        Patient  
      Signed: ______________________________        Witness  
      __________________________________________      Address        __________________________________________      City    State   Zip  